{"matching_results": 31887, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1542, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1182}, {"key": "negative", "matching_results": 354}, {"key": "neutral", "matching_results": 6}]}]}, {"key": "watchlistnews.com", "matching_results": 780, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 626}, {"key": "negative", "matching_results": 153}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "tickerreport.com", "matching_results": 752, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 639}, {"key": "negative", "matching_results": 113}]}]}, {"key": "wkrb13.com", "matching_results": 752, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 647}, {"key": "negative", "matching_results": 104}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 719, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 556}, {"key": "negative", "matching_results": 163}]}]}, {"key": "theolympiareport.com", "matching_results": 706, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 554}, {"key": "negative", "matching_results": 151}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 670, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 549}, {"key": "negative", "matching_results": 121}]}]}, {"key": "mylubbocktv.com", "matching_results": 572, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 468}, {"key": "negative", "matching_results": 104}]}]}, {"key": "marketscreener.com", "matching_results": 563, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 413}, {"key": "negative", "matching_results": 148}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "freelancer.com.co", "matching_results": 542, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 494}, {"key": "negative", "matching_results": 46}, {"key": "neutral", "matching_results": 2}]}]}]}], "results": [{"id": "DMZryAxWVwd2L3Vqb5hpw-c2acKE8i8vXhBWf2bDfSiz0q0px_tP2mXlmGwGIvdA", "result_metadata": {"score": 36.845352}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.670187, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.492359, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Norges Bank", "sentiment": {"score": -0.230595, "label": "negative"}, "relevance": 0.966282}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.8818}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240447}]}, "crawl_date": "2018-11-13T10:20:55Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45261587-norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T10:19:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.957808, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.923955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "YesShire PLC", "relevance": 0.788874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.7562, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.680231, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.680231, "type": "Quantity"}], "sentiment": {"document": {"score": -0.414576, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2.", "object": {"text": "a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2", "keywords": [{"text": "possible cash offer"}, {"text": "YesShire PLC"}, {"text": "N/A"}], "entities": [{"type": "Company", "text": "YesShire PLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945508, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.824762, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.672196, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.546544, "label": "/real estate/buying and selling homes"}, {"score": 0.482893, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.470469, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.963268}, {"text": "POSITION DISCLOSURE/DEALING DISCLOSURE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.835375}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.729269}, {"text": "disclosure Dealing Disclosure12/11/2018", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.6707}, {"text": "RELEVANT SECURITIES REPRESENTING", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642298}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552319}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514888}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501531}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470999}, {"text": "possible cash offer", "sentiment": {"score": 0.403939, "label": "positive"}, "relevance": 0.464383}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392215}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321408}, {"text": "Norges Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.313157}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310819}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291474}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.281263}, {"text": "vehicle companies", "sentiment": {"score": -0.502585, "label": "negative"}, "relevance": 0.277052}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260288}, {"text": "YesShire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2488}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237089}]}, "extracted_metadata": {"sha1": "abd9a069c904f84d47d25ec3ba9143258e357e56", "filename": "1542104455224.zip-3cc2d17d90a47b06fce31029fd8c0b18.xml", "file_type": "json"}, "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: Nachrichten zu Aktien aus asien"}, {"id": "0Rgy_KE-GWVjxWp_IGUTJZs9fuCZK7IZesNer3Ti2jwPUPb7oAvSRlC2z26dzoAf", "result_metadata": {"score": 34.48733}, "author": "euroinvestor.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.768513, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.920731}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544011}]}, "crawl_date": "2018-11-13T10:47:47Z", "url": "https://www.euroinvestor.com/news/2018/11/13/form-83-takeda-pharmaceutical-co-ltd/13928379", "host": "euroinvestor.com", "text": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd PR Newswire London, November 13 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \u201cCode\u201d) 1.", "country": "DK", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T10:16:00+01:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.847858, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.266625, "label": "negative"}, "text": "Norges Bank", "relevance": 0.796975, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.56299, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.555089, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.539276, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.532782, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.516759, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501703, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.489686, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.489686, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.489686, "type": "Quantity"}], "sentiment": {"document": {"score": 0.495591, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.978327, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.544009, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.523884, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.517917, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.467684, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.438678, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.422511, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.410813, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.387131, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Unit type", "relevance": 0.372252, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.371966, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.371413, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Security", "relevance": 0.362882, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Security", "relevance": 0.358251, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.358055, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Derivative", "relevance": 0.357874, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.338941, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Norges Bank", "relevance": 0.336251, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.704437, "label": "/real estate/buying and selling homes"}, {"score": 0.524467, "label": "/finance/financial news"}, {"score": 0.275586, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Purchase 25,000 JPY 4,504.9320 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.726237, "arguments": [{"text": "i", "location": [3227, 3228], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [3230, 3237], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3827, 3832], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3837, 3841], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4201, 4207], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4218, 4225], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 13/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5094, 5100], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5108, 5112], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5255, 5279], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5247, 5252], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5414, 5419], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5433, 5460], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.398424, "label": "positive"}, "relevance": 0.965012}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.838783}, {"text": "short positions", "sentiment": {"score": -0.446215, "label": "negative"}, "relevance": 0.627951}, {"text": "disclosure", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.564106}, {"text": "Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543336}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508231}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.493549}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.493087}, {"text": "Norges Bank", "sentiment": {"score": -0.266625, "label": "negative"}, "relevance": 0.475756}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.464755}, {"text": "derivative transactions", "sentiment": {"score": -0.426963, "label": "negative"}, "relevance": 0.460754}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459532}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.455801}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454453}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453562}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452339}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.446788}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.445782}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.429787, "label": "negative"}, "relevance": 0.44141}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.439894}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438437}, {"text": "long/short position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435827}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433495}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.432964}, {"text": "reference securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427637}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421591}, {"text": "person", "sentiment": {"score": 0.312573, "label": "positive"}, "relevance": 0.421246}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.398314}, {"text": "option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395123}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.393524}, {"text": "PR Newswire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.393131}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392037}, {"text": "agreements", "sentiment": {"score": 0.0297727, "label": "positive"}, "relevance": 0.391697}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.391539}, {"text": "vehicle companies", "sentiment": {"score": -0.671605, "label": "negative"}, "relevance": 0.391223}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387351}, {"text": "interests", "sentiment": {"score": -0.467783, "label": "negative"}, "relevance": 0.387036}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.385829}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.385522}, {"text": "options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384978}, {"text": "Option money", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380477}, {"text": "Cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380274}, {"text": "e.g. CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379291}, {"text": "employee options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379016}, {"text": "option relates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.378865}, {"text": "Telephone number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.378269}, {"text": "e.g. American", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.378256}, {"text": "Stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.378043}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377829}, {"text": "Expiry date", "sentiment": {"score": -0.343513, "label": "negative"}, "relevance": 0.377635}]}, "extracted_metadata": {"sha1": "36375dfc8823bf0713ec7a558de226c9b387fa2c", "filename": "1542106067639.zip-3667f65aa111e3ff5ceea3ffcd131eda.xml", "file_type": "json"}, "external_links": ["https://www.thetakeoverpanel.org.uk/", "https://www.xmlnews.org/ns/"], "title": "Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "Latest Financial News, Stock News, Forex News and Commodity Market News - Euroinvestor"}, {"id": "mxBzWDqKCyojRPxA0LYiGZqwLFqPggfpBwx_fOKzTaQkhSGK7ipW8ko0jMZMSLHh", "result_metadata": {"score": 33.71807}, "author": "mylubbocktv.com", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Grammy Award winners", "relevance": 0.861181, "dbpedia_resource": "http://dbpedia.org/resource/Grammy_Award_winners"}], "categories": [{"score": 0.63947, "label": "/health and fitness/disease/cancer"}, {"score": 0.449254, "label": "/health and fitness/therapy"}, {"score": 0.408691, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [{"type": "employedBy", "sentence": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor L", "score": 0.760684, "arguments": [{"text": "ASK1 Inhibitor L", "location": [48, 64], "entities": [{"type": "Person", "text": "ASK1 Inhibitor L"}]}, {"text": "Seal Rock Therapeutics Advancing Differentiated", "location": [0, 47], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics Advancing Differentiated"}]}]}], "keywords": [{"text": "Seal Rock Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.987096}, {"text": "Inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.660361}]}, "crawl_date": "2018-11-13T14:16:17Z", "url": "http://www.mylubbocktv.com/story/39452763/seal-rock-therapeutics-advancing-differentiated-ask1-inhibitor-lead-candidate-srt-015-in-nonalcoholic-steatohepatitis-nash", "host": "mylubbocktv.com", "text": "Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-09T00:00:00-05:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0.353437, "label": "positive"}, "text": "Seal Rock Therapeutics", "relevance": 0.7779, "type": "Company"}, {"count": 8, "sentiment": {"score": 0.621638, "label": "positive"}, "text": "SRT-015", "relevance": 0.526448, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.336538, "label": "positive"}, "text": "Seal Rock Therapeutics, Inc.", "relevance": 0.427219, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer of Seal Rock Therapeutics", "relevance": 0.407228, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": -0.405581, "label": "negative"}, "text": "NASH", "relevance": 0.399083, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.422937, "label": "negative"}, "text": "fatty liver", "relevance": 0.376412, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}, {"count": 1, "sentiment": {"score": -0.369421, "label": "negative"}, "text": "non-alcoholic fatty liver disease", "relevance": 0.323814, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}, {"count": 2, "sentiment": {"score": -0.520894, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.322388, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 3, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Neil McDonnell", "relevance": 0.290028, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Takeda", "relevance": 0.288086, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seal Rock", "relevance": 0.283193, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna Therapeutics", "relevance": 0.275172, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.568746, "label": "negative"}, "text": "fibrotic diseases", "relevance": 0.273866, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pathway Therapeutics", "relevance": 0.269358, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "liver fibrosis", "relevance": 0.264505, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}, {"count": 2, "sentiment": {"score": -0.0889629, "label": "negative"}, "text": "SEATTLE", "relevance": 0.263289, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "director", "relevance": 0.260484, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kathleen Elias", "relevance": 0.253617, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.499214, "label": "negative"}, "text": "metabolic disease", "relevance": 0.249687, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Brown", "relevance": 0.245203, "type": "Person", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President, Business Development", "relevance": 0.244763, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Artur Plonowski", "relevance": 0.243552, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Exelixis", "relevance": 0.243054, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President Research & Translational Medicine", "relevance": 0.234042, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "senior vice president", "relevance": 0.233811, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Keystone Symposia Integrated Pathways of Disease", "relevance": 0.233597, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.223405, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "vice president", "relevance": 0.219592, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.371387, "label": "positive"}, "text": "New Mexico", "relevance": 0.214248, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Rathbun Communications", "relevance": 0.214246, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.580282, "label": "negative"}, "text": "obesity", "relevance": 0.213877, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.213153, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "diabetes", "relevance": 0.210393, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": 0.310571, "label": "positive"}, "text": "Santa Fe", "relevance": 0.210276, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "managing director", "relevance": 0.209424, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": -0.542574, "label": "negative"}, "text": "Terry Porter", "relevance": 0.207547, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genentech", "relevance": 0.20443, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genentech", "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatocellular carcinoma", "relevance": 0.202828, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan", "relevance": 0.20261, "type": "Company", "disambiguation": {"subtype": [], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Scientific Officer", "relevance": 0.198922, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Julie Rathbun", "relevance": 0.198829, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akarna", "relevance": 0.194249, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cytokinetics", "relevance": 0.194229, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.19238, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatomegaly", "relevance": 0.184643, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pioglitazone", "relevance": 0.184455, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "metformin", "relevance": 0.183388, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "Metacrine", "relevance": 0.181791, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Domantis", "relevance": 0.181447, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.528252, "label": "negative"}, "text": "CEO", "relevance": 0.181307, "type": "JobTitle"}], "sentiment": {"document": {"score": -0.327644, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a discovery stage company", "keywords": [{"text": "discovery stage company"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "best-in-class treatments", "keywords": [{"text": "best-in-class treatments"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies,", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "discovery stage company"}, {"text": "best-in-class treatments"}, {"text": "available therapies"}], "entities": [{"type": "Location", "text": "SEATTLE", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Seattle", "dbpedia_resource": "http://dbpedia.org/resource/Seattle"}}, {"type": "Company", "text": "Seal Rock Therapeutics, Inc."}, {"type": "Company", "text": "Seal Rock Therapeutics"}, {"type": "HealthCondition", "text": "fibrotic diseases"}]}, "sentence": " SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "object": {"text": "its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued", "keywords": [{"text": "preclinical proof-of-concept findings"}, {"text": "differentiated inhibitor"}, {"text": "recent worldwide patent"}, {"text": "nonalcoholic steatohepatitis"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}]}, "sentence": " SRT-015 is a potent, liver-selective ASK1 inhibitor for NASH.", "object": {"text": "a potent, liver-selective ASK1 inhibitor for NASH", "keywords": [{"text": "liver-selective ASK1 inhibitor"}, {"text": "NASH"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "action": {"verb": {"text": "optimize", "tense": "past"}, "text": "was internally discovered and optimized", "normalized": "be internally discover and optimize"}}, {"subject": {"text": "The candidate", "keywords": [{"text": "candidate"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities demonstrated by other investigative approaches", "keywords": [{"text": "investigative approaches"}, {"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "avoid", "tense": "present"}, "text": "avoid", "normalized": "avoid"}}, {"subject": {"text": "by other investigative approaches", "keywords": [{"text": "investigative approaches"}]}, "sentence": " The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "object": {"text": "dose-limiting liabilities", "keywords": [{"text": "dose-limiting liabilities"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}, {"text": "Gubra"}, {"text": "model"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model", "keywords": [{"text": "therapeutic NASH mouse"}, {"text": "efficacy"}]}, "action": {"verb": {"text": "demonstrate", "tense": "past"}, "text": "demonstrated", "normalized": "demonstrate"}}, {"subject": {"text": "Preclinical research of SRT-015", "keywords": [{"text": "Preclinical research"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " Preclinical research of SRT-015 has demonstrated promising efficacy in the biopsy-proven, DIO-NASH Gubra therapeutic NASH mouse model.", "object": {"text": "efficacy", "keywords": [{"text": "efficacy"}]}, "action": {"verb": {"text": "promise", "tense": "present"}, "text": "has demonstrated promising", "normalized": "have demonstrate promise"}}, {"subject": {"text": "statistically significant positive effects on both metabolic parameters and liver-specific pathology", "keywords": [{"text": "significant positive effects"}, {"text": "metabolic parameters"}, {"text": "liver-specific pathology"}]}, "sentence": " This includes statistically significant positive effects on both metabolic parameters and liver-specific pathology.", "object": {"text": "This"}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " In addition, SRT-015 significantly reduced hepatomegaly, liver fibrosis, steatosis and inflammation, all key drivers for NASH.", "object": {"text": "hepatomegaly, liver fibrosis, steatosis and inflammation", "keywords": [{"text": "liver fibrosis"}, {"text": "steatosis"}, {"text": "inflammation"}], "entities": [{"type": "HealthCondition", "text": "hepatomegaly"}, {"type": "HealthCondition", "text": "liver fibrosis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Symptom", "Disease"], "name": "Cirrhosis", "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "object": {"text": "presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019", "keywords": [{"text": "Keystone Symposia Integrated"}, {"text": "Santa Fe"}, {"text": "NAFLD meeting"}, {"text": "New Mexico"}], "entities": [{"type": "PrintMedia", "text": "Keystone Symposia Integrated Pathways of Disease"}, {"type": "Location", "text": "Santa Fe", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Santa Fe, New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Santa_Fe,_New_Mexico"}}, {"type": "Location", "text": "New Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "New Mexico", "dbpedia_resource": "http://dbpedia.org/resource/New_Mexico"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "These findings", "keywords": [{"text": "findings"}]}, "sentence": " These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20\u201324, 2019.", "action": {"verb": {"text": "present", "tense": "future"}, "text": "will be presented", "normalized": "will be present"}}, {"subject": {"text": "SRT-015", "keywords": [{"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "a unique property", "keywords": [{"text": "unique property"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "the circulation or other tissues", "keywords": [{"text": "circulation"}, {"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "reduce risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "other tissues", "keywords": [{"text": "tissues"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "risk of side effects", "keywords": [{"text": "risk"}, {"text": "effects"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "helps reduce", "normalized": "help reduce"}}, {"subject": {"text": "Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "Chief Executive Officer"}, {"text": "Neil McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "JobTitle", "text": "Chief Executive Officer of Seal Rock Therapeutics"}]}, "sentence": " \"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "object": {"text": "SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses", "keywords": [{"text": "effective doses"}, {"text": "unique property"}, {"text": "tissues"}, {"text": "NASH"}], "entities": [{"type": "Company", "text": "SRT-015"}, {"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "we"}, "sentence": " \"Our preclinical findings are proving very robust, and we are pleased to be advancing with IND-enabling activities for SRT-015.\"", "object": {"text": "advancing with IND-enabling activities for SRT-015", "keywords": [{"text": "IND-enabling activities"}, {"text": "S-015"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Seal Rock Therapeutics", "keywords": [{"text": "Seal Rock Therapeutics"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "sentence": " Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "object": {"text": "the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof", "keywords": [{"text": "ASK1 inhibitor compounds"}, {"text": "international PCT patent"}, {"text": "publication"}, {"text": "application"}], "entities": [{"type": "Company", "text": "SRT-015"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The Patent Cooperation Treaty (PCT)", "keywords": [{"text": "Patent Cooperation Treaty"}, {"text": "PCT"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "151 countries", "keywords": [{"text": "countries"}]}, "sentence": " The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide.", "object": {"text": "an international patent law treaty", "keywords": [{"text": "patent law treaty"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine", "keywords": [{"text": "Chief Scientific Officer"}, {"text": "Vice President Research"}, {"text": "Neil McDonnell"}, {"text": "Artur Plonowski"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}, {"type": "Person", "text": "Artur Plonowski"}, {"type": "JobTitle", "text": "Chief Scientific Officer"}, {"type": "Person", "text": "Kathleen Elias"}, {"type": "JobTitle", "text": "Vice President Research & Translational Medicine"}]}, "sentence": " Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "object": {"text": "Seal Rock Therapeutics' founders", "keywords": [{"text": "Seal Rock Therapeutics"}, {"text": "founders"}], "entities": [{"type": "Company", "text": "Seal Rock Therapeutics"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. McDonnell", "keywords": [{"text": "Dr. McDonnell"}], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "object": {"text": "as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda", "keywords": [{"text": "senior vice president"}, {"text": "therapeutic area leader"}, {"text": "metabolic diseases"}, {"text": "Takeda"}], "entities": [{"type": "JobTitle", "text": "CEO"}, {"type": "Company", "text": "Metacrine"}, {"type": "JobTitle", "text": "senior vice president"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin)", "keywords": [{"text": "diabetes drugs"}, {"text": "pioglitazone"}, {"text": "metformin"}, {"text": "development"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "He", "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, "sentence": " He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "object": {"text": "in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone)", "keywords": [{"text": "obesity drug Contrave"}, {"text": "diabetes drugs"}, {"text": "partner Orexigen"}, {"text": "pioglitazone"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Drug", "text": "pioglitazone"}, {"type": "Person", "text": "Kazano"}, {"type": "Drug", "text": "metformin"}, {"type": "Person", "text": "Takeda"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Orexigen"}, {"type": "Drug", "text": "bupropion"}, {"type": "Drug", "text": "naltrexone"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "has been involved", "normalized": "have be involve"}}, {"subject": {"text": "Dr. Plonowski", "keywords": [{"text": "Dr. Plonowski"}], "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones", "keywords": [{"text": "NASH start-up"}, {"text": "Akarna Therapeutics"}, {"text": "Allergan"}, {"text": "pharmacology"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Akarna Therapeutics"}, {"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}, {"type": "Quantity", "text": "$50 million"}, {"type": "Quantity", "text": "$1 billion"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "acquired by Allergan in 2016", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Allergan", "keywords": [{"text": "Allergan"}], "entities": [{"type": "Company", "text": "Allergan", "disambiguation": {"subtype": ["Company"], "name": "Allergan", "dbpedia_resource": "http://dbpedia.org/resource/Allergan"}}]}, "sentence": " Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "object": {"text": "a NASH start-up", "keywords": [{"text": "NASH start-up"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "was acquired", "normalized": "be acquire"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Artur Plonowski"}]}, "sentence": " Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "object": {"text": "the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals,", "keywords": [{"text": "metabolic disease pharmacology"}, {"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "HealthCondition", "text": "metabolic disease", "disambiguation": {"subtype": ["Disease"], "name": "Inborn error of metabolism", "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "preclinical research"}, {"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}], "entities": [{"type": "JobTitle", "text": "director"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "Dr. Elias", "keywords": [{"text": "Dr. Elias"}], "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "object": {"text": "efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications", "keywords": [{"text": "oncology indications"}, {"text": "small molecule"}, {"text": "antibody"}, {"text": "efforts"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "establish", "tense": "past"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "she", "entities": [{"type": "Person", "text": "Kathleen Elias"}]}, "sentence": " Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "object": {"text": "the cell biology", "keywords": [{"text": "cell biology"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry", "keywords": [{"text": "Senior Vice President"}, {"text": "Terry Porter"}, {"text": "Business Development"}, {"text": "PhD"}], "entities": [{"type": "Person", "text": "Terry Porter"}, {"type": "JobTitle", "text": "Senior Vice President, Business Development"}, {"type": "Person", "text": "David Brown", "disambiguation": {"subtype": [], "name": "David Brown (professor)", "dbpedia_resource": "http://dbpedia.org/resource/David_Brown_(professor)"}}, {"type": "JobTitle", "text": "director"}]}, "sentence": " Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "object": {"text": "Additional members of the Seal Rock leadership team", "keywords": [{"text": "Seal Rock leadership"}, {"text": "Additional members"}, {"text": "team"}], "entities": [{"type": "Organization", "text": "Seal Rock"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Dr. Porter", "keywords": [{"text": "Dr. Porter"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "object": {"text": "as vice president of search & evaluation within global business development at Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "vice president"}, {"text": "global business development"}, {"text": "search"}], "entities": [{"type": "JobTitle", "text": "vice president"}, {"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " Prior to that, he was managing director at the corporate advisory group AquaPartners.", "object": {"text": "managing director at the corporate advisory group AquaPartners", "keywords": [{"text": "corporate advisory group"}, {"text": "director"}, {"text": "AquaPartners"}], "entities": [{"type": "JobTitle", "text": "managing director"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "action": {"verb": {"text": "create", "tense": "past"}, "text": "created", "normalized": "create"}}, {"subject": {"text": "he headed oncology licensing,", "keywords": [{"text": "oncology licensing"}], "entities": [{"type": "Person", "text": "Terry Porter"}]}, "sentence": " During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "object": {"text": "the external science and technology group", "keywords": [{"text": "external science"}, {"text": "technology group"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Dr. Brown", "keywords": [{"text": "Dr."}], "entities": [{"type": "Person", "text": "David Brown"}]}, "sentence": " Dr. Brown recently directed the medicinal chemistry team at Pathway Therapeutics, which led to the selective PI3Kdelta kinase inhibitor PWT143/MEI-401.", "object": {"text": "the medicinal chemistry team", "keywords": [{"text": "medicinal chemistry team"}]}, "action": {"verb": {"text": "direct", "tense": "past"}, "text": "directed", "normalized": "direct"}}, {"subject": {"text": "he"}, "sentence": " Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "object": {"text": "12 years", "entities": [{"type": "Quantity", "text": "12 years"}]}, "action": {"verb": {"text": "spend", "tense": "past"}, "text": "spent", "normalized": "spend"}}, {"subject": {"text": "NASH", "keywords": [{"text": "NASH"}]}, "sentence": " NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "a form of non-alcoholic fatty liver disease", "keywords": [{"text": "non-alcoholic fatty liver"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a form of non-alcoholic fatty liver disease (NAFLD)", "keywords": [{"text": "non-alcoholic fatty liver"}, {"text": "form"}, {"text": "disease"}, {"text": "NAFLD"}], "entities": [{"type": "HealthCondition", "text": "non-alcoholic fatty liver disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor"], "name": "Non-alcoholic fatty liver disease", "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}}]}, "sentence": " NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "it"}, "sentence": " NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "object": {"text": "one of the most common chronic liver diseases", "keywords": [{"text": "common chronic liver"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "associated with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "object": {"text": "with metabolic conditions such as obesity, diabetes, and high cholesterol", "keywords": [{"text": "metabolic conditions"}, {"text": "high cholesterol"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "is associated", "normalized": "be associate"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "typically characterized as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "NAFLD", "keywords": [{"text": "NAFLD"}]}, "sentence": " NAFLD is typically characterized as either fatty liver or steatohepatitis.", "object": {"text": "as either fatty liver or steatohepatitis", "keywords": [{"text": "fatty liver"}, {"text": "steatohepatitis"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "characterized", "normalized": "characterize"}}, {"subject": {"text": "Fatty liver", "keywords": [{"text": "Fatty liver"}], "entities": [{"type": "HealthCondition", "text": "fatty liver", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Fatty liver", "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}}]}, "sentence": " Fatty liver is generally non-progressive or progresses slowly compared to steatohepatitis.", "object": {"text": "generally non-progressive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Cirrhosis", "relevance": 0.955515, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Fatty liver", "relevance": 0.941852, "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}, {"text": "Patent Cooperation Treaty", "relevance": 0.914799, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Cooperation_Treaty"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.896163, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Hepatitis", "relevance": 0.735147, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Hepatology", "relevance": 0.621874, "dbpedia_resource": "http://dbpedia.org/resource/Hepatology"}, {"text": "Obesity", "relevance": 0.607661, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Patent", "relevance": 0.491737, "dbpedia_resource": "http://dbpedia.org/resource/Patent"}, {"text": "Steatosis", "relevance": 0.482758, "dbpedia_resource": "http://dbpedia.org/resource/Steatosis"}, {"text": "Patent application", "relevance": 0.481903, "dbpedia_resource": "http://dbpedia.org/resource/Patent_application"}, {"text": "Liver", "relevance": 0.472576, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Cancer", "relevance": 0.450262, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Metabolic syndrome", "relevance": 0.448096, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Pharmacology", "relevance": 0.440555, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Inborn error of metabolism", "relevance": 0.42072, "dbpedia_resource": "http://dbpedia.org/resource/Inborn_error_of_metabolism"}, {"text": "Hepatocellular carcinoma", "relevance": 0.412341, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Liver disease", "relevance": 0.406572, "dbpedia_resource": "http://dbpedia.org/resource/Liver_disease"}, {"text": "Medicine", "relevance": 0.406058, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Liver transplantation", "relevance": 0.403778, "dbpedia_resource": "http://dbpedia.org/resource/Liver_transplantation"}, {"text": "Hepatitis C", "relevance": 0.390092, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Vice President of the United States", "relevance": 0.380851, "dbpedia_resource": "http://dbpedia.org/resource/Vice_President_of_the_United_States"}, {"text": "Patent law", "relevance": 0.377488, "dbpedia_resource": "http://dbpedia.org/resource/Patent_law"}, {"text": "Drug discovery", "relevance": 0.375903, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Metabolism", "relevance": 0.375657, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Steatohepatitis", "relevance": 0.36571, "dbpedia_resource": "http://dbpedia.org/resource/Steatohepatitis"}, {"text": "Paris Convention for the Protection of Industrial Property", "relevance": 0.359336, "dbpedia_resource": "http://dbpedia.org/resource/Paris_Convention_for_the_Protection_of_Industrial_Property"}, {"text": "Metformin", "relevance": 0.352915, "dbpedia_resource": "http://dbpedia.org/resource/Metformin"}, {"text": "Chronic liver disease", "relevance": 0.352756, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_liver_disease"}, {"text": "Drug design", "relevance": 0.321103, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Hepatitis B", "relevance": 0.319323, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Patent Law Treaty", "relevance": 0.31664, "dbpedia_resource": "http://dbpedia.org/resource/Patent_Law_Treaty"}, {"text": "Substantive Patent Law Treaty", "relevance": 0.309937, "dbpedia_resource": "http://dbpedia.org/resource/Substantive_Patent_Law_Treaty"}, {"text": "Gastroenterology", "relevance": 0.309279, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Drug development", "relevance": 0.307377, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Pre-clinical development", "relevance": 0.306927, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Liver biopsy", "relevance": 0.306823, "dbpedia_resource": "http://dbpedia.org/resource/Liver_biopsy"}, {"text": "Enzyme inhibitor", "relevance": 0.306494, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_inhibitor"}, {"text": "Therapy", "relevance": 0.303716, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Management occupations", "relevance": 0.301703, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Chief executive officer", "relevance": 0.297576, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Classification of Pharmaco-Therapeutic Referrals", "relevance": 0.270718, "dbpedia_resource": "http://dbpedia.org/resource/Classification_of_Pharmaco-Therapeutic_Referrals"}, {"text": "Priority right", "relevance": 0.269059, "dbpedia_resource": "http://dbpedia.org/resource/Priority_right"}], "categories": [{"score": 0.594115, "label": "/health and fitness"}, {"score": 0.572131, "label": "/health and fitness/disease"}, {"score": 0.338149, "label": "/health and fitness/therapy"}], "relations": [{"type": "basedIn", "sentence": "Seal Rock Therapeutics, Inc. Preclinical Findings Highlight Potent Efficacy in the Therapeutic DIO-NASH (Gubra) Mouse Model International Patent Application for SRT-015 and Other ASK1 Inhibitors Published SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.48106, "arguments": [{"text": "ASK1 Inhibitors", "location": [179, 194], "entities": [{"type": "Organization", "text": "ASK1 Inhibitors"}]}, {"text": "SEATTLE", "location": [205, 212], "entities": [{"type": "GeopoliticalEntity", "text": "SEATTLE"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.995901, "arguments": [{"text": "Santa Fe", "location": [1382, 1390], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}, {"text": "New Mexico", "location": [1392, 1402], "entities": [{"type": "GeopoliticalEntity", "text": "New Mexico"}]}]}, {"type": "agentOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.920089, "arguments": [{"text": "Neil McDonnell", "location": [1712, 1726], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "said", "location": [1707, 1711], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"SRT-015 has a unique property that makes it particularly suitable for NASH: it is distributed to the liver where it is needed, but very little is present in the circulation or other tissues, which helps reduce risk of side effects and may allow for higher, more effective doses,\" said Neil McDonnell , Chief Executive Officer of Seal Rock Therapeutics.", "score": 0.71758, "arguments": [{"text": "Chief Executive Officer", "location": [1729, 1752], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "Seal Rock Therapeutics", "location": [1756, 1778], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}]}, {"type": "agentOf", "sentence": "\" Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "score": 0.991921, "arguments": [{"text": "Seal Rock Therapeutics", "location": [1923, 1945], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}, {"text": "announced", "location": [1946, 1955], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "basedIn", "sentence": "\" Additionally, Seal Rock Therapeutics announced the publication of an international PCT patent application for SRT-015 that includes ASK1 inhibitor compounds and uses thereof.", "score": 0.263455, "arguments": [{"text": "ASK1 inhibitor", "location": [2041, 2055], "entities": [{"type": "Organization", "text": "ASK1 Inhibitors"}]}, {"text": "compounds", "location": [2056, 2065], "entities": [{"type": "Location", "text": "compounds"}]}]}, {"type": "employedBy", "sentence": "Seal Rock Therapeutics' founders include Neil McDonnell , PharmD; Artur Plonowski , MD, PhD, Chief Scientific Officer; and; Kathleen Elias , PhD, Vice President Research & Translational Medicine.", "score": 0.417282, "arguments": [{"text": "founders", "location": [2265, 2273], "entities": [{"type": "Person", "text": "founders"}]}, {"text": "Seal Rock Therapeutics", "location": [2241, 2263], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}]}, {"type": "residesIn", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.300954, "arguments": [{"text": "leader", "location": [2536, 2542], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "area", "location": [2531, 2535], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "hasAttribute", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.580563, "arguments": [{"text": "leader", "location": [2536, 2542], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "cardiovascular", "location": [2547, 2561], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "employedBy", "sentence": "Dr. McDonnell previously served as CEO of Metacrine and senior vice president and therapeutic area leader for cardiovascular and metabolic diseases at Takeda.", "score": 0.799635, "arguments": [{"text": "leader", "location": [2536, 2542], "entities": [{"type": "Person", "text": "Metacrine"}]}, {"text": "Takeda", "location": [2588, 2594], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "He has been involved in the development of diabetes drugs Nesina (alogliptin), Oseni (alogliptin + pioglitazone), and Kazano (alogliptin + metformin), and with Takeda's partner Orexigen, the obesity drug Contrave (bupropion and naltrexone).", "score": 0.758695, "arguments": [{"text": "partner", "location": [2765, 2772], "entities": [{"type": "Person", "text": "Orexigen"}]}, {"text": "Takeda", "location": [2756, 2762], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Seal Rock Therapeutics, Inc. Preclinical Findings Highlight Potent Efficacy in the Therapeutic DIO-NASH (Gubra) Mouse Model International Patent Application for SRT-015 and Other ASK1 Inhibitors Published SEATTLE , Nov. 9, Seal Rock Therapeutics, Inc., a discovery stage company developing best-in-class treatments for inflammatory and fibrotic diseases with no available therapies, today announced its lead compound, SRT-015, a differentiated inhibitor of apoptosis signal-regulating kinase 1 (ASK1) for nonalcoholic steatohepatitis (NASH), with promising preclinical proof-of-concept findings and recent worldwide patent application issued.", "score": 0.889777, "arguments": [{"text": "today", "location": [383, 388], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [389, 398], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.528062, "arguments": [{"text": "director of pharmacology", "location": [2870, 2894], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "Akarna Therapeutics", "location": [2898, 2917], "entities": [{"type": "Organization", "text": "Akarna Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.474504, "arguments": [{"text": "Allergan", "location": [2961, 2969], "entities": [{"type": "Organization", "text": "Allergan"}]}, {"text": "acquired", "location": [2949, 2957], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Dr. Plonowski recently served as director of pharmacology at Akarna Therapeutics, Ltd, a NASH start-up that was acquired by Allergan in 2016 for $50 million and $1 billion in milestones.", "score": 0.97932, "arguments": [{"text": "2016", "location": [2973, 2977], "entities": [{"type": "Date", "text": "2016"}]}, {"text": "acquired", "location": [2949, 2957], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.802833, "arguments": [{"text": "he", "location": [3041, 3043], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "cardiovascular", "location": [3052, 3066], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.489941, "arguments": [{"text": "he", "location": [3041, 3043], "entities": [{"type": "Person", "text": "Neil McDonnell"}]}, {"text": "metabolic disease", "location": [3078, 3095], "entities": [{"type": "HealthCondition", "text": "metabolic diseases"}]}]}, {"type": "partOf", "sentence": "Prior to Akarna, he led the cardiovascular, renal and metabolic disease pharmacology group at Takeda Pharmaceuticals, and served for 10 years at Exelixis with scientific and leadership responsibilities in CV, metabolic, renal, oncology, and inflammation therapeutic areas.", "score": 0.849637, "arguments": [{"text": "pharmacology group", "location": [3096, 3114], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}, {"text": "Takeda Pharmaceuticals", "location": [3118, 3140], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Dr. Elias previously served as director of preclinical research at Takeda, and led efforts to develop small molecule, antibody and antibody drug conjugates for immune, metabolic and oncology indications.", "score": 0.74674, "arguments": [{"text": "director of preclinical research", "location": [3328, 3360], "entities": [{"type": "Person", "text": "Elias"}]}, {"text": "Takeda", "location": [3364, 3370], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Prior to that, at Cytokinetics, she established and led the cell biology and pharmacology efforts to identity and develop a myosin activator therapeutic for heart failure, and at Genentech, identified therapeutics for endocrine and cardiac indications.", "score": 0.763089, "arguments": [{"text": "she", "location": [3533, 3536], "entities": [{"type": "Person", "text": "PharmD; Artur Plonowski"}]}, {"text": "heart failure", "location": [3658, 3671], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "partOfMany", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.79386, "arguments": [{"text": "members", "location": [3765, 3772], "entities": [{"type": "Person", "text": "members"}]}, {"text": "leadership team", "location": [3790, 3805], "entities": [{"type": "Person", "text": "leadership team"}]}]}, {"type": "employedBy", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.452223, "arguments": [{"text": "leadership team", "location": [3790, 3805], "entities": [{"type": "Person", "text": "leadership team"}]}, {"text": "Seal Rock", "location": [3780, 3789], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}]}, {"type": "employedBy", "sentence": "SRT-015 is a potent, liver-selective ASK1 inhibitor for NASH.", "score": 0.366448, "arguments": [{"text": "NASH", "location": [699, 703], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "ASK1 inhibitor", "location": [680, 694], "entities": [{"type": "Organization", "text": "ASK1 Inhibitors"}]}]}, {"type": "residesIn", "sentence": "Additional members of the Seal Rock leadership team include Terry Porter , PhD, Senior Vice President, Business Development; and David Brown , PhD, Director, Chemistry.", "score": 0.67597, "arguments": [{"text": "David Brown", "location": [3883, 3894], "entities": [{"type": "Person", "text": "David Brown"}]}, {"text": "PhD", "location": [3897, 3900], "entities": [{"type": "GeopoliticalEntity", "text": "PhD"}]}]}, {"type": "employedBy", "sentence": "Dr. Porter previously served as vice president of search & evaluation within global business development at Takeda Pharmaceuticals.", "score": 0.571629, "arguments": [{"text": "vice president", "location": [3955, 3969], "entities": [{"type": "Person", "text": "Terry Porter"}]}, {"text": "Takeda Pharmaceuticals", "location": [4031, 4053], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, he was managing director at the corporate advisory group AquaPartners.", "score": 0.786842, "arguments": [{"text": "managing director", "location": [4077, 4094], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [4121, 4126], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "employedBy", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.477414, "arguments": [{"text": "member", "location": [4162, 4168], "entities": [{"type": "Person", "text": "managing director"}]}, {"text": "group", "location": [4207, 4212], "entities": [{"type": "Organization", "text": "AquaPartners"}]}]}, {"type": "partOf", "sentence": "He was also a senior member of the worldwide business development group at GlaxoSmithKline.", "score": 0.78002, "arguments": [{"text": "group", "location": [4207, 4212], "entities": [{"type": "Organization", "text": "AquaPartners"}]}, {"text": "GlaxoSmithKline", "location": [4216, 4231], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "During this time, he headed oncology licensing, created and led the external science and technology group and co-led GSK's $450 million acquisition of Domantis.", "score": 0.667072, "arguments": [{"text": "GSK", "location": [4350, 4353], "entities": [{"type": "Organization", "text": "GSK"}]}, {"text": "acquisition", "location": [4369, 4380], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "residesIn", "sentence": "Prior to that, he spent 12 years at Exelixis where his kinase work contributed to 5 clinical candidates in the areas of oncology and inflammation.", "score": 0.421297, "arguments": [{"text": "candidates", "location": [4639, 4649], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "areas", "location": [4657, 4662], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "hasAttribute", "sentence": "About NASH NASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects one in four individuals worldwide, making it one of the most common chronic liver diseases.", "score": 0.608891, "arguments": [{"text": "NASH\nNASH", "location": [4699, 4708], "entities": [{"type": "Person", "text": "NASH\nNASH"}]}, {"text": "disease", "location": [4748, 4755], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "NAFLD is associated with metabolic conditions such as obesity, diabetes, and high cholesterol.", "score": 0.790092, "arguments": [{"text": "NAFLD", "location": [4869, 4874], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "diabetes", "location": [4932, 4940], "entities": [{"type": "HealthCondition", "text": "diabetes"}]}]}, {"type": "agentOf", "sentence": "NAFLD is typically characterized as either fatty liver or steatohepatitis.", "score": 0.969466, "arguments": [{"text": "NAFLD", "location": [4964, 4969], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "characterized", "location": [4983, 4996], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "agentOf", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.702372, "arguments": [{"text": "NASH", "location": [5130, 5134], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "characterized", "location": [5187, 5200], "entities": [{"type": "EventCommunication", "text": "characterized"}]}]}, {"type": "educatedAt", "sentence": "The candidate was internally discovered and optimized by Seal Rock Therapeutics to improve upon and avoid dose-limiting liabilities demonstrated by other investigative approaches.", "score": 0.365602, "arguments": [{"text": "candidate", "location": [709, 718], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Seal Rock Therapeutics", "location": [762, 784], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}]}, {"type": "hasAttribute", "sentence": "NASH, which is steatohepatitis not caused by alcohol, is characterized by inflammation of the liver, which progresses to fibrotic remodeling (scarring) in 30-50% of individuals, increasing the risk for cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC, liver cancer).", "score": 0.561306, "arguments": [{"text": "individuals", "location": [5295, 5306], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "cirrhosis", "location": [5332, 5341], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.694633, "arguments": [{"text": "NASH", "location": [5415, 5419], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "liver transplantation", "location": [5461, 5482], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "hasAttribute", "sentence": "NASH is currently the second leading cause of liver transplantation overall, and the leading cause in women.", "score": 0.676101, "arguments": [{"text": "women", "location": [5517, 5522], "entities": [{"type": "Person", "text": "women"}]}, {"text": "liver transplantation", "location": [5461, 5482], "entities": [{"type": "HealthCondition", "text": "liver transplantation"}]}]}, {"type": "locatedAt", "sentence": "About Seal Rock Therapeutics Seal Rock Therapeutics is a privately held, discovery stage company based in Seattle focused on the development of best-in-class treatments for inflammatory and fibrotic diseases with no available therapies.", "score": 0.738152, "arguments": [{"text": "company", "location": [5719, 5726], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}, {"text": "Seattle", "location": [5736, 5743], "entities": [{"type": "GeopoliticalEntity", "text": "SEATTLE"}]}]}, {"type": "employedBy", "sentence": "The company's lead product candidate, SRT-015, is a differentiated ASK1 inhibitor for NASH.", "score": 0.381222, "arguments": [{"text": "candidate", "location": [5894, 5903], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "company", "location": [5871, 5878], "entities": [{"type": "Organization", "text": "Seal Rock Therapeutics, Inc.\nPreclinical Findings Highlight Potent Efficacy"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.592035, "arguments": [{"text": "Keystone Symposia Integrated Pathways", "location": [1303, 1340], "entities": [{"type": "Organization", "text": "Keystone Symposia Integrated Pathways"}]}, {"text": "meeting", "location": [1370, 1377], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "hasAttribute", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.658529, "arguments": [{"text": "NASH", "location": [1355, 1359], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "Disease", "location": [1344, 1351], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.67241, "arguments": [{"text": "NASH", "location": [1355, 1359], "entities": [{"type": "Person", "text": "NASH start-up"}]}, {"text": "meeting", "location": [1370, 1377], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "participantIn", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.960106, "arguments": [{"text": "NAFLD", "location": [1364, 1369], "entities": [{"type": "Person", "text": "NAFLD"}]}, {"text": "meeting", "location": [1370, 1377], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "locatedAt", "sentence": "These findings will be presented at the Keystone Symposia Integrated Pathways of Disease in NASH and NAFLD meeting, in Santa Fe, New Mexico , January 20-24, 2019.", "score": 0.854132, "arguments": [{"text": "meeting", "location": [1370, 1377], "entities": [{"type": "EventMeeting", "text": "meeting"}]}, {"text": "Santa Fe", "location": [1382, 1390], "entities": [{"type": "GeopoliticalEntity", "text": "Santa Fe"}]}]}], "keywords": [{"text": "Seal Rock Therapeutics", "sentiment": {"score": 0.347804, "label": "positive"}, "relevance": 0.925938}, {"text": "discovery stage company", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.644987}, {"text": "senior vice president", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.64114}, {"text": "NASH", "sentiment": {"score": 0.153021, "label": "positive"}, "relevance": 0.64055}, {"text": "ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.635503}, {"text": "Gubra therapeutic NASH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.633744}, {"text": "fatty liver", "sentiment": {"score": -0.396179, "label": "negative"}, "relevance": 0.622559}, {"text": "patent application", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.617822}, {"text": "Seal Rock leadership", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.610557}, {"text": "preclinical proof-of-concept findings", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.610362}, {"text": "Preclinical Findings Highlight", "sentiment": {"score": 0.454247, "label": "positive"}, "relevance": 0.60917}, {"text": "liver-selective ASK1 inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.608337}, {"text": "business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.604066}, {"text": "fatty liver disease", "sentiment": {"score": -0.369421, "label": "negative"}, "relevance": 0.601594}, {"text": "preclinical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597913}, {"text": "ASK1 inhibitor compounds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59643}, {"text": "PI3Kdelta kinase inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.596052}, {"text": "chronic liver diseases", "sentiment": {"score": -0.695458, "label": "negative"}, "relevance": 0.595608}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": -0.520894, "label": "negative"}, "relevance": 0.593704}, {"text": "worldwide patent application", "sentiment": {"score": 0.233112, "label": "positive"}, "relevance": 0.593291}, {"text": "International Patent Application", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592374}, {"text": "metabolic disease pharmacology", "sentiment": {"score": -0.499214, "label": "negative"}, "relevance": 0.592302}, {"text": "differentiated ASK1 inhibitor", "sentiment": {"score": -0.272078, "label": "negative"}, "relevance": 0.589332}, {"text": "inflammation therapeutic areas", "sentiment": {"score": -0.409165, "label": "negative"}, "relevance": 0.587907}, {"text": "ASK1 Inhibitors Published", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587676}, {"text": "best-in-class treatments", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.587581}, {"text": "international PCT patent", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585552}, {"text": "NASH start-up", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585275}, {"text": "Akarna Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583586}, {"text": "worldwide business development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58257}, {"text": "mouse model", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.582161}, {"text": "Vice President Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.582121}, {"text": "Neil McDonnell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581735}, {"text": "international patent law", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580951}, {"text": "global business development", "sentiment": {"score": -0.542574, "label": "negative"}, "relevance": 0.579897}, {"text": "therapeutic area leader", "sentiment": {"score": -0.528252, "label": "negative"}, "relevance": 0.578702}, {"text": "fibrotic diseases", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.578638}, {"text": "myosin activator therapeutic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578468}, {"text": "Pathway Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578221}, {"text": "Patent Cooperation Treaty", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576358}, {"text": "available therapies", "sentiment": {"score": -0.568746, "label": "negative"}, "relevance": 0.575676}, {"text": "obesity drug Contrave", "sentiment": {"score": -0.205465, "label": "negative"}, "relevance": 0.575484}, {"text": "drug development efforts", "sentiment": {"score": -0.486984, "label": "negative"}, "relevance": 0.575298}, {"text": "significant positive effects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574223}, {"text": "major pharmaceutical markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573758}, {"text": "corporate advisory group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.572882}, {"text": "Symposia Integrated Pathways", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57285}, {"text": "liver fibrosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570227}, {"text": "differentiated inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569279}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569139}]}, "extracted_metadata": {"sha1": "d7d96171224a603e449cb1cdbcd8cfb74d41f718", "filename": "1542118577746.zip-fbfbb74fb5a8ee66690582642f5d44af.xml", "file_type": "json"}, "external_links": ["http://www.sealrocktx.com/", "http://www.xmlnews.org/ns/", "http://www.prnewswire.com/news-releases/seal-rock-therapeutics-advancing-differentiated-ask1-inhibitor-lead-candidate-srt-015-in-nonalcoholic-steatohepatitis-nash-300747392.html"], "title": "Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor L", "forum_title": "Biotechnology"}, {"id": "b_HCI2BGmn7aU8M22hmzjOJuBaZqr06jBeissDvf10-wMph_z8t39BNIE-a_6MXk", "result_metadata": {"score": 33.350792}, "author": "Asif Suria", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Arbitrage", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Arbitrage"}, {"text": "Risk arbitrage", "relevance": 0.8704, "dbpedia_resource": "http://dbpedia.org/resource/Risk_arbitrage"}], "categories": [{"score": 0.984504, "label": "/business and industrial/company/merger and acquisition"}], "relations": [], "keywords": [{"text": "Merger Arbitrage Mondays", "sentiment": {"score": 0.41854, "label": "positive"}, "relevance": 0.987121}]}, "crawl_date": "2018-11-13T11:40:40Z", "url": "https://seekingalpha.com/article/4221602-merger-arbitrage-mondays-november-12-2018", "host": "seekingalpha.com", "text": "November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "main_image_url": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T06:14:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barrick Gold Corporation", "relevance": 0.533369, "type": "Company", "disambiguation": {"subtype": [], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Finisar Corporation", "relevance": 0.487477, "type": "Company", "disambiguation": {"subtype": [], "name": "Finisar", "dbpedia_resource": "http://dbpedia.org/resource/Finisar"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vista Equity Partners", "relevance": 0.422415, "type": "Company", "disambiguation": {"subtype": [], "name": "Vista Equity Partners", "dbpedia_resource": "http://dbpedia.org/resource/Vista_Equity_Partners"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "K2M Group Holdings", "relevance": 0.415688, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.269682, "label": "positive"}, "text": "Stryker Corporation", "relevance": 0.394826, "type": "Company", "disambiguation": {"subtype": [], "name": "Stryker Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Stryker_Corporation"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "magicJack", "relevance": 0.382066, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Datawatch Corporation", "relevance": 0.379138, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ITG", "relevance": 0.36304, "type": "Company", "disambiguation": {"subtype": [], "name": "Investment Technology Group", "dbpedia_resource": "http://dbpedia.org/resource/Investment_Technology_Group"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ConversionPoint Technologies", "relevance": 0.361077, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Black Box Corporation", "relevance": 0.354627, "type": "Company", "disambiguation": {"subtype": [], "name": "Black Box Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Black_Box_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asterias Biotherapeutics", "relevance": 0.34654, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ready Capital Corporation", "relevance": 0.345843, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ConvergeOne Holdings", "relevance": 0.340602, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Avista Corporation", "relevance": 0.333694, "type": "Company", "disambiguation": {"subtype": [], "name": "Avista", "dbpedia_resource": "http://dbpedia.org/resource/Avista"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Randgold Resources", "relevance": 0.33006, "type": "Company", "disambiguation": {"subtype": [], "name": "Randgold Resources", "dbpedia_resource": "http://dbpedia.org/resource/Randgold_Resources"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asterias", "relevance": 0.327744, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Gas Equity Partners", "relevance": 0.326779, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ready Capital", "relevance": 0.325588, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Gas Partners", "relevance": 0.325345, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "II-VI Incorporated", "relevance": 0.325296, "type": "Company", "disambiguation": {"subtype": [], "name": "II-VI Incorporated", "dbpedia_resource": "http://dbpedia.org/resource/II-VI_Incorporated"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ITG", "relevance": 0.324916, "type": "Organization", "disambiguation": {"subtype": [], "name": "Investment Technology Group", "dbpedia_resource": "http://dbpedia.org/resource/Investment_Technology_Group"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Altair", "relevance": 0.32176, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "WGP", "relevance": 0.319933, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Virtu Financial", "relevance": 0.317622, "type": "Company", "disambiguation": {"subtype": [], "name": "Virtu Financial", "dbpedia_resource": "http://dbpedia.org/resource/Virtu_Financial"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "WES", "relevance": 0.310243, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Thomas H. Lee Partners", "relevance": 0.308455, "type": "Company", "disambiguation": {"subtype": [], "name": "Thomas H. Lee Partners", "dbpedia_resource": "http://dbpedia.org/resource/Thomas_H._Lee_Partners"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Owens Realty Mortgage", "relevance": 0.307796, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inuvo", "relevance": 0.306628, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.507687, "label": "positive"}, "text": "Walt Disney", "relevance": 0.306278, "type": "Person", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "AwardNominee", "AwardWinner", "ComicBookCreator", "CompanyFounder", "FilmActor", "FilmDirector", "FilmProducer", "HallOfFameInductee", "TVActor", "VisualArtist", "FilmWriter"], "name": "Walt Disney", "dbpedia_resource": "http://dbpedia.org/resource/Walt_Disney"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ARRS", "relevance": 0.30614, "type": "Organization", "disambiguation": {"subtype": [], "name": "American Roentgen Ray Society", "dbpedia_resource": "http://dbpedia.org/resource/American_Roentgen_Ray_Society"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bojangles", "relevance": 0.303539, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CVC Fund VII", "relevance": 0.302956, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dun & Bradstreet", "relevance": 0.301609, "type": "Company", "disambiguation": {"subtype": [], "name": "Dun & Bradstreet", "dbpedia_resource": "http://dbpedia.org/resource/Dun_&_Bradstreet"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Editor", "relevance": 0.299817, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ARRIS International", "relevance": 0.297488, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AGC Networks", "relevance": 0.296878, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.295401, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Durational Capital Management", "relevance": 0.295059, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "KLA-Tencor Corporation", "relevance": 0.293109, "type": "Company", "disambiguation": {"subtype": [], "name": "KLA Tencor", "dbpedia_resource": "http://dbpedia.org/resource/KLA_Tencor"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reliance Industries Limited", "relevance": 0.292092, "type": "Company", "disambiguation": {"subtype": [], "name": "Reliance Industries", "dbpedia_resource": "http://dbpedia.org/resource/Reliance_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.290683, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": -0.277783, "label": "negative"}, "text": "Hydro One Limited", "relevance": 0.290528, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Apptio", "relevance": 0.289459, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Washington", "relevance": 0.287802, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "MilitaryPost", "PlaceWithNeighborhoods", "USCounty", "City"], "name": "Washington, D.C.", "dbpedia_resource": "http://dbpedia.org/resource/Washington,_D.C."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Disney", "relevance": 0.286863, "type": "Company", "disambiguation": {"subtype": [], "name": "The Walt Disney Company", "dbpedia_resource": "http://dbpedia.org/resource/The_Walt_Disney_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CC Capital Partners LLC", "relevance": 0.286129, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.285929, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "B. Riley Financial", "relevance": 0.283037, "type": "Company"}], "sentiment": {"document": {"score": 0.533431, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Merger activity", "keywords": [{"text": "Merger activity"}]}, "sentence": "Merger activity increased last week with twelve new deals announced and three pending deals closing.", "action": {"verb": {"text": "increase", "tense": "past"}, "text": "increased", "normalized": "increase"}}, {"subject": {"text": "We"}, "sentence": " We added DWCH as a potential deal to the Deals in the Works section on January 5, 2018, and the price after the news of the potential deal came out was $11.40.", "object": {"text": "DWCH", "keywords": [{"text": "DWCH"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "added", "normalized": "add"}}, {"subject": {"text": "the news of the potential deal", "keywords": [{"text": "potential deal"}, {"text": "news"}]}, "sentence": " We added DWCH as a potential deal to the Deals in the Works section on January 5, 2018, and the price after the news of the potential deal came out was $11.40.", "object": {"text": "$11.40", "entities": [{"type": "Quantity", "text": "$11.40"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We added BOJA as a potential deal to the Deals in the Works section on September 28, 2018, and the price after the news of the potential deal came out was $15.70.", "object": {"text": "BOJA", "keywords": [{"text": "BOJA"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "added", "normalized": "add"}}, {"subject": {"text": "the news of the potential deal", "keywords": [{"text": "potential deal"}, {"text": "news"}]}, "sentence": " We added BOJA as a potential deal to the Deals in the Works section on September 28, 2018, and the price after the news of the potential deal came out was $15.70.", "object": {"text": "$15.70", "entities": [{"type": "Quantity", "text": "$15.70"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We added ITG as a potential deal to the Deals in the Works section on October 4, 2018, and the price after the news of the potential deal came out was $27.65.", "object": {"text": "ITG", "entities": [{"type": "Company", "text": "ITG", "disambiguation": {"subtype": [], "name": "Investment Technology Group", "dbpedia_resource": "http://dbpedia.org/resource/Investment_Technology_Group"}}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "added", "normalized": "add"}}, {"subject": {"text": "the news of the potential deal", "keywords": [{"text": "potential deal"}, {"text": "news"}]}, "sentence": " We added ITG as a potential deal to the Deals in the Works section on October 4, 2018, and the price after the news of the potential deal came out was $27.65.", "object": {"text": "$27.65", "entities": [{"type": "Quantity", "text": "$27.65"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "each ORM share", "keywords": [{"text": "ORM share"}]}, "sentence": " Under the terms of the agreement, each ORM share will be converted into 1.441 Ready Capital shares, based on a fixed exchange ratio.", "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be converted", "normalized": "will be convert"}}, {"subject": {"text": "each ORM share", "keywords": [{"text": "ORM share"}]}, "sentence": " Under the terms of the agreement, each ORM share will be converted into 1.441 Ready Capital shares, based on a fixed exchange ratio.", "object": {"text": "into 1.441 Ready Capital shares, based on a fixed exchange ratio", "keywords": [{"text": "fixed exchange ratio"}, {"text": "Ready Capital shares"}], "entities": [{"type": "Company", "text": "Ready Capital"}]}, "action": {"verb": {"text": "convert", "tense": "future"}, "text": "will be converted", "normalized": "will be convert"}}, {"subject": {"text": "The exchange ratio", "keywords": [{"text": "exchange ratio"}]}, "sentence": " The exchange ratio is subject to certain adjustments if either company\u2019s book value per share, as defined in the merger agreement, declines by more than 3%.", "object": {"text": "subject to certain adjustments", "keywords": [{"text": "certain adjustments"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "either company", "keywords": [{"text": "company"}]}, "sentence": " The exchange ratio is subject to certain adjustments if either company\u2019s book value per share, as defined in the merger agreement, declines by more than 3%.", "object": {"text": "book value", "keywords": [{"text": "book value"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Asterias stockholders", "keywords": [{"text": "Asterias stockholders"}], "entities": [{"type": "Company", "text": "Asterias"}]}, "sentence": " Under the terms of the merger agreement, Asterias stockholders will receive 0.71 common share of BioTime for each share of common stock of Asterias they own.", "object": {"text": "0.71 common share of BioTime", "keywords": [{"text": "common share"}, {"text": "BioTime"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "they"}, "sentence": " Under the terms of the merger agreement, Asterias stockholders will receive 0.71 common share of BioTime for each share of common stock of Asterias they own.", "object": {"text": "Asterias"}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "own", "normalized": "own"}}, {"subject": {"text": "the public unitholders of WES", "keywords": [{"text": "WES"}, {"text": "public unitholders"}], "entities": [{"type": "Company", "text": "WES"}]}, "sentence": " Under the terms of the Agreement, the public unitholders of WES will receive 1.525 units of WGP per WES unit owned.", "object": {"text": "1.525 units of WGP per WES unit owned", "keywords": [{"text": "WES unit"}, {"text": "WGP"}, {"text": "units"}], "entities": [{"type": "Company", "text": "Western Gas Partners"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "Finisar", "keywords": [{"text": "Finisar"}], "entities": [{"type": "Company", "text": "Finisar Corporation", "disambiguation": {"subtype": [], "name": "Finisar", "dbpedia_resource": "http://dbpedia.org/resource/Finisar"}}]}, "sentence": " Under the terms of the agreement, Finisar\u2019s stockholders will receive $15.60 per share in cash and 0.2218 shares of II-VI common stock.", "object": {"text": "stockholders will receive $15.60 per share in cash and 0.2218 shares of II-VI common stock", "keywords": [{"text": "II-VI common stock"}, {"text": "stockholders"}, {"text": "cash"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "$15.60"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Finisar\u2019s stockholders", "keywords": [{"text": "Finisar"}, {"text": "stockholders"}], "entities": [{"type": "Company", "text": "Finisar Corporation", "disambiguation": {"subtype": [], "name": "Finisar", "dbpedia_resource": "http://dbpedia.org/resource/Finisar"}}]}, "sentence": " Under the terms of the agreement, Finisar\u2019s stockholders will receive $15.60 per share in cash and 0.2218 shares of II-VI common stock.", "object": {"text": "$15.60 per share in cash and 0.2218 shares of II-VI common stock", "keywords": [{"text": "II-VI common stock"}, {"text": "cash"}, {"text": "share"}, {"text": "shares"}], "entities": [{"type": "Quantity", "text": "$15.60"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "2018, Barrick Gold Corporation ( ABX )", "keywords": [{"text": "Barrick Gold Corporation"}, {"text": "ABX"}], "entities": [{"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"type": "Company", "text": "ABX"}]}, "sentence": " On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company\u2019s shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "object": {"text": "that the company\u2019s shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD )", "keywords": [{"text": "Barrick common shares"}, {"text": "Randgold Resources Limited"}, {"text": "GOLD )"}, {"text": "issuance"}], "entities": [{"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"type": "Company", "text": "Randgold Resources Limited"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company\u2019s shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "object": {"text": "shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD )", "keywords": [{"text": "Barrick common shares"}, {"text": "Randgold Resources Limited"}, {"text": "GOLD )"}, {"text": "issuance"}], "entities": [{"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"type": "Company", "text": "Randgold Resources Limited"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the company\u2019s shareholders", "keywords": [{"text": "shareholders"}, {"text": "company"}]}, "sentence": " On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company\u2019s shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "object": {"text": "to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD )", "keywords": [{"text": "Barrick common shares"}, {"text": "Randgold Resources Limited"}, {"text": "GOLD )"}, {"text": "issuance"}], "entities": [{"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}, {"type": "Company", "text": "Randgold Resources Limited"}]}, "action": {"verb": {"text": "vote", "tense": "past"}, "text": "voted", "normalized": "vote"}}, {"subject": {"text": "B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL )", "keywords": [{"text": "magicJack VocalTec"}, {"text": "B. Riley Financial"}], "entities": [{"type": "Company", "text": "B. Riley Financial"}, {"type": "Company", "text": "magicJack"}]}, "sentence": " On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley\u2019s pending acquisition of magicJack.", "object": {"text": "that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley\u2019s pending acquisition of magicJack", "keywords": [{"text": "U.S. Federal Communications"}, {"text": "regulatory approval"}, {"text": "B. Riley"}, {"text": "magicJack"}], "entities": [{"type": "Organization", "text": "U.S. Federal Communications Commission"}, {"type": "Person", "text": "B. Riley"}, {"type": "Company", "text": "magicJack"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The parties", "keywords": [{"text": "parties"}]}, "sentence": " The parties have agreed to a scheduled closing date of November 14, 2018.", "object": {"text": "to a scheduled closing date of November 14, 2018", "keywords": [{"text": "closing date"}]}, "action": {"verb": {"text": "agree", "tense": "past"}, "text": "have agreed", "normalized": "have agree"}}, {"subject": {"text": "Walt Disney", "keywords": [{"text": "Walt Disney"}], "entities": [{"type": "Person", "text": "Walt Disney", "disambiguation": {"subtype": ["Actor", "MusicalArtist", "AwardNominee", "AwardWinner", "ComicBookCreator", "CompanyFounder", "FilmActor", "FilmDirector", "FilmProducer", "HallOfFameInductee", "TVActor", "VisualArtist", "FilmWriter"], "name": "Walt Disney", "dbpedia_resource": "http://dbpedia.org/resource/Walt_Disney"}}]}, "sentence": " On November 6, 2018, Walt Disney's ( DIS ) offer to buy Twenty-First Century Fox Inc's ( FOXA ) entertainment assets won approval from the European Commission , subject to Disney selling interests in factual TV channels in Europe.", "object": {"text": "Twenty-First Century Fox Inc", "keywords": [{"text": "Twenty-First Century Fox"}], "entities": [{"type": "Company", "text": "Century Fox Inc"}]}, "action": {"verb": {"text": "buy", "tense": "future"}, "text": "to buy", "normalized": "to buy"}}, {"subject": {"text": "entertainment assets", "keywords": [{"text": "entertainment assets"}]}, "sentence": " On November 6, 2018, Walt Disney's ( DIS ) offer to buy Twenty-First Century Fox Inc's ( FOXA ) entertainment assets won approval from the European Commission , subject to Disney selling interests in factual TV channels in Europe.", "object": {"text": "approval from the European Commission", "keywords": [{"text": "approval"}, {"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "action": {"verb": {"text": "win", "tense": "past"}, "text": "won", "normalized": "win"}}, {"subject": {"text": "Randgold Resources shareholders", "keywords": [{"text": "Randgold Resources shareholders"}], "entities": [{"type": "Company", "text": "Randgold Resources", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Randgold Resources", "dbpedia_resource": "http://dbpedia.org/resource/Randgold_Resources"}}]}, "sentence": " On November 7, 2018, Randgold Resources shareholders approved the all-stock takeover by Barrick Gold.", "object": {"text": "the all-stock takeover by Barrick Gold", "keywords": [{"text": "all-stock takeover"}, {"text": "Barrick Gold"}], "entities": [{"type": "Company", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Barrick Gold", "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA )", "keywords": [{"text": "Avista Corporation"}, {"text": "AVA"}, {"text": "Hydro"}, {"text": "HRNNF"}], "entities": [{"type": "Company", "text": "Hydro One Limited"}, {"type": "Company", "text": "Avista Corporation", "disambiguation": {"subtype": [], "name": "Avista", "dbpedia_resource": "http://dbpedia.org/resource/Avista"}}]}, "sentence": " On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "object": {"text": "the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon", "keywords": [{"text": "new Avista Board"}, {"text": "utility commissions"}, {"text": "independent directors"}, {"text": "merger"}], "entities": [{"type": "Organization", "text": "Avista Board of Directors"}, {"type": "Location", "text": "Washington", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "MilitaryPost", "PlaceWithNeighborhoods", "USCounty", "CityTown", "City"], "name": "Washington, D.C.", "dbpedia_resource": "http://dbpedia.org/resource/Washington,_D.C."}}, {"type": "Location", "text": "Idaho", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Idaho", "dbpedia_resource": "http://dbpedia.org/resource/Idaho"}}, {"type": "Location", "text": "Oregon", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the proposed merger", "keywords": [{"text": "merger"}]}, "sentence": " On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "action": {"verb": {"text": "approve", "tense": "past"}, "text": "is approved", "normalized": "be approve"}}, {"subject": {"text": "Dun & Bradstreet ( DNB )", "keywords": [{"text": "Bradstreet"}, {"text": "DNB"}, {"text": "Dun"}], "entities": [{"type": "Company", "text": "Dun & Bradstreet", "disambiguation": {"subtype": ["Company"], "name": "Dun & Bradstreet", "dbpedia_resource": "http://dbpedia.org/resource/Dun_&_Bradstreet"}}]}, "sentence": " On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M.", "object": {"text": "that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M", "keywords": [{"text": "K2M Group Holdings"}, {"text": "Austin Merger Sub"}, {"text": "CC Capital Partners"}, {"text": "merger transaction"}], "entities": [{"type": "Company", "text": "CC Capital Partners LLC"}, {"type": "Company", "text": "Bilcar"}, {"type": "Company", "text": "Cannae Holdings"}, {"type": "Organization", "text": "CNNE"}, {"type": "Company", "text": "Thomas H. Lee Partners", "disambiguation": {"subtype": ["Company"], "name": "Thomas H. Lee Partners", "dbpedia_resource": "http://dbpedia.org/resource/Thomas_H._Lee_Partners"}}, {"type": "Company", "text": "K2M Group Holdings"}, {"type": "Company", "text": "Stryker Corporation", "disambiguation": {"subtype": ["Company"], "name": "Stryker Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Stryker_Corporation"}}, {"type": "Company", "text": "SYK"}, {"type": "Company", "text": "Austin Merger Sub Corp."}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7", "keywords": [{"text": "CC Capital Partners"}, {"text": "Thomas H. Lee"}, {"text": "Cannae Holdings"}, {"text": "affiliates"}], "entities": [{"type": "Company", "text": "CC Capital Partners LLC"}, {"type": "Company", "text": "Bilcar"}, {"type": "Company", "text": "Cannae Holdings"}, {"type": "Organization", "text": "CNNE"}, {"type": "Company", "text": "Thomas H. Lee Partners", "disambiguation": {"subtype": ["Company"], "name": "Thomas H. Lee Partners", "dbpedia_resource": "http://dbpedia.org/resource/Thomas_H._Lee_Partners"}}]}, "sentence": " On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M.", "object": {"text": "an investor group", "keywords": [{"text": "investor group"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "Takeda Pharmaceutical ( OTCPK:TKPHF )", "keywords": [{"text": "TKPHF"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "object": {"text": "that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8", "keywords": [{"text": "investor backing"}, {"text": "Shire"}, {"text": "acquisition"}, {"text": "deal"}], "entities": []}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "it"}, "sentence": " November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "object": {"text": "to close the deal on January 8", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "aim", "tense": "present"}, "text": "aims", "normalized": "aim"}}, {"subject": {"text": "it"}, "sentence": " November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "close", "tense": "future"}, "text": "aims to close", "normalized": "aim to close"}}, {"subject": {"text": "it"}, "sentence": " Takeda also said that it would hold an extraordinary general meeting of shareholders to vote on the purchase on December 5, 2018.", "object": {"text": "an extraordinary general meeting of shareholders", "keywords": [{"text": "extraordinary general meeting"}, {"text": "shareholders"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "would hold", "normalized": "would hold"}}, {"subject": {"text": "an extraordinary general meeting of shareholders", "keywords": [{"text": "extraordinary general meeting"}, {"text": "shareholders"}]}, "sentence": " Takeda also said that it would hold an extraordinary general meeting of shareholders to vote on the purchase on December 5, 2018.", "object": {"text": "on the purchase", "keywords": [{"text": "purchase"}]}, "action": {"verb": {"text": "vote", "tense": "future"}, "text": "to vote", "normalized": "to vote"}}, {"subject": {"text": "It"}, "sentence": " It took 117 days for this deal to be completed.", "object": {"text": "117 days", "entities": [{"type": "Quantity", "text": "117 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 117 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It took 62 days for this deal to be completed.", "object": {"text": "62 days", "entities": [{"type": "Quantity", "text": "62 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 62 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It took 71 days for this deal to be completed.", "object": {"text": "71 days", "entities": [{"type": "Quantity", "text": "71 days"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "this deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " It took 71 days for this deal to be completed.", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Please"}, "sentence": " Please do your own due diligence before buying or selling any securities mentioned in this article.", "object": {"text": "your own"}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "any securities", "keywords": [{"text": "securities"}]}, "sentence": " Please do your own due diligence before buying or selling any securities mentioned in this article.", "action": {"verb": {"text": "mention", "tense": "past"}, "text": "mentioned", "normalized": "mention"}}, {"subject": {"text": "We"}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "object": {"text": "not warrant the completeness or accuracy of the content or data provided in this article", "keywords": [{"text": "completeness"}, {"text": "accuracy"}, {"text": "content"}, {"text": "data"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "We"}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "object": {"text": "the completeness or accuracy of the content or data provided in this article", "keywords": [{"text": "completeness"}, {"text": "accuracy"}, {"text": "content"}, {"text": "data"}]}, "action": {"verb": {"text": "warrant", "tense": "present", "negated": true}, "text": "warrant", "normalized": "warrant"}}, {"subject": {"text": "the content or data", "keywords": [{"text": "content"}, {"text": "data"}]}, "sentence": " We do not warrant the completeness or accuracy of the content or data provided in this article.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "I am/we"}, "sentence": " Disclosure: I am/we are long FNSR, COL, P, RSYS, CALL.", "object": {"text": "long FNSR", "keywords": [{"text": "long FNSR"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "I"}, "sentence": " I wrote this article myself, and it expresses my own opinions.", "object": {"text": "myself"}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "it"}, "sentence": " I wrote this article myself, and it expresses my own opinions.", "object": {"text": "my own opinions", "keywords": [{"text": "opinions"}]}, "action": {"verb": {"text": "express", "tense": "present"}, "text": "expresses", "normalized": "express"}}, {"subject": {"text": "I"}, "sentence": " I am not receiving compensation for it.", "object": {"text": "not receiving compensation for it", "keywords": [{"text": "compensation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "I"}, "sentence": " I am not receiving compensation for it.", "object": {"text": "compensation", "keywords": [{"text": "compensation"}]}, "action": {"verb": {"text": "receive", "tense": "present", "negated": true}, "text": "receiving", "normalized": "receive"}}, {"subject": {"text": "I"}, "sentence": " I have no business relationship with any company whose stock is mentioned in this article.", "object": {"text": "no business relationship with any company whose stock is mentioned in this article", "keywords": [{"text": "business relationship"}, {"text": "company"}, {"text": "stock"}, {"text": "article"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}], "concepts": [{"text": "Stock", "relevance": 0.978629, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Barrick Gold", "relevance": 0.735132, "dbpedia_resource": "http://dbpedia.org/resource/Barrick_Gold"}, {"text": "Stock market", "relevance": 0.690482, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Shareholder", "relevance": 0.569055, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "Share", "relevance": 0.498561, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}], "categories": [{"score": 0.807276, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.365222, "label": "/finance/financial news"}, {"score": 0.293253, "label": "/finance/investing"}], "relations": [{"type": "timeOf", "sentence": "Merger activity increased last week with twelve new deals announced and three pending deals closing.", "score": 0.868, "arguments": [{"text": "last week", "location": [26, 35], "entities": [{"type": "Date", "text": "last week"}]}, {"text": "announced", "location": [58, 67], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Bojangles' ( BOJA ) by Durational Capital Management and The Jordan Company for $675.15 million, or $16.10 per share in cash.", "score": 0.413083, "arguments": [{"text": "Durational Capital Management", "location": [815, 844], "entities": [{"type": "Organization", "text": "Durational Capital Management", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [777, 788], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Bojangles' ( BOJA ) by Durational Capital Management and The Jordan Company for $675.15 million, or $16.10 per share in cash.", "score": 0.456142, "arguments": [{"text": "The Jordan Company", "location": [849, 867], "entities": [{"type": "Organization", "text": "The Jordan Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [777, 788], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of ConvergeOne Holdings ( CVON ) by affiliates of CVC Fund VII for $1.8 billion, or $12.50 per share in cash.", "score": 0.426743, "arguments": [{"text": "ConvergeOne Holdings", "location": [1100, 1120], "entities": [{"type": "Organization", "text": "ConvergeOne Holdings"}]}, {"text": "acquisition", "location": [1085, 1096], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of ConvergeOne Holdings ( CVON ) by affiliates of CVC Fund VII for $1.8 billion, or $12.50 per share in cash.", "score": 0.421708, "arguments": [{"text": "affiliates", "location": [1133, 1143], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "acquisition", "location": [1085, 1096], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "The acquisition of ConvergeOne Holdings ( CVON ) by affiliates of CVC Fund VII for $1.8 billion, or $12.50 per share in cash.", "score": 0.869752, "arguments": [{"text": "affiliates", "location": [1133, 1143], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "CVC Fund VII", "location": [1147, 1159], "entities": [{"type": "Organization", "text": "CVC Fund VII"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of ConvergeOne Holdings ( CVON ) by affiliates of CVC Fund VII for $1.8 billion, or $12.50 per share in cash.", "score": 0.574163, "arguments": [{"text": "CVC Fund VII", "location": [1147, 1159], "entities": [{"type": "Organization", "text": "CVC Fund VII"}]}, {"text": "$1.8 billion", "location": [1164, 1176], "entities": [{"type": "Money", "text": "$1.8 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "affectedBy", "sentence": "The acquisition of Owens Realty Mortgage ( ORM ) by Ready Capital Corporation ( RC ) for $257.89 million in an all-stock deal.", "score": 0.426743, "arguments": [{"text": "Owens Realty Mortgage", "location": [1518, 1539], "entities": [{"type": "Organization", "text": "Owens Realty Mortgage"}]}, {"text": "acquisition", "location": [1503, 1514], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Owens Realty Mortgage ( ORM ) by Ready Capital Corporation ( RC ) for $257.89 million in an all-stock deal.", "score": 0.487994, "arguments": [{"text": "Ready Capital Corporation", "location": [1551, 1576], "entities": [{"type": "Organization", "text": "Ready Capital Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1503, 1514], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "The exchange ratio is subject to certain adjustments if either company's book value per share, as defined in the merger agreement, declines by more than 3%.", "score": 0.368161, "arguments": [{"text": "company", "location": [1822, 1829], "entities": [{"type": "Organization", "text": "Deals"}]}, {"text": "merger", "location": [1872, 1878], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of Asterias Biotherapeutics ( AST ) by BioTime ( BTX ) for $79.21 million in an all-stock deal.", "score": 0.426549, "arguments": [{"text": "Asterias Biotherapeutics", "location": [1935, 1959], "entities": [{"type": "Organization", "text": "Asterias Biotherapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1920, 1931], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "managerOf", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 141 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 47 Stock Deals 33 Stock & Cash Deals 17 Special Conditions 6 Total Number of Pending Deals 103 Total Deal Size $1.32 trillion New Deals: The acquisition of Datawatch Corporation ( DWCH ) by Altair ( ALTR ) for $176 million, or $13.10 per share in cash.", "score": 0.340966, "arguments": [{"text": "Cash Deals", "location": [273, 283], "entities": [{"type": "Person", "text": "Cash Deals"}]}, {"text": "Special Conditions 6 Total Number", "location": [287, 320], "entities": [{"type": "Organization", "text": "Special Conditions 6 Total Number"}]}]}, {"type": "employedBy", "sentence": "Under the terms of the merger agreement, Asterias stockholders will receive 0.71 common share of BioTime for each share of common stock of Asterias they own.", "score": 0.65971, "arguments": [{"text": "stockholders", "location": [2078, 2090], "entities": [{"type": "Person", "text": "stockholders"}]}, {"text": "Asterias", "location": [2069, 2077], "entities": [{"type": "Organization", "text": "Asterias Biotherapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "The acquisition of Western Gas Partners ( WES ) by Western Gas Equity Partners ( WGP ) for $11.47 billion in an all-stock deal.", "score": 0.422685, "arguments": [{"text": "Western Gas Partners", "location": [2205, 2225], "entities": [{"type": "Organization", "text": "Western Gas Equity Partners", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2190, 2201], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of ARRIS International ( ARRS ) by CommScope ( COMM ) for $7.4 billion, or $31.75 per share in cash.", "score": 0.420713, "arguments": [{"text": "ARRIS International", "location": [2449, 2468], "entities": [{"type": "Organization", "text": "ARRIS International"}]}, {"text": "acquisition", "location": [2434, 2445], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of ARRIS International ( ARRS ) by CommScope ( COMM ) for $7.4 billion, or $31.75 per share in cash.", "score": 0.484759, "arguments": [{"text": "CommScope", "location": [2481, 2490], "entities": [{"type": "Organization", "text": "CommScope", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2434, 2445], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "employedBy", "sentence": "Under the terms of the agreement, Finisar's stockholders will receive $15.60 per share in cash and 0.2218 shares of II-VI common stock.", "score": 0.658531, "arguments": [{"text": "stockholders", "location": [2715, 2727], "entities": [{"type": "Person", "text": "stockholders"}]}, {"text": "Finisar", "location": [2705, 2712], "entities": [{"type": "Organization", "text": "Finisar Corporation"}]}]}, {"type": "hasAttribute", "sentence": "Under the terms of the agreement, Finisar's stockholders will receive $15.60 per share in cash and 0.2218 shares of II-VI common stock.", "score": 0.679973, "arguments": [{"text": "stockholders", "location": [2715, 2727], "entities": [{"type": "Person", "text": "stockholders"}]}, {"text": "$15.60", "location": [2741, 2747], "entities": [{"type": "Money", "text": "$15.60", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "affectedBy", "sentence": "The acquisition of Black Box Corporation ( BBOX ) by AGC Networks for $209.52 million, or $1.08 per share in cash.", "score": 0.508056, "arguments": [{"text": "Black Box Corporation", "location": [2826, 2847], "entities": [{"type": "Organization", "text": "Black Box Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2811, 2822], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Black Box Corporation ( BBOX ) by AGC Networks for $209.52 million, or $1.08 per share in cash.", "score": 0.45794, "arguments": [{"text": "AGC Networks", "location": [2860, 2872], "entities": [{"type": "Organization", "text": "AGC Networks Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2811, 2822], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Black Box Corporation ( BBOX ) by AGC Networks for $209.52 million, or $1.08 per share in cash.", "score": 0.903104, "arguments": [{"text": "AGC Networks", "location": [2860, 2872], "entities": [{"type": "Organization", "text": "AGC Networks Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$209.52 million", "location": [2877, 2892], "entities": [{"type": "Money", "text": "$209.52 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "The acquisition of Apptio ( APTI ) by an affiliate of Vista Equity Partners for $1.94 billion, or $38.00 per share in cash.", "score": 0.414609, "arguments": [{"text": "Equity Partners", "location": [2982, 2997], "entities": [{"type": "Organization", "text": "Western Gas Equity Partners", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2926, 2937], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 141 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 47 Stock Deals 33 Stock & Cash Deals 17 Special Conditions 6 Total Number of Pending Deals 103 Total Deal Size $1.32 trillion New Deals: The acquisition of Datawatch Corporation ( DWCH ) by Altair ( ALTR ) for $176 million, or $13.10 per share in cash.", "score": 0.560133, "arguments": [{"text": "Special Conditions 6 Total Number", "location": [287, 320], "entities": [{"type": "Organization", "text": "Special Conditions 6 Total Number"}]}, {"text": "Pending Deals 103 Total Deal Size", "location": [324, 357], "entities": [{"type": "Organization", "text": "Pending Deals 103 Total Deal Size"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Apptio ( APTI ) by an affiliate of Vista Equity Partners for $1.94 billion, or $38.00 per share in cash.", "score": 0.897384, "arguments": [{"text": "Apptio", "location": [2941, 2947], "entities": [{"type": "Organization", "text": "Apptio"}]}, {"text": "APTI", "location": [2950, 2954], "entities": [{"type": "Ticker", "text": "APTI"}]}]}, {"type": "productOf", "sentence": "The acquisition of Apptio ( APTI ) by an affiliate of Vista Equity Partners for $1.94 billion, or $38.00 per share in cash.", "score": 0.511037, "arguments": [{"text": "Vista", "location": [2976, 2981], "entities": [{"type": "Product", "text": "Vista"}]}, {"text": "Apptio", "location": [2941, 2947], "entities": [{"type": "Organization", "text": "Apptio"}]}]}, {"type": "partOf", "sentence": "The acquisition of Apptio ( APTI ) by an affiliate of Vista Equity Partners for $1.94 billion, or $38.00 per share in cash.", "score": 0.413552, "arguments": [{"text": "Apptio", "location": [2941, 2947], "entities": [{"type": "Organization", "text": "Apptio"}]}, {"text": "Equity Partners", "location": [2982, 2997], "entities": [{"type": "Organization", "text": "Western Gas Equity Partners", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Apptio ( APTI ) by an affiliate of Vista Equity Partners for $1.94 billion, or $38.00 per share in cash.", "score": 0.861756, "arguments": [{"text": "Equity Partners", "location": [2982, 2997], "entities": [{"type": "Organization", "text": "Western Gas Equity Partners", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$1.94 billion", "location": [3002, 3015], "entities": [{"type": "Money", "text": "$1.94 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "timeOf", "sentence": "Deal Updates: On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company's shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "score": 0.871229, "arguments": [{"text": "November 5, 2018", "location": [3063, 3079], "entities": [{"type": "Date", "text": "November 5, 2018"}]}, {"text": "announced", "location": [3114, 3123], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Deal Updates: On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company's shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "score": 0.916459, "arguments": [{"text": "Barrick Gold Corporation", "location": [3081, 3105], "entities": [{"type": "Organization", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [3114, 3123], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Deal Updates: On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company's shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "score": 0.709432, "arguments": [{"text": "ABX", "location": [3108, 3111], "entities": [{"type": "Organization", "text": "Barrick Gold Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [3114, 3123], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Deal Updates: On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company's shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "score": 0.986256, "arguments": [{"text": "shareholders", "location": [3143, 3155], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3133, 3140], "entities": [{"type": "Organization", "text": "Apptio"}]}]}, {"type": "agentOf", "sentence": "Deal Updates: On November 5, 2018, Barrick Gold Corporation ( ABX ) announced that the company's shareholders have voted to approve the issuance of Barrick common shares in connection with the merger of Barrick and Randgold Resources Limited ( GOLD ).", "score": 0.347912, "arguments": [{"text": "shareholders", "location": [3143, 3155], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "merger", "location": [3239, 3245], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley's pending acquisition of magicJack.", "score": 0.644995, "arguments": [{"text": "November 6, 2018", "location": [3301, 3317], "entities": [{"type": "Date", "text": "November 6, 2018"}]}, {"text": "announced", "location": [3379, 3388], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley's pending acquisition of magicJack.", "score": 0.300851, "arguments": [{"text": "B. Riley Financial", "location": [3319, 3337], "entities": [{"type": "Person", "text": "B. Riley Financial"}]}, {"text": "CALL", "location": [3372, 3376], "entities": [{"type": "Organization", "text": "CALL"}]}]}, {"type": "agentOf", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 141 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 47 Stock Deals 33 Stock & Cash Deals 17 Special Conditions 6 Total Number of Pending Deals 103 Total Deal Size $1.32 trillion New Deals: The acquisition of Datawatch Corporation ( DWCH ) by Altair ( ALTR ) for $176 million, or $13.10 per share in cash.", "score": 0.509111, "arguments": [{"text": "Pending Deals 103 Total Deal Size", "location": [324, 357], "entities": [{"type": "Organization", "text": "Pending Deals 103 Total Deal Size"}]}, {"text": "acquisition", "location": [388, 399], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley's pending acquisition of magicJack.", "score": 0.536401, "arguments": [{"text": "B. Riley Financial", "location": [3319, 3337], "entities": [{"type": "Person", "text": "B. Riley Financial"}]}, {"text": "announced", "location": [3379, 3388], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOfMany", "sentence": "On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley's pending acquisition of magicJack.", "score": 0.890473, "arguments": [{"text": "B. Riley Financial", "location": [3319, 3337], "entities": [{"type": "Person", "text": "B. Riley Financial"}]}, {"text": "they", "location": [3394, 3398], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "partOf", "sentence": "On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley's pending acquisition of magicJack.", "score": 0.985636, "arguments": [{"text": "Federal Communications Commission", "location": [3447, 3480], "entities": [{"type": "Organization", "text": "Federal Communications Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "U.S.", "location": [3442, 3446], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley's pending acquisition of magicJack.", "score": 0.483986, "arguments": [{"text": "Federal Communications Commission", "location": [3447, 3480], "entities": [{"type": "Organization", "text": "Federal Communications Commission", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "acquisition", "location": [3511, 3522], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "On November 6, 2018, B. Riley Financial ( RILY ) and magicJack VocalTec ( CALL ) announced that they have received regulatory approval from the U.S. Federal Communications Commission related to B. Riley's pending acquisition of magicJack.", "score": 0.263273, "arguments": [{"text": "B. Riley", "location": [3492, 3500], "entities": [{"type": "Person", "text": "B. Riley Financial"}]}, {"text": "acquisition", "location": [3511, 3522], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "On November 6, 2018, Walt Disney's ( DIS ) offer to buy Twenty-First Century Fox Inc's ( FOXA ) entertainment assets won approval from the European Commission , subject to Disney selling interests in factual TV channels in Europe.", "score": 0.833846, "arguments": [{"text": "Twenty-First Century Fox Inc", "location": [3667, 3695], "entities": [{"type": "Organization", "text": "Twenty-First Century Fox Inc"}]}, {"text": "FOXA", "location": [3700, 3704], "entities": [{"type": "Ticker", "text": "FOXA"}]}]}, {"type": "timeOf", "sentence": "On November 7, 2018, Randgold Resources shareholders approved the all-stock takeover by Barrick Gold.", "score": 0.589971, "arguments": [{"text": "November 7, 2018", "location": [3845, 3861], "entities": [{"type": "Date", "text": "November 7, 2018"}]}, {"text": "takeover", "location": [3918, 3926], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "employedBy", "sentence": "On November 7, 2018, Randgold Resources shareholders approved the all-stock takeover by Barrick Gold.", "score": 0.495607, "arguments": [{"text": "shareholders", "location": [3882, 3894], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "Randgold Resources", "location": [3863, 3881], "entities": [{"type": "Organization", "text": "Randgold Resources Limited"}]}]}, {"type": "agentOf", "sentence": "On November 7, 2018, Randgold Resources shareholders approved the all-stock takeover by Barrick Gold.", "score": 0.958087, "arguments": [{"text": "Barrick Gold", "location": [3930, 3942], "entities": [{"type": "Person", "text": "Barrick Gold"}]}, {"text": "takeover", "location": [3918, 3926], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "timeOf", "sentence": "On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "score": 0.763247, "arguments": [{"text": "November 7, 2018", "location": [3947, 3963], "entities": [{"type": "Date", "text": "November 7, 2018"}]}, {"text": "announced", "location": [4028, 4037], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "hasAttribute", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 141 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 47 Stock Deals 33 Stock & Cash Deals 17 Special Conditions 6 Total Number of Pending Deals 103 Total Deal Size $1.32 trillion New Deals: The acquisition of Datawatch Corporation ( DWCH ) by Altair ( ALTR ) for $176 million, or $13.10 per share in cash.", "score": 0.465261, "arguments": [{"text": "Pending Deals 103 Total Deal Size", "location": [324, 357], "entities": [{"type": "Organization", "text": "Pending Deals 103 Total Deal Size"}]}, {"text": "ALTR", "location": [446, 450], "entities": [{"type": "Ticker", "text": "ALTR"}]}]}, {"type": "agentOf", "sentence": "On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "score": 0.874036, "arguments": [{"text": "Avista Corporation", "location": [4001, 4019], "entities": [{"type": "Organization", "text": "Avista Corporation"}]}, {"text": "announced", "location": [4028, 4037], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "score": 0.731183, "arguments": [{"text": "AVA", "location": [4022, 4025], "entities": [{"type": "Organization", "text": "Avista Corporation"}]}, {"text": "announced", "location": [4028, 4037], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "score": 0.757064, "arguments": [{"text": "directors", "location": [4059, 4068], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "announced", "location": [4028, 4037], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "score": 0.485206, "arguments": [{"text": "utility commissions", "location": [4164, 4183], "entities": [{"type": "Organization", "text": "utility commissions"}]}, {"text": "merger", "location": [4142, 4148], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "score": 0.539178, "arguments": [{"text": "utility commissions", "location": [4164, 4183], "entities": [{"type": "Organization", "text": "utility commissions"}]}, {"text": "Washington", "location": [4187, 4197], "entities": [{"type": "GeopoliticalEntity", "text": "Washington"}]}]}, {"type": "locatedAt", "sentence": "On November 7, 2018, Hydro One Limited ( OTC:HRNNF ) and Avista Corporation ( AVA ) announced the five independent directors selected to serve on the new Avista Board of Directors , if the proposed merger is approved by utility commissions in Washington, Idaho and Oregon.", "score": 0.706825, "arguments": [{"text": "Washington", "location": [4187, 4197], "entities": [{"type": "GeopoliticalEntity", "text": "Washington"}]}, {"text": "Idaho", "location": [4199, 4204], "entities": [{"type": "GeopoliticalEntity", "text": "Idaho"}]}]}, {"type": "agentOf", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.812551, "arguments": [{"text": "Dun & Bradstreet", "location": [4238, 4254], "entities": [{"type": "Organization", "text": "Dun & Bradstreet", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [4263, 4272], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.698592, "arguments": [{"text": "DNB", "location": [4257, 4260], "entities": [{"type": "Organization", "text": "Dun & Bradstreet", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [4263, 4272], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "employedBy", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.593747, "arguments": [{"text": "stockholders", "location": [4282, 4294], "entities": [{"type": "Person", "text": "stockholders"}]}, {"text": "its", "location": [4278, 4281], "entities": [{"type": "Organization", "text": "Avista Corporation"}]}]}, {"type": "affectedBy", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.719001, "arguments": [{"text": "investor group", "location": [4352, 4366], "entities": [{"type": "Organization", "text": "CC Capital Partners LLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "merger", "location": [4325, 4331], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.32023, "arguments": [{"text": "investor group", "location": [4352, 4366], "entities": [{"type": "Organization", "text": "CC Capital Partners LLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "affiliates", "location": [4374, 4384], "entities": [{"type": "Organization", "text": "affiliates"}]}]}, {"type": "partOf", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.563432, "arguments": [{"text": "affiliates", "location": [4374, 4384], "entities": [{"type": "Organization", "text": "affiliates"}]}, {"text": "CC Capital Partners LLC", "location": [4388, 4411], "entities": [{"type": "Organization", "text": "CC Capital Partners LLC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 141 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 47 Stock Deals 33 Stock & Cash Deals 17 Special Conditions 6 Total Number of Pending Deals 103 Total Deal Size $1.32 trillion New Deals: The acquisition of Datawatch Corporation ( DWCH ) by Altair ( ALTR ) for $176 million, or $13.10 per share in cash.", "score": 0.44829, "arguments": [{"text": "Altair", "location": [437, 443], "entities": [{"type": "Organization", "text": "Altair", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [388, 399], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.940417, "arguments": [{"text": "Cannae Holdings, Inc.", "location": [4426, 4447], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CNNE", "location": [4450, 4454], "entities": [{"type": "Ticker", "text": "CNNE"}]}]}, {"type": "employedBy", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.530257, "arguments": [{"text": "stockholders", "location": [4533, 4545], "entities": [{"type": "Person", "text": "stockholders"}]}, {"text": "K2M Group Holdings", "location": [4549, 4567], "entities": [{"type": "Organization", "text": "K2M Group Holdings"}]}]}, {"type": "hasAttribute", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.850623, "arguments": [{"text": "Takeda Pharmaceutical", "location": [4751, 4772], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TKPHF", "location": [4781, 4786], "entities": [{"type": "Ticker", "text": "TKPHF"}]}]}, {"type": "affectedBy", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.644164, "arguments": [{"text": "its", "location": [4838, 4841], "entities": [{"type": "Organization", "text": "Dun & Bradstreet", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [4842, 4853], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.661162, "arguments": [{"text": "Shire", "location": [4857, 4862], "entities": [{"type": "Organization", "text": "Shire"}]}, {"text": "acquisition", "location": [4842, 4853], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.818699, "arguments": [{"text": "next month", "location": [4872, 4882], "entities": [{"type": "Date", "text": "next month"}]}, {"text": "acquisition", "location": [4842, 4853], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "On November 7, 2018, Dun & Bradstreet ( DNB ) announced that its stockholders voted to approve the proposed merger transaction with an investor group led by affiliates of CC Capital Partners LLC, Bilcar, LLC, Cannae Holdings, Inc. ( CNNE ) and funds affiliated with Thomas H. Lee Partners, L.P. On November 7, 2018, stockholders of K2M Group Holdings ( KTWO ) approved the adoption of the Agreement and Plan of Merger by and among Stryker Corporation ( SYK ), Austin Merger Sub Corp. and K2M. November 12, 2018: According to Reuters, Takeda Pharmaceutical ( OTCPK:TKPHF ) announced that it will seek investor backing for its acquisition of Shire ( SHPG ) next month and aims to close the deal on January 8, 2019 .", "score": 0.920515, "arguments": [{"text": "Shire", "location": [4857, 4862], "entities": [{"type": "Organization", "text": "Shire"}]}, {"text": "SHPG", "location": [4865, 4869], "entities": [{"type": "Ticker", "text": "SHPG"}]}]}, {"type": "agentOf", "sentence": "Takeda also said that it would hold an extraordinary general meeting of shareholders to vote on the purchase on December 5, 2018.", "score": 0.965757, "arguments": [{"text": "Takeda", "location": [4931, 4937], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "said", "location": [4943, 4947], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "participantIn", "sentence": "Takeda also said that it would hold an extraordinary general meeting of shareholders to vote on the purchase on December 5, 2018.", "score": 0.90159, "arguments": [{"text": "shareholders", "location": [5003, 5015], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "meeting", "location": [4992, 4999], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "timeOf", "sentence": "Takeda also said that it would hold an extraordinary general meeting of shareholders to vote on the purchase on December 5, 2018.", "score": 0.799385, "arguments": [{"text": "December 5, 2018", "location": [5043, 5059], "entities": [{"type": "Date", "text": "December 5, 2018"}]}, {"text": "meeting", "location": [4992, 4999], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "hasAttribute", "sentence": "Deal Statistics: Total Number of Deals Closed in 2018 141 Total Number of Deals Not Completed in 2018 14 Total Number of Pending Deals Cash Deals 47 Stock Deals 33 Stock & Cash Deals 17 Special Conditions 6 Total Number of Pending Deals 103 Total Deal Size $1.32 trillion New Deals: The acquisition of Datawatch Corporation ( DWCH ) by Altair ( ALTR ) for $176 million, or $13.10 per share in cash.", "score": 0.922043, "arguments": [{"text": "Altair", "location": [437, 443], "entities": [{"type": "Organization", "text": "Altair", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "ALTR", "location": [446, 450], "entities": [{"type": "Ticker", "text": "ALTR"}]}]}, {"type": "agentOf", "sentence": "Closed Deals: The acquisition of CA, Inc. ( CA ) by Broadcom ( AVGO ) on November 5, 2018.", "score": 0.36611, "arguments": [{"text": "Broadcom", "location": [5113, 5121], "entities": [{"type": "Organization", "text": "Broadcom", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [5079, 5090], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Closed Deals: The acquisition of CA, Inc. ( CA ) by Broadcom ( AVGO ) on November 5, 2018.", "score": 0.86198, "arguments": [{"text": "November 5, 2018", "location": [5134, 5150], "entities": [{"type": "Date", "text": "November 5, 2018"}]}, {"text": "acquisition", "location": [5079, 5090], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Closed Deals: The acquisition of CA, Inc. ( CA ) by Broadcom ( AVGO ) on November 5, 2018.", "score": 0.527741, "arguments": [{"text": "Inc.", "location": [5098, 5102], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "AVGO", "location": [5124, 5128], "entities": [{"type": "Ticker", "text": "AVGO"}]}]}, {"type": "hasAttribute", "sentence": "Closed Deals: The acquisition of CA, Inc. ( CA ) by Broadcom ( AVGO ) on November 5, 2018.", "score": 0.504434, "arguments": [{"text": "CA", "location": [5105, 5107], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "AVGO", "location": [5124, 5128], "entities": [{"type": "Ticker", "text": "AVGO"}]}]}, {"type": "hasAttribute", "sentence": "Closed Deals: The acquisition of CA, Inc. ( CA ) by Broadcom ( AVGO ) on November 5, 2018.", "score": 0.964308, "arguments": [{"text": "Broadcom", "location": [5113, 5121], "entities": [{"type": "Organization", "text": "Broadcom", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "AVGO", "location": [5124, 5128], "entities": [{"type": "Ticker", "text": "AVGO"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of WSI Industries ( WSCI ) by Polaris Industries ( PII ) on November 7, 2018.", "score": 0.423849, "arguments": [{"text": "WSI Industries", "location": [5219, 5233], "entities": [{"type": "Organization", "text": "WSI Industries"}]}, {"text": "acquisition", "location": [5204, 5215], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The acquisition of WSI Industries ( WSCI ) by Polaris Industries ( PII ) on November 7, 2018.", "score": 0.906729, "arguments": [{"text": "November 7, 2018", "location": [5276, 5292], "entities": [{"type": "Date", "text": "November 7, 2018"}]}, {"text": "acquisition", "location": [5204, 5215], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "The acquisition of K2M Group Holdings by Stryker Corporation on November 9, 2018.", "score": 0.451716, "arguments": [{"text": "K2M Group Holdings", "location": [5360, 5378], "entities": [{"type": "Organization", "text": "K2M Group Holdings"}]}, {"text": "acquisition", "location": [5345, 5356], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The acquisition of K2M Group Holdings by Stryker Corporation on November 9, 2018.", "score": 0.89019, "arguments": [{"text": "November 9, 2018", "location": [5405, 5421], "entities": [{"type": "Date", "text": "November 9, 2018"}]}, {"text": "acquisition", "location": [5345, 5356], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "The acquisition of K2M Group Holdings by Stryker Corporation on November 9, 2018.", "score": 0.706379, "arguments": [{"text": "Stryker Corporation", "location": [5382, 5401], "entities": [{"type": "Organization", "text": "Stryker Corporation"}]}, {"text": "K2M Group Holdings", "location": [5360, 5378], "entities": [{"type": "Organization", "text": "K2M Group Holdings"}]}]}, {"type": "hasAttribute", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 231.44% APTI 11/11/2018 An affiliate of Vista Equity Partners (N/A) $38.00 $24.85 03/31/2019 52.92% 138.96% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $15.9 10/31/2018 29.56% -899.11% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.5 12/31/2018 28.57% 212.83% BBOX 11/11/2018 AGC Networks Ltd (N/A) $1.08 $0.87 12/31/2018 24.14% 179.80% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $48.34 $40.18 12/31/2018 20.30% 151.19% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. ( OTC:HHRBF )", "score": 0.46743, "arguments": [{"text": "N", "location": [5757, 5758], "entities": [{"type": "Organization", "text": "Western Gas Equity Partners", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$38.00 $24.85", "location": [5762, 5775], "entities": [{"type": "Money", "text": "$38.00 $24.85"}]}]}, {"type": "agentOf", "sentence": "The acquisition of Inuvo ( INUV ) by ConversionPoint Technologies for $75.5 million, or $2.22 per share in cash.", "score": 0.414541, "arguments": [{"text": "ConversionPoint Technologies", "location": [697, 725], "entities": [{"type": "Organization", "text": "ConversionPoint Technologies, Inc."}]}, {"text": "acquisition", "location": [664, 675], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "employedBy", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 231.44% APTI 11/11/2018 An affiliate of Vista Equity Partners (N/A) $38.00 $24.85 03/31/2019 52.92% 138.96% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $15.9 10/31/2018 29.56% -899.11% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.5 12/31/2018 28.57% 212.83% BBOX 11/11/2018 AGC Networks Ltd (N/A) $1.08 $0.87 12/31/2018 24.14% 179.80% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $48.34 $40.18 12/31/2018 20.30% 151.19% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. ( OTC:HHRBF )", "score": 0.314014, "arguments": [{"text": "KANG", "location": [5802, 5806], "entities": [{"type": "Person", "text": "KANG"}]}, {"text": "IK Healthcare Investment Limited", "location": [5818, 5850], "entities": [{"type": "Organization", "text": "IK Healthcare Investment Limited"}]}]}, {"type": "hasAttribute", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 231.44% APTI 11/11/2018 An affiliate of Vista Equity Partners (N/A) $38.00 $24.85 03/31/2019 52.92% 138.96% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $15.9 10/31/2018 29.56% -899.11% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.5 12/31/2018 28.57% 212.83% BBOX 11/11/2018 AGC Networks Ltd (N/A) $1.08 $0.87 12/31/2018 24.14% 179.80% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $48.34 $40.18 12/31/2018 20.30% 151.19% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. ( OTC:HHRBF )", "score": 0.538808, "arguments": [{"text": "EHIC", "location": [5897, 5901], "entities": [{"type": "Organization", "text": "EHIC"}]}, {"text": "04/06/2018", "location": [5902, 5912], "entities": [{"type": "Web", "text": "04/06/2018"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 231.44% APTI 11/11/2018 An affiliate of Vista Equity Partners (N/A) $38.00 $24.85 03/31/2019 52.92% 138.96% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $15.9 10/31/2018 29.56% -899.11% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.5 12/31/2018 28.57% 212.83% BBOX 11/11/2018 AGC Networks Ltd (N/A) $1.08 $0.87 12/31/2018 24.14% 179.80% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $48.34 $40.18 12/31/2018 20.30% 151.19% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. ( OTC:HHRBF )", "score": 0.587516, "arguments": [{"text": "Teamsport Parent Limited", "location": [5913, 5937], "entities": [{"type": "Organization", "text": "Teamsport Parent Limited"}]}, {"text": "EHIC", "location": [5897, 5901], "entities": [{"type": "Organization", "text": "EHIC"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 231.44% APTI 11/11/2018 An affiliate of Vista Equity Partners (N/A) $38.00 $24.85 03/31/2019 52.92% 138.96% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $15.9 10/31/2018 29.56% -899.11% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.5 12/31/2018 28.57% 212.83% BBOX 11/11/2018 AGC Networks Ltd (N/A) $1.08 $0.87 12/31/2018 24.14% 179.80% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $48.34 $40.18 12/31/2018 20.30% 151.19% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. ( OTC:HHRBF )", "score": 0.641009, "arguments": [{"text": "Dominion Energy, Inc.", "location": [6075, 6096], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SCG", "location": [6060, 6063], "entities": [{"type": "Organization", "text": "SCG"}]}]}, {"type": "partOf", "sentence": "Top 10 deals with largest spreads: Symbol AnnouncedDate Acquiring Company Closing Price Last Price Closing Date Profit Annualized Profit INUV 11/05/2018 ConversionPoint Technologies, Inc. (N/A) $2.22 $1.18 03/31/2019 88.14% 231.44% APTI 11/11/2018 An affiliate of Vista Equity Partners (N/A) $38.00 $24.85 03/31/2019 52.92% 138.96% KANG 03/26/2018 IK Healthcare Investment Limited (N/A) $20.60 $15.9 10/31/2018 29.56% -899.11% EHIC 04/06/2018 Teamsport Parent Limited (N/A) $13.50 $10.5 12/31/2018 28.57% 212.83% BBOX 11/11/2018 AGC Networks Ltd (N/A) $1.08 $0.87 12/31/2018 24.14% 179.80% SCG 01/03/2018 Dominion Energy, Inc. ( D ) $48.34 $40.18 12/31/2018 20.30% 151.19% GNW 10/23/2016 China Oceanwide Holdings Group Co., Ltd. ( OTC:HHRBF )", "score": 0.660386, "arguments": [{"text": "Oceanwide Holdings Group Co., Ltd.", "location": [6164, 6198], "entities": [{"type": "Organization", "text": "Oceanwide Holdings Group Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [6158, 6163], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "$5.43 $4.63 12/01/2018 17.28% 331.93% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.68 $54.7 12/31/2018 14.59% 108.67% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.04 $6.19 06/30/2019 13.79% 21.89% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.54 12/31/2018 11.69% 87.07% Disclaimer: I hold positions in Finisar Corp., Rockwell Collins ( COL ), Pandora ( P ), Radisys, and magicJack VocalTec.", "score": 0.428706, "arguments": [{"text": "ORBK", "location": [6251, 6255], "entities": [{"type": "Person", "text": "ORBK"}]}, {"text": "KLA-Tencor Corporation", "location": [6267, 6289], "entities": [{"type": "Organization", "text": "KLA-Tencor Corporation"}]}]}, {"type": "hasAttribute", "sentence": "$5.43 $4.63 12/01/2018 17.28% 331.93% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.68 $54.7 12/31/2018 14.59% 108.67% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.04 $6.19 06/30/2019 13.79% 21.89% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.54 12/31/2018 11.69% 87.07% Disclaimer: I hold positions in Finisar Corp., Rockwell Collins ( COL ), Pandora ( P ), Radisys, and magicJack VocalTec.", "score": 0.954826, "arguments": [{"text": "T-Mobile US, Inc.", "location": [6351, 6368], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TMUS", "location": [6371, 6375], "entities": [{"type": "Ticker", "text": "TMUS"}]}]}, {"type": "hasAttribute", "sentence": "$5.43 $4.63 12/01/2018 17.28% 331.93% ORBK 03/19/2018 KLA-Tencor Corporation ( KLAC ) $62.68 $54.7 12/31/2018 14.59% 108.67% S 04/29/2018 T-Mobile US, Inc. ( TMUS ) $7.04 $6.19 06/30/2019 13.79% 21.89% RSYS 07/02/2018 Reliance Industries Limited (N/A) $1.72 $1.54 12/31/2018 11.69% 87.07% Disclaimer: I hold positions in Finisar Corp., Rockwell Collins ( COL ), Pandora ( P ), Radisys, and magicJack VocalTec.", "score": 0.508017, "arguments": [{"text": "T-Mobile US, Inc.", "location": [6351, 6368], "entities": [{"type": "Organization", "text": "Dominion Energy, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$7.04 $6.19", "location": [6378, 6389], "entities": [{"type": "Money", "text": "$7.04 $6.19"}]}]}, {"type": "agentOf", "sentence": "I wrote this article myself, and it expresses my own opinions.", "score": 0.996992, "arguments": [{"text": "I", "location": [6874, 6875], "entities": [{"type": "Person", "text": "Radisys"}]}, {"text": "wrote", "location": [6876, 6881], "entities": [{"type": "EventCommunication", "text": "wrote"}]}]}, {"type": "employedBy", "sentence": "I have no business relationship with any company whose stock is mentioned in this article.", "score": 0.536126, "arguments": [{"text": "whose", "location": [7026, 7031], "entities": [{"type": "Person", "text": "Radisys"}]}, {"text": "company", "location": [7018, 7025], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "hasAttribute", "sentence": "The acquisition of Inuvo ( INUV ) by ConversionPoint Technologies for $75.5 million, or $2.22 per share in cash.", "score": 0.900991, "arguments": [{"text": "Inuvo", "location": [679, 684], "entities": [{"type": "Organization", "text": "Inuvo"}]}, {"text": "INUV", "location": [687, 691], "entities": [{"type": "Ticker", "text": "INUV"}]}]}], "keywords": [{"text": "potential deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.964352}, {"text": "Deals Cash Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.865478}, {"text": "acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.820141}, {"text": "all-stock deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.80718}, {"text": "K2M Group Holdings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.775473}, {"text": "Total Deal Size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763176}, {"text": "Total Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.757468}, {"text": "Vista Equity Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.747465}, {"text": "Works section", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.746823}, {"text": "new deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.715281}, {"text": "Pending Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.714871}, {"text": "Deal Statistics", "sentiment": {"score": 0.467484, "label": "positive"}, "relevance": 0.690085}, {"text": "merger agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.689297}, {"text": "Barrick Gold Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.68435}, {"text": "Stock Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.676993}, {"text": "Barrick common shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.669954}, {"text": "Deals Not Completed", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.669694}, {"text": "Deal Updates", "sentiment": {"score": 0.488589, "label": "positive"}, "relevance": 0.664308}, {"text": "Ready Capital Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662399}, {"text": "cash-plus-stock deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.661599}, {"text": "Merger Sub Corp.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.661257}, {"text": "magicJack VocalTec", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.661133}, {"text": "II-VI common stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.657409}, {"text": "Randgold Resources", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.656759}, {"text": "Black Box Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.655952}, {"text": "Durational Capital Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.653981}, {"text": "Randgold Resources Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.653826}, {"text": "Randgold Resources shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.651451}, {"text": "Western Gas Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.651071}, {"text": "Stryker Corporation", "sentiment": {"score": 0.269682, "label": "positive"}, "relevance": 0.650032}, {"text": "ConversionPoint Technologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.647213}, {"text": "Gas Equity Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646999}, {"text": "AGC Networks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646702}, {"text": "Capital Partners LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646029}, {"text": "Company Closing Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.645346}, {"text": "Ready Capital shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.644173}, {"text": "closing date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641613}, {"text": "Oceanwide Holdings Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641063}, {"text": "H. Lee Partners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64075}, {"text": "new Avista Board", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.640299}, {"text": "Price Closing Date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.638508}, {"text": "Owens Realty Mortgage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636924}, {"text": "exchange ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.635454}, {"text": "fixed exchange ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.634856}, {"text": "Federal Communications Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.634507}]}, "extracted_metadata": {"sha1": "27ab00be6227849bfd2ae021d85b4ecf518521ab", "filename": "1542109240147.zip-312538e7a53866fccca7194f82a47d66.xml", "file_type": "json"}, "external_links": ["https://finance.yahoo.com/quote/ORM?p=ORM", "https://www.blackbox.com/en-us/press-releases/press-release-details/agc-networks-to-acquire-black-box", "https://www.sec.gov/Archives/edgar/data/1572552/000114036118042682/ex99_1.htm", "https://finance.yahoo.com/quote/FNSR?p=FNSR", "https://www.sec.gov/Archives/edgar/data/1499807/000119312518323171/d638678d8k.htm", "https://finance.yahoo.com/quote/ITG?p=ITG", "https://finance.yahoo.com/news/takeda-sets-vote-date-aims-081307476.html", "https://finance.yahoo.com/quote/ABX/?p=ABX", "https://finance.yahoo.com/news/randgold-resources-shareholders-greenlight-takeover-145655343.html", "https://finance.yahoo.com/quote/WGP/?p=WGP", "https://finance.yahoo.com/quote/BTX?p=BTX", "https://finance.yahoo.com/quote/IIVI/?p=IIVI", "https://finance.yahoo.com/quote/RC/?p=RC", "https://finance.yahoo.com/quote/CALL/?p=CALL", "https://finance.yahoo.com/quote/KTWO/?p=KTWO", "http://finance.yahoo.com/q?s=KLAC", "https://finance.yahoo.com/quote/DNB/?p=DNB", "https://finance.yahoo.com/quote/INUV/?p=INUV", "https://finance.yahoo.com/quote/SYK/?p=SYK", "https://finance.yahoo.com/quote/WES?p=WES", "https://finance.yahoo.com/quote/APTI?p=APTI", "https://finance.yahoo.com/quote/RILY/?p=RILY", "https://www.sec.gov/Archives/edgar/data/920424/000155837018008715/ex-99d1.htm", "https://www.sec.gov/Archives/edgar/data/1645494/000114420418058106/tv506632_ex99-2.htm", "https://finance.yahoo.com/quote/DIS/?p=DIS", "https://www.sec.gov/Archives/edgar/data/1697152/000119312518319093/d603577dex99i.htm", "https://www.sec.gov/Archives/edgar/data/829323/000165495418011966/inuv_ex999.htm", "https://www.sec.gov/Archives/edgar/data/1630132/000119312518319023/d561154dex991.htm", "http://finance.yahoo.com/q?s=S", "https://finance.yahoo.com/quote/COMM/?p=COMM", "https://www.sec.gov/Archives/edgar/data/104897/000149315218015322/form8-k.htm", "https://finance.yahoo.com/news/barrick-shareholders-overwhelmingly-approve-randgold-172929968.html", "https://finance.yahoo.com/quote/AVA/press-releases?p=AVA", "https://finance.yahoo.com/quote/SHPG/?p=SHPG", "https://finance.yahoo.com/news/eu-approves-disney-buy-fox-162231184.html", "https://finance.yahoo.com/quote/CVON?p=CVON", "http://finance.yahoo.com/q?s=KANG", "http://finance.yahoo.com/q?s=EHIC", "http://investors.apptio.com/news-releases/news-release-details/apptio-enters-definitive-agreement-be-acquired-vista-equity", "https://finance.yahoo.com/quote/PII/?p=PII", "https://finance.yahoo.com/quote/GOLD?p=GOLD", "http://finance.yahoo.com/q?s=TMUS", "https://finance.yahoo.com/quote/AVGO/?p=AVGO", "https://www.sec.gov/Archives/edgar/data/1556364/000155636418000067/exhibit99-1.htm", "https://www.sec.gov/Archives/edgar/data/1414475/000141447518000037/wgp20188-kxnovemberxex991.htm", "http://finance.yahoo.com/q?s=ORBK", "https://finance.yahoo.com/quote/AST?p=AST", "https://www.sec.gov/Archives/edgar/data/1115222/000110465918066519/a18-39681_1ex99d1.htm", "https://finance.yahoo.com/quote/ARRS?p=ARRS", "https://finance.yahoo.com/quote/VIRT/?p=VIRT", "https://www.sec.gov/Archives/edgar/data/1005699/000117891318002291/exhibit_99-1.htm", "https://finance.yahoo.com/quote/ALTR/?p=ALTR", "https://www.sec.gov/Archives/edgar/data/356028/000119312518317918/d631849d8k.htm", "https://www.sec.gov/Archives/edgar/data/1094739/000110465918067123/a18-39922_1ex99d1.htm", "https://www.sec.gov/Archives/edgar/data/1499807/000119312518320339/d651646dex991.htm", "https://www.sec.gov/Archives/edgar/data/792130/000114420418057170/tv506254_ex99-2.htm", "https://finance.yahoo.com/news/hydro-one-avista-announce-selection-230000859.html", "http://finance.yahoo.com/q?s=SCG", "http://finance.yahoo.com/q?s=D", "https://finance.yahoo.com/quote/DWCH?p=DWCH", "http://finance.yahoo.com/q?s=RSYS", "https://finance.yahoo.com/quote/FOXA/?p=FOXA", "https://finance.yahoo.com/quote/BBOX?p=BBOX", "http://finance.yahoo.com/q?s=GNW"], "title": "Merger Arbitrage Mondays - November 12, 2018", "forum_title": "All Articles on Seeking Alpha"}, {"id": "_vDsO3aCRVIfb16VKNk8mCBIGgtM668oSp60GXEjYyfhvNrpRdM6qS-WCJeN7uib", "result_metadata": {"score": 33.118042}, "author": "manavigator.com", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.955351, "label": "/news/national news"}, {"score": 0.914695, "label": "/business and industrial/business news"}], "relations": [], "keywords": [{"text": "Navigator", "sentiment": {"score": 0.367007, "label": "positive"}, "relevance": 0.991094}]}, "crawl_date": "2018-11-13T08:25:06Z", "url": "http://manavigator.com/news/takeda-schedules-5-december-shareholder-vote-on-usd-62bn-shire-acquisition", "host": "manavigator.com", "text": "12 November 2018 - Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T00:00:00Z", "enriched_text": {"entities": [{"count": 20, "sentiment": {"score": 0.623613, "label": "positive"}, "text": "Takeda", "relevance": 0.961221, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.678 Takeda ADSs", "relevance": 0.403606, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.368288, "type": "Company"}, {"count": 6, "sentiment": {"score": 0.633544, "label": "positive"}, "text": "Shire", "relevance": 0.327095, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.5 Takeda", "relevance": 0.295343, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.21318, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.209851, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Irish drugmaker Shire plc", "relevance": 0.199815, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.185053, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.131263, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo Stock Exchange", "relevance": 0.104833, "type": "Company", "disambiguation": {"subtype": [], "name": "Tokyo Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ariad Pharmaceuticals", "relevance": 0.104522, "type": "Company", "disambiguation": {"subtype": [], "name": "ARIAD Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/ARIAD_Pharmaceuticals"}}, {"count": 3, "sentiment": {"score": 0.633544, "label": "positive"}, "text": "Japan", "relevance": 0.0977736, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston", "relevance": 0.0965446, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Boston", "dbpedia_resource": "http://dbpedia.org/resource/Boston"}}, {"count": 1, "sentiment": {"score": 0.603583, "label": "positive"}, "text": "NYSE", "relevance": 0.088439, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Morgan Chase Bank", "relevance": 0.0863072, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.0838039, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore", "relevance": 0.0800135, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Singapore", "dbpedia_resource": "http://dbpedia.org/resource/Singapore"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.0799609, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MUFG Bank, Ltd.", "relevance": 0.0798999, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sumitomo Mitsui Banking Corp.", "relevance": 0.0798037, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "50%", "relevance": 0.0798037, "type": "Quantity"}], "sentiment": {"document": {"score": 0.724597, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd. (TSX: 4502)", "keywords": [{"text": "Japanese drugmaker Takeda"}, {"text": "Pharmaceutical Company Ltd."}, {"text": "TSX"}, {"text": "Shareholders"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": "12 November 2018 - Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd. (TSX: 4502) will vote on 5 December on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP), the company said.", "object": {"text": "on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP)", "keywords": [{"text": "Irish drugmaker Shire"}, {"text": "SHP"}, {"text": "LON"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Company", "text": "Irish drugmaker Shire plc"}]}, "action": {"verb": {"text": "vote", "tense": "future"}, "text": "will vote", "normalized": "will vote"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": "12 November 2018 - Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd. (TSX: 4502) will vote on 5 December on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP), the company said.", "object": {"text": "on 5 December on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP)", "keywords": [{"text": "Irish drugmaker Shire"}, {"text": "SHP"}, {"text": "LON"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Company", "text": "Irish drugmaker Shire plc"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "the companies", "keywords": [{"text": "companies"}]}, "sentence": " In May, the companies announced a deal under which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire, the companies said.", "object": {"text": "a deal under which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire", "keywords": [{"text": "ordinary share capital"}, {"text": "Takeda"}, {"text": "deal"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "announce", "tense": "future"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the companies", "keywords": [{"text": "companies"}]}, "sentence": " In May, the companies announced a deal under which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire, the companies said.", "object": {"text": "Takeda will acquire the entire issued and to be issued ordinary share capital of Shire", "keywords": [{"text": "ordinary share capital"}, {"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "each Shire shareholder", "keywords": [{"text": "Shire shareholder"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Under the terms of the acquisition, each Shire shareholder will be entitled to receive USD 30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.", "object": {"text": "entitled to receive USD 30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs", "keywords": [{"text": "new Takeda shares"}, {"text": "Takeda ADSs"}, {"text": "Shire share"}, {"text": "USD"}], "entities": [{"type": "Location", "text": "USD", "disambiguation": {"subtype": ["Country"]}}, {"type": "Organization", "text": "Shire"}, {"type": "Company", "text": "1.678 Takeda ADSs"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "to receive USD 30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs", "keywords": [{"text": "new Takeda shares"}, {"text": "Takeda ADSs"}, {"text": "Shire share"}, {"text": "USD"}], "entities": [{"type": "Location", "text": "USD", "disambiguation": {"subtype": ["Country"]}}, {"type": "Organization", "text": "Shire"}, {"type": "Company", "text": "1.678 Takeda ADSs"}]}, "sentence": " Under the terms of the acquisition, each Shire shareholder will be entitled to receive USD 30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.", "object": {"text": "each Shire shareholder", "keywords": [{"text": "Shire shareholder"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "entitle", "tense": "future"}, "text": "entitled", "normalized": "entitle"}}, {"subject": {"text": "each Shire shareholder", "keywords": [{"text": "Shire shareholder"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Under the terms of the acquisition, each Shire shareholder will be entitled to receive USD 30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.", "object": {"text": "USD 30.33", "keywords": [{"text": "USD"}], "entities": [{"type": "Location", "text": "USD", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will be entitled to receive", "normalized": "will be entitle to receive"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction has been approved by both companies' boards of directors, and is expected to close in the first half of calendar year 2019.", "object": {"text": "been approved by both companies' boards of directors", "keywords": [{"text": "companies"}, {"text": "boards"}, {"text": "directors"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction has been approved by both companies' boards of directors, and is expected to close in the first half of calendar year 2019.", "object": {"text": "approved by both companies' boards of directors", "keywords": [{"text": "companies"}, {"text": "boards"}, {"text": "directors"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "by both companies' boards of directors", "keywords": [{"text": "companies"}, {"text": "boards"}, {"text": "directors"}]}, "sentence": " The transaction has been approved by both companies' boards of directors, and is expected to close in the first half of calendar year 2019.", "object": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "has been approved", "normalized": "have be approve"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction has been approved by both companies' boards of directors, and is expected to close in the first half of calendar year 2019.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected to close", "normalized": "be expect to close"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction has been approved by both companies' boards of directors, and is expected to close in the first half of calendar year 2019.", "action": {"verb": {"text": "close", "tense": "future"}, "text": "is expected to close", "normalized": "be expect to close"}}, {"subject": {"text": "Takeda shareholders", "keywords": [{"text": "Takeda shareholders"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Upon the closing of the transaction, Takeda shareholders will own approximately 50% of the combined group.", "object": {"text": "approximately 50% of the combined group", "keywords": [{"text": "group"}], "entities": [{"type": "Quantity", "text": "50"}]}, "action": {"verb": {"text": "own", "tense": "future"}, "text": "will own", "normalized": "will own"}}, {"subject": {"text": "The companies", "keywords": [{"text": "companies"}]}, "sentence": " The companies say the deal brings together complementary positions in GI and neuroscience; provides leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and focused efforts in vaccines", "object": {"text": "the deal brings together complementary positions in GI and neuroscience", "keywords": [{"text": "complementary positions"}, {"text": "GI"}, {"text": "deal"}, {"text": "neuroscience"}], "entities": []}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "say", "normalized": "say"}}, {"subject": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The companies say the deal brings together complementary positions in GI and neuroscience; provides leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and focused efforts in vaccines", "object": {"text": "complementary positions in GI and neuroscience", "keywords": [{"text": "complementary positions"}, {"text": "GI"}, {"text": "neuroscience"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "brings", "normalized": "bring"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda said the acquisition of Shire will accelerate Takeda's transformation by bringing together Takeda and Shire's complementary positions in GI and neuroscience.", "object": {"text": "the acquisition of Shire will accelerate Takeda's transformation by bringing together Takeda and Shire's complementary positions in GI and neuroscience", "keywords": [{"text": "Takeda"}, {"text": "Shire"}, {"text": "GI"}, {"text": "transformation"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Company", "text": "Takeda"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "the acquisition of Shire", "keywords": [{"text": "Shire"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Takeda said the acquisition of Shire will accelerate Takeda's transformation by bringing together Takeda and Shire's complementary positions in GI and neuroscience.", "object": {"text": "Takeda and Shire's complementary positions in GI and neuroscience", "keywords": [{"text": "Takeda"}, {"text": "GI"}, {"text": "Shire"}, {"text": "neuroscience"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "bringing", "normalized": "bring"}}, {"subject": {"text": "It"}, "sentence": " It will also provide the combined group with leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and focused efforts in vaccines.", "object": {"text": "the combined group", "keywords": [{"text": "group"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "will also provide", "normalized": "will also provide"}}, {"subject": {"text": "Takeda's vaccine business", "keywords": [{"text": "vaccine business"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " In addition, Takeda's vaccine business will continue to address the world's most pressing public health needs.", "object": {"text": "the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "will continue to address", "normalized": "will continue to address"}}, {"subject": {"text": "the world", "keywords": [{"text": "world"}]}, "sentence": " In addition, Takeda's vaccine business will continue to address the world's most pressing public health needs.", "object": {"text": "most pressing public health needs", "keywords": [{"text": "public health needs"}], "entities": []}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "from Takeda's strong international presence in emerging markets and Japan", "keywords": [{"text": "Takeda"}, {"text": "markets"}, {"text": "Japan"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Shire's portfolio will benefit from Takeda's strong international presence in emerging markets and Japan.", "object": {"text": "Shire's portfolio", "keywords": [{"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "benefit", "tense": "future"}, "text": "will benefit", "normalized": "will benefit"}}, {"subject": {"text": "The integrated company", "keywords": [{"text": "integrated company"}]}, "sentence": " The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "object": {"text": "headquartered"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The integrated company", "keywords": [{"text": "integrated company"}]}, "sentence": " The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "action": {"verb": {"text": "headquarter", "tense": "future"}, "text": "will continue to be headquartered", "normalized": "will continue to be headquarter"}}, {"subject": {"text": "The integrated company", "keywords": [{"text": "integrated company"}]}, "sentence": " The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "object": {"text": "its R and D presence", "keywords": [{"text": "presence"}]}, "action": {"verb": {"text": "expand", "tense": "present"}, "text": "expand", "normalized": "expand"}}, {"subject": {"text": "The integrated company", "keywords": [{"text": "integrated company"}]}, "sentence": " The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "object": {"text": "major regional locations", "keywords": [{"text": "major regional locations"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Takeda and Shire", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Person", "text": "Shire"}]}, "sentence": " Takeda and Shire say they have highly complementary pipelines.", "object": {"text": "they have highly complementary pipelines", "keywords": [{"text": "highly complementary pipelines"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "say", "normalized": "say"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Organization", "text": "Shire"}]}, "sentence": " Shire has strong expertise in rare diseases, an attractive modality-diverse mid- and late-stage pipeline, enriched with large-molecule programs, as well as cutting-edge technologies in gene therapy and recombinant proteins.", "object": {"text": "strong expertise in rare diseases, an attractive modality-diverse mid- and late-stage pipeline, enriched with large-molecule programs", "keywords": [{"text": "attractive modality-diverse mid"}, {"text": "late-stage pipeline"}, {"text": "strong expertise"}, {"text": "rare diseases"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "an attractive modality-diverse mid- and late-stage pipeline", "keywords": [{"text": "attractive modality-diverse mid"}, {"text": "late-stage pipeline"}]}, "sentence": " Shire has strong expertise in rare diseases, an attractive modality-diverse mid- and late-stage pipeline, enriched with large-molecule programs, as well as cutting-edge technologies in gene therapy and recombinant proteins.", "object": {"text": "with large-molecule programs, as well as cutting-edge technologies in gene therapy and recombinant proteins", "keywords": [{"text": "recombinant proteins"}, {"text": "cutting-edge technologies"}, {"text": "gene therapy"}, {"text": "large-molecule programs"}]}, "action": {"verb": {"text": "enrich", "tense": "past"}, "text": "enriched", "normalized": "enrich"}}, {"subject": {"text": "this"}, "sentence": " Combining this with Takeda's early development and research-oriented R and D program will result in a highly complementary, robust, modality-diverse pipeline and a strengthened R and D engine focused on breakthrough innovation.", "object": {"text": "with Takeda's early development and research-oriented R and D program", "keywords": [{"text": "Takeda"}, {"text": "early development"}, {"text": "program"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "Combining", "tense": "present"}, "text": "Combining", "normalized": "Combining"}}, {"subject": {"text": "Combining this with Takeda's early development and research-oriented R and D program", "keywords": [{"text": "early development"}, {"text": "Takeda"}, {"text": "program"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Combining this with Takeda's early development and research-oriented R and D program will result in a highly complementary, robust, modality-diverse pipeline and a strengthened R and D engine focused on breakthrough innovation.", "object": {"text": "in a highly complementary, robust, modality-diverse pipeline", "keywords": [{"text": "modality-diverse pipeline"}]}, "action": {"verb": {"text": "result", "tense": "future"}, "text": "will result", "normalized": "will result"}}, {"subject": {"text": "The combined group", "keywords": [{"text": "group"}]}, "sentence": " The combined group will build on existing partnerships, including Takeda's more than 180 active partnerships with academia, biotechnology companies and startups, to further enrich the pipeline.", "action": {"verb": {"text": "build", "tense": "future"}, "text": "will build", "normalized": "will build"}}, {"subject": {"text": "Takeda's more than 180 active partnerships with academia, biotechnology companies and startups", "keywords": [{"text": "active partnerships"}, {"text": "biotechnology companies"}, {"text": "Takeda"}, {"text": "startups"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The combined group will build on existing partnerships, including Takeda's more than 180 active partnerships with academia, biotechnology companies and startups, to further enrich the pipeline.", "object": {"text": "existing partnerships", "keywords": [{"text": "partnerships"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The combined group will build on existing partnerships, including Takeda's more than 180 active partnerships with academia, biotechnology companies and startups, to further enrich the pipeline.", "object": {"text": "the pipeline", "keywords": [{"text": "pipeline"}]}, "action": {"verb": {"text": "enrich", "tense": "present"}, "text": "enrich", "normalized": "enrich"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda intends to maintain its investment grade credit rating, with a target net debt to EBITDA ratio of 2.0x or less in the medium term.", "object": {"text": "to maintain its investment grade credit rating, with a target net debt to EBITDA ratio of 2.0x or less in the medium term", "keywords": [{"text": "target net debt"}, {"text": "investment grade credit"}, {"text": "EBITDA ratio"}, {"text": "medium term"}], "entities": []}, "action": {"verb": {"text": "intend", "tense": "present"}, "text": "intends", "normalized": "intend"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda intends to maintain its investment grade credit rating, with a target net debt to EBITDA ratio of 2.0x or less in the medium term.", "object": {"text": "its investment grade credit rating", "keywords": [{"text": "investment grade credit"}, {"text": "rating"}], "entities": []}, "action": {"verb": {"text": "maintain", "tense": "future"}, "text": "intends to maintain", "normalized": "intend to maintain"}}, {"subject": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " Takeda is confident that the acquisition will create an opportunity to recognize significant recurring cost synergies, with potential for additional revenue synergies from the combination of Shire and Takeda's combined infrastructure, market presence and development capabilities.", "object": {"text": "an opportunity to recognize significant recurring cost synergies, with potential for additional revenue synergies from the combination of Shire and Takeda's combined infrastructure, market presence and development capabilities", "keywords": [{"text": "additional revenue synergies"}, {"text": "significant recurring cost"}, {"text": "market presence"}, {"text": "development capabilities"}], "entities": [{"type": "Person", "text": "Shire"}, {"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "will create", "normalized": "will create"}}, {"subject": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " Takeda is confident that the acquisition will create an opportunity to recognize significant recurring cost synergies, with potential for additional revenue synergies from the combination of Shire and Takeda's combined infrastructure, market presence and development capabilities.", "object": {"text": "significant recurring cost synergies", "keywords": [{"text": "cost synergies"}]}, "action": {"verb": {"text": "recognize", "tense": "future"}, "text": "to recognize", "normalized": "to recognize"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Takeda expects recurring pre-tax cost synergies for the combined group to reach a run-rate of at least USD 1.4bn per annum by the end of the third fiscal year following completion of the acquisition.", "object": {"text": "recurring pre-tax cost synergies for the combined group to reach a run-rate of at least USD 1.4bn per annum by the end of the third fiscal year following completion of the acquisition", "keywords": [{"text": "pre-tax cost synergies"}, {"text": "annum"}, {"text": "USD"}, {"text": "completion"}], "entities": [{"type": "Location", "text": "USD", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "Shire shareholders", "keywords": [{"text": "Shire shareholders"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Under the terms of the acquisition, Shire shareholders will be entitled to receive, for each Shire share, USD30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs.", "object": {"text": "to receive, for each Shire share, USD30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs", "keywords": [{"text": "new Takeda shares"}, {"text": "Takeda ADSs"}, {"text": "Shire share"}, {"text": "cash"}], "entities": [{"type": "Organization", "text": "Shire"}, {"type": "Company", "text": "1.678 Takeda ADSs"}]}, "action": {"verb": {"text": "entitle", "tense": "future"}, "text": "entitled", "normalized": "entitle"}}, {"subject": {"text": "Shire shareholders", "keywords": [{"text": "Shire shareholders"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Under the terms of the acquisition, Shire shareholders will be entitled to receive, for each Shire share, USD30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs.", "object": {"text": "USD30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs", "keywords": [{"text": "new Takeda shares"}, {"text": "Takeda ADSs"}, {"text": "cash"}], "entities": [{"type": "Company", "text": "1.678 Takeda ADSs"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will be entitled to receive", "normalized": "will be entitle to receive"}}, {"subject": {"text": "The acquisition terms", "keywords": [{"text": "acquisition terms"}]}, "sentence": " The acquisition terms imply an equivalent value of GBP 48.17 per Shire share based on the closing price of JPY 4,535 per Takeda share on May 2, 2018.", "object": {"text": "an equivalent value of GBP 48.17 per Shire share based on the closing price of JPY 4,535 per Takeda share on May 2, 2018", "keywords": [{"text": "equivalent value"}, {"text": "Takeda share"}, {"text": "Shire share"}, {"text": "GBP"}], "entities": [{"type": "Organization", "text": "Shire"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "imply", "tense": "present"}, "text": "imply", "normalized": "imply"}}, {"subject": {"text": "This transaction", "keywords": [{"text": "transaction"}]}, "sentence": " This transaction has been approved by the boards of both companies, and is subject to the approval of Shire and Takeda shareholders and certain customary closing conditions, including regulatory approvals.", "object": {"text": "been approved by the boards of both companies", "keywords": [{"text": "boards"}, {"text": "companies"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "This transaction", "keywords": [{"text": "transaction"}]}, "sentence": " This transaction has been approved by the boards of both companies, and is subject to the approval of Shire and Takeda shareholders and certain customary closing conditions, including regulatory approvals.", "object": {"text": "approved by the boards of both companies", "keywords": [{"text": "boards"}, {"text": "companies"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "by the boards of both companies", "keywords": [{"text": "boards"}, {"text": "companies"}]}, "sentence": " This transaction has been approved by the boards of both companies, and is subject to the approval of Shire and Takeda shareholders and certain customary closing conditions, including regulatory approvals.", "object": {"text": "This transaction", "keywords": [{"text": "transaction"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "has been approved", "normalized": "have be approve"}}, {"subject": {"text": "This transaction", "keywords": [{"text": "transaction"}]}, "sentence": " This transaction has been approved by the boards of both companies, and is subject to the approval of Shire and Takeda shareholders and certain customary closing conditions, including regulatory approvals.", "object": {"text": "subject to the approval of Shire and Takeda shareholders", "keywords": [{"text": "Takeda shareholders"}, {"text": "approval"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "regulatory approvals", "keywords": [{"text": "regulatory approvals"}]}, "sentence": " This transaction has been approved by the boards of both companies, and is subject to the approval of Shire and Takeda shareholders and certain customary closing conditions, including regulatory approvals.", "object": {"text": "certain customary closing conditions", "keywords": [{"text": "certain customary closing"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " The acquisition is expected to close in the first half of calendar year 2019.", "action": {"verb": {"text": "close", "tense": "future"}, "text": "is expected to close", "normalized": "be expect to close"}}, {"subject": {"text": "the new Takeda shares", "keywords": [{"text": "new Takeda shares"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Upon completion, the new Takeda shares will be listed on the Tokyo Stock Exchange, and local Japanese stock exchanges.", "object": {"text": "on the Tokyo Stock Exchange, and local Japanese stock exchanges", "keywords": [{"text": "Tokyo Stock Exchange"}, {"text": "Japanese stock exchanges"}], "entities": [{"type": "Company", "text": "Tokyo Stock Exchange", "disambiguation": {"subtype": ["Company"], "name": "Tokyo Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}}]}, "action": {"verb": {"text": "list", "tense": "future"}, "text": "will be listed", "normalized": "will be list"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " In addition, Takeda will apply for its ADSs (each representing 0.5 Takeda shares) to be listed on the NYSE effective on or shortly after the effective date.", "object": {"text": "for its ADSs (each representing 0.5 Takeda shares) to be listed on the NYSE effective on or shortly after the effective date", "keywords": [{"text": "Takeda shares"}, {"text": "effective date"}, {"text": "ADSs"}, {"text": "NYSE"}], "entities": [{"type": "Company", "text": "0.5 Takeda"}, {"type": "Company", "text": "NYSE"}]}, "action": {"verb": {"text": "apply", "tense": "future"}, "text": "will apply", "normalized": "will apply"}}, {"subject": {"text": "each representing 0.5 Takeda shares)", "keywords": [{"text": "Takeda shares"}], "entities": [{"type": "Company", "text": "0.5 Takeda"}]}, "sentence": " In addition, Takeda will apply for its ADSs (each representing 0.5 Takeda shares) to be listed on the NYSE effective on or shortly after the effective date.", "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}], "concepts": [{"text": "Stock", "relevance": 0.97442, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock market", "relevance": 0.911664, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "JPMorgan Chase", "relevance": 0.777588, "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}, {"text": "Share", "relevance": 0.729523, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Tokyo Stock Exchange", "relevance": 0.727902, "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.71022, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Stock exchange", "relevance": 0.65453, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Shareholder", "relevance": 0.609383, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}], "categories": [{"score": 0.70892, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.461772, "label": "/finance/financial news"}, {"score": 0.323675, "label": "/finance/investing"}], "relations": [{"type": "partOfMany", "sentence": "12 November 2018 - Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd. (TSX: 4502) will vote on 5 December on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP), the company said.", "score": 0.863307, "arguments": [{"text": "drugmaker", "location": [44, 53], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "Japanese", "location": [35, 43], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Takeda will continue to focus on the acceleration of its oncology business, following its recent acquisition of Ariad Pharmaceuticals.", "score": 0.461794, "arguments": [{"text": "its", "location": [1489, 1492], "entities": [{"type": "Organization", "text": "group"}]}, {"text": "Ariad Pharmaceuticals", "location": [1515, 1536], "entities": [{"type": "Organization", "text": "Ariad Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Takeda will continue to focus on the acceleration of its oncology business, following its recent acquisition of Ariad Pharmaceuticals.", "score": 0.59192, "arguments": [{"text": "Ariad Pharmaceuticals", "location": [1515, 1536], "entities": [{"type": "Organization", "text": "Ariad Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1500, 1511], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "locatedAt", "sentence": "The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "score": 0.918273, "arguments": [{"text": "area", "location": [1864, 1868], "entities": [{"type": "Location", "text": "area"}]}, {"text": "Boston", "location": [1857, 1863], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}]}, {"type": "locatedAt", "sentence": "The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "score": 0.941333, "arguments": [{"text": "locations", "location": [1893, 1902], "entities": [{"type": "Location", "text": "locations"}]}, {"text": "Japan", "location": [1906, 1911], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "score": 0.588769, "arguments": [{"text": "locations", "location": [1893, 1902], "entities": [{"type": "Location", "text": "locations"}]}, {"text": "Singapore", "location": [1913, 1922], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The integrated company will continue to be headquartered in Japan, expand its R and D presence in the Boston area and have major regional locations in Japan, Singapore, Switzerland and the US.", "score": 0.552026, "arguments": [{"text": "locations", "location": [1893, 1902], "entities": [{"type": "Location", "text": "locations"}]}, {"text": "Switzerland", "location": [1924, 1935], "entities": [{"type": "GeopoliticalEntity", "text": "Switzerland", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Takeda and Shire say they have highly complementary pipelines.", "score": 0.928405, "arguments": [{"text": "Takeda", "location": [1948, 1954], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "they", "location": [1969, 1973], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "locatedAt", "sentence": "Takeda and Shire say they have highly complementary pipelines.", "score": 0.447952, "arguments": [{"text": "Takeda", "location": [1948, 1954], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "pipelines", "location": [2000, 2009], "entities": [{"type": "Facility", "text": "pipelines"}]}]}, {"type": "agentOf", "sentence": "Takeda and Shire say they have highly complementary pipelines.", "score": 0.966336, "arguments": [{"text": "Shire", "location": [1959, 1964], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "say", "location": [1965, 1968], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "partOfMany", "sentence": "Takeda and Shire say they have highly complementary pipelines.", "score": 0.940145, "arguments": [{"text": "Shire", "location": [1959, 1964], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "they", "location": [1969, 1973], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "employedBy", "sentence": "12 November 2018 - Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd. (TSX: 4502) will vote on 5 December on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP), the company said.", "score": 0.438086, "arguments": [{"text": "Takeda Pharmaceutical", "location": [54, 75], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "Company Ltd.", "location": [76, 88], "entities": [{"type": "Organization", "text": "Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Shire has strong expertise in rare diseases, an attractive modality-diverse mid- and late-stage pipeline, enriched with large-molecule programs, as well as cutting-edge technologies in gene therapy and recombinant proteins.", "score": 0.869727, "arguments": [{"text": "Shire", "location": [2011, 2016], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "diseases", "location": [2046, 2054], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "hasAttribute", "sentence": "The combined group will build on existing partnerships, including Takeda's more than 180 active partnerships with academia, biotechnology companies and startups, to further enrich the pipeline.", "score": 0.867587, "arguments": [{"text": "Takeda", "location": [2529, 2535], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "academia", "location": [2577, 2585], "entities": [{"type": "HealthCondition", "text": "academia"}]}]}, {"type": "agentOf", "sentence": "The acquisition terms imply an equivalent value of GBP 48.17 per Shire share based on the closing price of JPY 4,535 per Takeda share on May 2, 2018.", "score": 0.549074, "arguments": [{"text": "GBP", "location": [3507, 3510], "entities": [{"type": "Organization", "text": "GBP", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [3460, 3471], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOfMany", "sentence": "This transaction has been approved by the boards of both companies, and is subject to the approval of Shire and Takeda shareholders and certain customary closing conditions, including regulatory approvals.", "score": 0.487873, "arguments": [{"text": "Shire", "location": [3708, 3713], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "shareholders", "location": [3725, 3737], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "partOfMany", "sentence": "This transaction has been approved by the boards of both companies, and is subject to the approval of Shire and Takeda shareholders and certain customary closing conditions, including regulatory approvals.", "score": 0.463957, "arguments": [{"text": "Takeda", "location": [3718, 3724], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "shareholders", "location": [3725, 3737], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "productOf", "sentence": "In addition, Takeda will apply for its ADSs (each representing 0.5 Takeda shares) to be listed on the NYSE effective on or shortly after the effective date.", "score": 0.940281, "arguments": [{"text": "ADSs", "location": [4048, 4052], "entities": [{"type": "Product", "text": "ADSs"}]}, {"text": "its", "location": [4044, 4047], "entities": [{"type": "Organization", "text": "its", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Takeda has entered into a bridge facility agreement of USD 30.85bn with, among others, J.P. Morgan Chase Bank N.A., Sumitomo Mitsui Banking Corp. and MUFG Bank, Ltd., part of the proceeds of which will be used to fund the cash consideration payable to Shire shareholders in connection with the acquisition.", "score": 0.585163, "arguments": [{"text": "Takeda", "location": [4166, 4172], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "bridge facility", "location": [4192, 4207], "entities": [{"type": "Facility", "text": "bridge facility"}]}]}, {"type": "colleague", "sentence": "Takeda has entered into a bridge facility agreement of USD 30.85bn with, among others, J.P. Morgan Chase Bank N.A., Sumitomo Mitsui Banking Corp. and MUFG Bank, Ltd., part of the proceeds of which will be used to fund the cash consideration payable to Shire shareholders in connection with the acquisition.", "score": 0.309433, "arguments": [{"text": "Shire", "location": [4418, 4423], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "shareholders", "location": [4424, 4436], "entities": [{"type": "Person", "text": "Shareholders"}]}]}, {"type": "agentOf", "sentence": "12 November 2018 - Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd. (TSX: 4502) will vote on 5 December on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP), the company said.", "score": 0.696667, "arguments": [{"text": "company", "location": [152, 159], "entities": [{"type": "Organization", "text": "R"}]}, {"text": "acquisition", "location": [170, 181], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOfMany", "sentence": "12 November 2018 - Shareholders of Japanese drugmaker Takeda Pharmaceutical Company Ltd. (TSX: 4502) will vote on 5 December on matters relating to the company's pending acquisition of Irish drugmaker Shire plc (LON: SHP), the company said.", "score": 0.662135, "arguments": [{"text": "drugmaker", "location": [191, 200], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "Irish", "location": [185, 190], "entities": [{"type": "GeopoliticalEntity", "text": "Irish", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "In May, the companies announced a deal under which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire, the companies said.", "score": 0.975958, "arguments": [{"text": "companies", "location": [253, 262], "entities": [{"type": "Organization", "text": "biotechnology companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [263, 272], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "In May, the companies announced a deal under which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire, the companies said.", "score": 0.951316, "arguments": [{"text": "companies", "location": [384, 393], "entities": [{"type": "Organization", "text": "biotechnology companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "said", "location": [394, 398], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "colleague", "sentence": "Under the terms of the acquisition, each Shire shareholder will be entitled to receive USD 30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.", "score": 0.464088, "arguments": [{"text": "Shire", "location": [441, 446], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "shareholder", "location": [447, 458], "entities": [{"type": "Person", "text": "shareholder"}]}]}, {"type": "agentOf", "sentence": "The companies say the deal brings together complementary positions in GI and neuroscience; provides leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and focused efforts in vaccines Takeda said the acquisition of Shire will accelerate Takeda's transformation by bringing together Takeda and Shire's complementary positions in GI and neuroscience.", "score": 0.97952, "arguments": [{"text": "companies", "location": [834, 843], "entities": [{"type": "Organization", "text": "biotechnology companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "say", "location": [844, 847], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "The companies say the deal brings together complementary positions in GI and neuroscience; provides leading positions in rare diseases and plasma-derived therapies to complement strength in oncology and focused efforts in vaccines Takeda said the acquisition of Shire will accelerate Takeda's transformation by bringing together Takeda and Shire's complementary positions in GI and neuroscience.", "score": 0.997485, "arguments": [{"text": "Takeda", "location": [1061, 1067], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "said", "location": [1068, 1072], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Takeda will continue to focus on the acceleration of its oncology business, following its recent acquisition of Ariad Pharmaceuticals.", "score": 0.720811, "arguments": [{"text": "its", "location": [1489, 1492], "entities": [{"type": "Organization", "text": "group"}]}, {"text": "acquisition", "location": [1500, 1511], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": 0.623613, "label": "positive"}, "relevance": 0.911871}, {"text": "new Takeda shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.771795}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.648153}, {"text": "Takeda ADSs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.636287}, {"text": "Takeda shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621435}, {"text": "Shire", "sentiment": {"score": 0.633544, "label": "positive"}, "relevance": 0.484074}, {"text": "Shire share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429518}, {"text": "Irish drugmaker Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423863}, {"text": "rare diseases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392286}, {"text": "bridge facility agreement", "sentiment": {"score": -0.422952, "label": "negative"}, "relevance": 0.389009}, {"text": "Shire shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383618}, {"text": "Shire shareholder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362217}, {"text": "acquisition", "sentiment": {"score": 0.707608, "label": "positive"}, "relevance": 0.350094}, {"text": "ordinary share capital", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330507}, {"text": "cost synergies", "sentiment": {"score": 0.707608, "label": "positive"}, "relevance": 0.329075}, {"text": "plasma-derived therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324858}, {"text": "pre-tax cost synergies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324838}, {"text": "additional revenue synergies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.320326}, {"text": "public health needs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315724}, {"text": "highly complementary pipelines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314181}, {"text": "major regional locations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.314142}, {"text": "Sumitomo Mitsui Banking", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.310728}, {"text": "investment grade credit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.309953}, {"text": "customary closing conditions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.30911}, {"text": "attractive modality-diverse mid", "sentiment": {"score": 0.589688, "label": "positive"}, "relevance": 0.308575}, {"text": "significant recurring cost", "sentiment": {"score": 0.707608, "label": "positive"}, "relevance": 0.308275}, {"text": "available cash resources", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.307266}, {"text": "Chase Bank N.A.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.304604}, {"text": "target net debt", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303965}, {"text": "local Japanese stock", "sentiment": {"score": 0.381939, "label": "positive"}, "relevance": 0.302423}, {"text": "Tokyo Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.300605}, {"text": "recent acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.296843}, {"text": "acquisition terms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.288643}, {"text": "companies", "sentiment": {"score": 0.338194, "label": "positive"}, "relevance": 0.273981}, {"text": "complementary positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.272319}, {"text": "leading positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26595}, {"text": "integrated company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26431}, {"text": "late-stage pipeline", "sentiment": {"score": 0.589688, "label": "positive"}, "relevance": 0.264229}, {"text": "oncology business", "sentiment": {"score": 0.389966, "label": "positive"}, "relevance": 0.263897}, {"text": "biotechnology companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262648}, {"text": "Boston area", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262234}, {"text": "Ariad Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261797}, {"text": "large-molecule programs", "sentiment": {"score": 0.267401, "label": "positive"}, "relevance": 0.261368}, {"text": "modality-diverse pipeline", "sentiment": {"score": 0.725934, "label": "positive"}, "relevance": 0.261362}, {"text": "vaccine business", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26104}, {"text": "cutting-edge technologies", "sentiment": {"score": 0.643254, "label": "positive"}, "relevance": 0.260898}, {"text": "early development", "sentiment": {"score": 0.763333, "label": "positive"}, "relevance": 0.260369}, {"text": "medium term", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259756}, {"text": "recombinant proteins", "sentiment": {"score": 0.643254, "label": "positive"}, "relevance": 0.259148}, {"text": "cash consideration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25907}]}, "extracted_metadata": {"sha1": "b71080929f17cae0bad2cd498a7b9e721a6fc01e", "filename": "1542097506134.zip-f9ea21691bb2319917a2b1f6b96822e8.xml", "file_type": "json"}, "title": "M & A Navigator - Latest News", "forum_title": "M &amp; A Navigator - Latest News"}, {"id": "VXiNA-HwFnswM0v3R6gbWJ4jlK9UpUEG0IboYZC7BJIaRPUiu32anKjj3K84x6lX", "result_metadata": {"score": 33.06033}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.626346, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Steady Growth", "keywords": [{"text": "Steady Growth"}]}, "sentence": "Global Cardiovascular Drugs Incur Steady Growth", "object": {"text": "Global Cardiovascular Drugs", "keywords": [{"text": "Global Cardiovascular Drugs"}]}, "action": {"verb": {"text": "Incur", "tense": "present"}, "text": "Incur", "normalized": "Incur"}}], "concepts": [{"text": "Immune system", "relevance": 0.85695, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}], "categories": [{"score": 0.780988, "label": "/health and fitness"}, {"score": 0.353516, "label": "/science/medicine/cardiology"}, {"score": 0.338987, "label": "/health and fitness/disease/heart disease"}], "relations": [], "keywords": [{"text": "Global Cardiovascular Drugs", "sentiment": {"score": -0.490992, "label": "negative"}, "relevance": 0.90026}, {"text": "Steady Growth", "sentiment": {"score": -0.490992, "label": "negative"}, "relevance": 0.605217}]}, "crawl_date": "2018-11-13T12:05:41Z", "url": "https://www.findmarketresearch.org/2018/11/global-cardiovascular-drugs-market-to-incur-steady-growth-during-2015-2021/", "host": "findmarketresearch.org", "text": "Some of the major cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T04:23:00+05:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.867064, "label": "negative"}, "text": "hypertensive heart disease", "relevance": 0.9038, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}, {"count": 2, "sentiment": {"score": -0.911619, "label": "negative"}, "text": "inflammatory heart disease", "relevance": 0.736307, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.75901, "label": "negative"}, "text": "Cerebrovascular disease", "relevance": 0.552018, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.787412, "label": "negative"}, "text": "rheumatic fever", "relevance": 0.452422, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"count": 6, "sentiment": {"score": -0.37452, "label": "negative"}, "text": "Japan", "relevance": 0.395128, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.832513, "label": "negative"}, "text": "kawasaki disease", "relevance": 0.315768, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}, {"count": 3, "sentiment": {"score": -0.0134332, "label": "negative"}, "text": "Asia", "relevance": 0.306481, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 2, "sentiment": {"score": -0.767521, "label": "negative"}, "text": "group A streptococcal infection", "relevance": 0.290587, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}, {"count": 2, "sentiment": {"score": -0.450286, "label": "negative"}, "text": "North America", "relevance": 0.277481, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.306977, "label": "negative"}, "text": "subarachnoid hemorrhage", "relevance": 0.246639, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Subarachnoid hemorrhage", "dbpedia_resource": "http://dbpedia.org/resource/Subarachnoid_hemorrhage"}}, {"count": 1, "sentiment": {"score": -0.336336, "label": "negative"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.215022, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tredaptive", "relevance": 0.207485, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eliquis", "relevance": 0.206422, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.20425, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.20249, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.197703, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca PLC", "relevance": 0.196613, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Solvay SA", "relevance": 0.196083, "type": "Company", "disambiguation": {"subtype": [], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.194985, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": -0.224413, "label": "negative"}, "text": "Bayer AG", "relevance": 0.19374, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Forest Laboratories Inc.", "relevance": 0.187157, "type": "Company", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.180185, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Co. Ltd.", "relevance": 0.180038, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Pfizer Inc.", "relevance": 0.179803, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.177165, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories Inc.", "relevance": 0.173252, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.171185, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.169452, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.168786, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.168444, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.164958, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.163154, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.160741, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.151307, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.151307, "type": "Quantity"}], "sentiment": {"document": {"score": -0.707135, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Cardiovascular diseases,", "keywords": [{"text": "Cardiovascular diseases"}]}, "sentence": "Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "as heart diseases", "keywords": [{"text": "heart diseases"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "also known", "normalized": "also know"}}, {"subject": {"text": "Cardiovascular diseases, also known as heart diseases,", "keywords": [{"text": "Cardiovascular diseases"}, {"text": "heart diseases"}]}, "sentence": "Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "diseases of heart and circulatory system", "keywords": [{"text": "diseases"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some of the most common cardiovascular diseases", "keywords": [{"text": "common cardiovascular diseases"}]}, "sentence": " Some of the most common cardiovascular diseases are hypertensive heart disease, rheumatic heart disease, cerebrovascular heart disease, ischemic heart disease and inflammatory heart disease.", "object": {"text": "hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Major problems", "keywords": [{"text": "Major problems"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "heart failure, hypertrophy, coronary heart disease and angina", "keywords": [{"text": "coronary heart disease"}, {"text": "heart failure"}, {"text": "hypertrophy"}, {"text": "angina"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "Major problems associated with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}, {"text": "Major problems"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by preceding group A streptococcal infection", "keywords": [{"text": "streptococcal infection"}, {"text": "group"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "sentence": " Rheumatic fever occurs by preceding group A streptococcal infection.", "object": {"text": "Rheumatic fever", "keywords": [{"text": "Rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "object": {"text": "one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries", "keywords": [{"text": "heart diseases"}, {"text": "countries"}, {"text": "children"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Cerebrovascular disease", "keywords": [{"text": "Cerebrovascular disease"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Cerebrovascular disease affects blood vessels of the brain.", "object": {"text": "blood vessels of the brain", "keywords": [{"text": "blood vessels"}, {"text": "brain"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "Most common types of cerebrovascular disease", "keywords": [{"text": "cerebrovascular disease"}, {"text": "common types"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "object": {"text": "vascular dementia", "keywords": [{"text": "vascular dementia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common causes of death in western parts of the world.", "object": {"text": "one of the most common causes of death in western parts of the world", "keywords": [{"text": "common causes"}, {"text": "western parts"}, {"text": "death"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Inflammatory heart disease", "keywords": [{"text": "Inflammatory heart disease"}], "entities": [{"type": "HealthCondition", "text": "inflammatory heart disease", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " Inflammatory heart disease occurs due to the infection of bacteria and virus.", "object": {"text": "due to the infection of bacteria and virus", "keywords": [{"text": "bacteria"}, {"text": "infection"}, {"text": "virus"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "often associated with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "Anti-hypertensive drug segment", "keywords": [{"text": "Anti-hypertensive drug segment"}]}, "sentence": " Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "object": {"text": "further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL", "keywords": [{"text": "Benicar/Benicar HCT"}, {"text": "Micardis/Micardis HCT"}, {"text": "Exforge/Exforge HCT"}, {"text": "Norvasc"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive", "keywords": [{"text": "Niaspan"}, {"text": "Crestor"}, {"text": "Lipitor"}, {"text": "TriCor/Trilipix"}], "entities": [{"type": "Location", "text": "Tredaptive", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Anti-dyslipidemics drug segment includes Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive.", "object": {"text": "Anti-dyslipidemics drug segment", "keywords": [{"text": "Anti-dyslipidemics drug segment"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Anti-thrombotics drug segment", "keywords": [{"text": "Anti-thrombotics drug segment"}]}, "sentence": " Anti-thrombotics drug segment is further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis.", "object": {"text": "further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis", "keywords": [{"text": "Plavix"}, {"text": "Lovenox"}, {"text": "Pradaxa"}, {"text": "Xarelto"}], "entities": [{"type": "Location", "text": "Eliquis", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " In terms of geographic, North America dominates the global cardiovascular drugs market .", "object": {"text": "the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "The U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The U.S. represents cardiovascular drugs followed by Canada in North America.", "object": {"text": "cardiovascular drugs followed by Canada in North America", "keywords": [{"text": "cardiovascular drugs"}, {"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "the U.K., Spain, Italy and France", "keywords": [{"text": "U.K."}, {"text": "Spain"}, {"text": "Italy"}, {"text": "France"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "Spain", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}]}, "sentence": " In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "object": {"text": "major share of cardiovascular drugs market", "keywords": [{"text": "cardiovascular drugs"}, {"text": "major share"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "Asia", "keywords": [{"text": "Asia"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " However, Asia is expected to show high growth rates in the next five years in global cardiovascular drugs market.", "object": {"text": "high growth rates", "keywords": [{"text": "high growth rates"}]}, "action": {"verb": {"text": "show", "tense": "future"}, "text": "is expected to show", "normalized": "be expect to show"}}, {"subject": {"text": "many companies", "keywords": [{"text": "companies"}]}, "sentence": " This is due to many companies constructing their R&D facilities in the region.", "object": {"text": "their R&D facilities in the region", "keywords": [{"text": "R&D facilities"}, {"text": "region"}]}, "action": {"verb": {"text": "construct", "tense": "present"}, "text": "constructing", "normalized": "construct"}}, {"subject": {"text": "Less stringent wages and availability of skilled labor", "keywords": [{"text": "stringent wages"}, {"text": "skilled labor"}, {"text": "availability"}]}, "sentence": " Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "object": {"text": "manufacturing companies", "keywords": [{"text": "manufacturing companies"}]}, "action": {"verb": {"text": "attract", "tense": "present"}, "text": "attracts", "normalized": "attract"}}, {"subject": {"text": "increasing awareness about heart related problems", "keywords": [{"text": "awareness"}, {"text": "heart"}, {"text": "problems"}]}, "sentence": " In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region.", "action": {"verb": {"text": "support", "tense": "present"}, "text": "is also supporting", "normalized": "be also support"}}, {"subject": {"text": "Japan, China and India", "keywords": [{"text": "Japan"}, {"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "object": {"text": "the fastest growing cardiovascular drugs markets in Asia", "keywords": [{"text": "cardiovascular drugs"}, {"text": "markets"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "increasing prevalence of heart diseases and extensive pipeline drugs", "keywords": [{"text": "extensive pipeline drugs"}, {"text": "prevalence"}, {"text": "heart diseases"}]}, "sentence": " In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "object": {"text": "some of the major drivers of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "major drivers"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Rising number of diabetic patients", "keywords": [{"text": "diabetic patients"}, {"text": "number"}]}, "sentence": " Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.", "object": {"text": "immense potential to the growth of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "immense potential"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "stringent regulations and side-effects of cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}, {"text": "stringent regulations"}, {"text": "side-effects"}]}, "sentence": " However, stringent regulations and side-effects of cardiovascular drugs hamper the growth of global cardiovascular drugs market.", "object": {"text": "the growth of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patent expiry of various blockbuster drugs", "keywords": [{"text": "various blockbuster drugs"}, {"text": "patent expiry"}]}, "sentence": " Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "object": {"text": "the growth of the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "obstruct", "tense": "present"}, "text": "obstructs", "normalized": "obstruct"}}, {"subject": {"text": "Some of the major cardiovascular drugs market", "keywords": [{"text": "major cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Some of the major cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "object": {"text": "Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Forest Laboratories Inc."}, {"text": "F. Hoffmann-La Roche"}, {"text": "AstraZeneca PLC"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Abbott Laboratories Inc."}, {"type": "Company", "text": "AstraZeneca PLC", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd."}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Forest Laboratories Inc.", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Roche Ltd."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Daiichi Sankyo Co. Ltd."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Solvay SA", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Hypertension", "relevance": 0.984979, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Heart", "relevance": 0.81553, "dbpedia_resource": "http://dbpedia.org/resource/Heart"}, {"text": "Cardiology", "relevance": 0.794174, "dbpedia_resource": "http://dbpedia.org/resource/Cardiology"}, {"text": "Heart disease", "relevance": 0.78584, "dbpedia_resource": "http://dbpedia.org/resource/Heart_disease"}, {"text": "Blood", "relevance": 0.679286, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Circulatory system", "relevance": 0.642599, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_system"}, {"text": "Blood vessel", "relevance": 0.624738, "dbpedia_resource": "http://dbpedia.org/resource/Blood_vessel"}, {"text": "Bristol-Myers Squibb", "relevance": 0.596431, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Myocardial infarction", "relevance": 0.595694, "dbpedia_resource": "http://dbpedia.org/resource/Myocardial_infarction"}, {"text": "Genetic disorder", "relevance": 0.56278, "dbpedia_resource": "http://dbpedia.org/resource/Genetic_disorder"}, {"text": "Cardiovascular system", "relevance": 0.558799, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_system"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.551508, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Ischaemic heart disease", "relevance": 0.545418, "dbpedia_resource": "http://dbpedia.org/resource/Ischaemic_heart_disease"}, {"text": "Ischemia", "relevance": 0.530462, "dbpedia_resource": "http://dbpedia.org/resource/Ischemia"}, {"text": "Pfizer", "relevance": 0.523978, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Aspirin", "relevance": 0.519945, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Cardiovascular diseases", "relevance": 0.519226, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_diseases"}, {"text": "Stroke", "relevance": 0.507295, "dbpedia_resource": "http://dbpedia.org/resource/Stroke"}, {"text": "Diseases and disorders", "relevance": 0.479267, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Circulatory System", "relevance": 0.453981, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_System"}, {"text": "Heart failure", "relevance": 0.437229, "dbpedia_resource": "http://dbpedia.org/resource/Heart_failure"}, {"text": "Streptococcus", "relevance": 0.431719, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus"}, {"text": "Rheumatic fever", "relevance": 0.42854, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}, {"text": "Clopidogrel", "relevance": 0.411171, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Pharmaceutical industry", "relevance": 0.395565, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Coronary artery disease", "relevance": 0.387194, "dbpedia_resource": "http://dbpedia.org/resource/Coronary_artery_disease"}, {"text": "Infection", "relevance": 0.38518, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Atherosclerosis", "relevance": 0.384217, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Blood pressure", "relevance": 0.36763, "dbpedia_resource": "http://dbpedia.org/resource/Blood_pressure"}, {"text": "Multinational companies", "relevance": 0.362471, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Pulmonary vein", "relevance": 0.347304, "dbpedia_resource": "http://dbpedia.org/resource/Pulmonary_vein"}, {"text": "Inflammation", "relevance": 0.342516, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Immune system", "relevance": 0.340666, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Rheumatism", "relevance": 0.337354, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatism"}, {"text": "Medicine", "relevance": 0.335086, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Genentech", "relevance": 0.334589, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Amlodipine", "relevance": 0.333835, "dbpedia_resource": "http://dbpedia.org/resource/Amlodipine"}, {"text": "Disease", "relevance": 0.323333, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Infectious disease", "relevance": 0.319539, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Hypercholesterolemia", "relevance": 0.313926, "dbpedia_resource": "http://dbpedia.org/resource/Hypercholesterolemia"}, {"text": "Arthralgia", "relevance": 0.313346, "dbpedia_resource": "http://dbpedia.org/resource/Arthralgia"}, {"text": "Irbesartan", "relevance": 0.308974, "dbpedia_resource": "http://dbpedia.org/resource/Irbesartan"}, {"text": "Streptococcus pyogenes", "relevance": 0.307294, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus_pyogenes"}, {"text": "Cerebral hemorrhage", "relevance": 0.3032, "dbpedia_resource": "http://dbpedia.org/resource/Cerebral_hemorrhage"}, {"text": "AstraZeneca", "relevance": 0.301724, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Pharmaceutical drug", "relevance": 0.298451, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Transient ischemic attack", "relevance": 0.298364, "dbpedia_resource": "http://dbpedia.org/resource/Transient_ischemic_attack"}, {"text": "Artery", "relevance": 0.291457, "dbpedia_resource": "http://dbpedia.org/resource/Artery"}, {"text": "Cardiovascular disease", "relevance": 0.288201, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}, {"text": "Cardiac muscle", "relevance": 0.287037, "dbpedia_resource": "http://dbpedia.org/resource/Cardiac_muscle"}], "categories": [{"score": 0.993983, "label": "/health and fitness/disease/heart disease"}], "relations": [{"type": "affectedBy", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.668725, "arguments": [{"text": "group", "location": [573, 578], "entities": [{"type": "Person", "text": "group"}]}, {"text": "preceding", "location": [563, 572], "entities": [{"type": "EventCommunication", "text": "preceding"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Benicar HCT", "location": [1515, 1526], "entities": [{"type": "GeopoliticalEntity", "text": "Benicar HCT"}]}, {"text": "Micardis", "location": [1528, 1536], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Micardis HCT", "location": [1537, 1549], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}, {"text": "Aprovel", "location": [1551, 1558], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.623328, "arguments": [{"text": "CoAprovel", "location": [1559, 1568], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}, {"text": "Tekturna", "location": [1570, 1578], "entities": [{"type": "GeopoliticalEntity", "text": "Tekturna"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.829898, "arguments": [{"text": "Rasilez", "location": [1579, 1586], "entities": [{"type": "GeopoliticalEntity", "text": "Rasilez"}]}, {"text": "Edarbi", "location": [1588, 1594], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.529909, "arguments": [{"text": "Edarbi", "location": [1588, 1594], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}, {"text": "Cozaar", "location": [1596, 1602], "entities": [{"type": "GeopoliticalEntity", "text": "Cozaar"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.92593, "arguments": [{"text": "Hyzaar", "location": [1603, 1609], "entities": [{"type": "GeopoliticalEntity", "text": "Hyzaar"}]}, {"text": "Norvasc", "location": [1611, 1618], "entities": [{"type": "GeopoliticalEntity", "text": "Norvasc"}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents cardiovascular drugs followed by Canada in North America.", "score": 0.886537, "arguments": [{"text": "drugs", "location": [2117, 2122], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Canada", "location": [2135, 2141], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents cardiovascular drugs followed by Canada in North America.", "score": 0.575289, "arguments": [{"text": "drugs", "location": [2117, 2122], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "North America", "location": [2145, 2158], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.954556, "arguments": [{"text": "Europe", "location": [2163, 2169], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "Germany", "location": [2171, 2178], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.704525, "arguments": [{"text": "U.K.", "location": [2184, 2188], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "Spain", "location": [2190, 2195], "entities": [{"type": "GeopoliticalEntity", "text": "Spain", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.881228, "arguments": [{"text": "group", "location": [573, 578], "entities": [{"type": "Person", "text": "group"}]}, {"text": "infection", "location": [595, 604], "entities": [{"type": "HealthCondition", "text": "cerebrovascular disease"}]}]}, {"type": "ownerOf", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.268793, "arguments": [{"text": "companies", "location": [2398, 2407], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "facilities", "location": [2431, 2441], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.950849, "arguments": [{"text": "facilities", "location": [2431, 2441], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2449, 2455], "entities": [{"type": "GeopoliticalEntity", "text": "Tredaptive"}]}]}, {"type": "locatedAt", "sentence": "Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "score": 0.397101, "arguments": [{"text": "companies", "location": [2535, 2544], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Asia", "location": [2558, 2562], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "score": 0.602137, "arguments": [{"text": "drugs", "location": [2783, 2788], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Asia", "location": [2800, 2804], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "score": 0.744416, "arguments": [{"text": "drivers", "location": [2913, 2920], "entities": [{"type": "Person", "text": "drivers"}]}, {"text": "cardiovascular", "location": [2931, 2945], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Increasing aging population and rising number of life-style diseases are also contributing in the growth of global cardiovascular drugs market.", "score": 0.743664, "arguments": [{"text": "population", "location": [2977, 2987], "entities": [{"type": "Person", "text": "population"}]}, {"text": "diseases", "location": [3020, 3028], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "hasAttribute", "sentence": "Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.", "score": 0.909393, "arguments": [{"text": "patients", "location": [3130, 3138], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diabetic", "location": [3121, 3129], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "locatedAt", "sentence": "Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "score": 0.499794, "arguments": [{"text": "drugs", "location": [3392, 3397], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [3380, 3391], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "affectedBy", "sentence": "Increasing mergers and acquisitions between drug manufacturing companies and rapid product launches are key trends of the global cardiovascular drugs market.", "score": 0.48594, "arguments": [{"text": "companies", "location": [3530, 3539], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisitions", "location": [3490, 3502], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "hasAttribute", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.927547, "arguments": [{"text": "children", "location": [662, 670], "entities": [{"type": "Person", "text": "children"}]}, {"text": "heart diseases", "location": [644, 658], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.463019, "arguments": [{"text": "children", "location": [662, 670], "entities": [{"type": "Person", "text": "children"}]}, {"text": "countries", "location": [679, 688], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.466845, "arguments": [{"text": "countries", "location": [679, 688], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "world", "location": [696, 701], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "score": 0.50584, "arguments": [{"text": "TIA", "location": [930, 933], "entities": [{"type": "Person", "text": "TIA"}]}, {"text": "attack", "location": [922, 928], "entities": [{"type": "EventViolence", "text": "attack"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.506713, "arguments": [{"text": "western", "location": [1062, 1069], "entities": [{"type": "Location", "text": "western"}]}, {"text": "parts", "location": [1070, 1075], "entities": [{"type": "Location", "text": "parts"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.780669, "arguments": [{"text": "parts", "location": [1070, 1075], "entities": [{"type": "Location", "text": "parts"}]}, {"text": "world", "location": [1083, 1088], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.68216, "arguments": [{"text": "Co-Diovan", "location": [1486, 1495], "entities": [{"type": "GeopoliticalEntity", "text": "Co-Diovan"}]}, {"text": "Blopress", "location": [1497, 1505], "entities": [{"type": "GeopoliticalEntity", "text": "Blopress"}]}]}], "keywords": [{"text": "global cardiovascular drugs", "sentiment": {"score": -0.573464, "label": "negative"}, "relevance": 0.975547}, {"text": "cardiovascular drugs market", "sentiment": {"score": -0.59135, "label": "negative"}, "relevance": 0.867544}, {"text": "heart disease", "sentiment": {"score": -0.8808, "label": "negative"}, "relevance": 0.709092}, {"text": "hypertensive heart disease", "sentiment": {"score": -0.867064, "label": "negative"}, "relevance": 0.6394}, {"text": "major cardiovascular drugs", "sentiment": {"score": -0.336336, "label": "negative"}, "relevance": 0.621134}, {"text": "rheumatic heart disease", "sentiment": {"score": -0.881368, "label": "negative"}, "relevance": 0.593578}, {"text": "common cardiovascular diseases", "sentiment": {"score": -0.916874, "label": "negative"}, "relevance": 0.584133}, {"text": "ischemic heart disease", "sentiment": {"score": -0.914676, "label": "negative"}, "relevance": 0.583673}, {"text": "inflammatory heart disease", "sentiment": {"score": -0.911619, "label": "negative"}, "relevance": 0.573744}, {"text": "various anti-hypertensive drugs", "sentiment": {"score": -0.448266, "label": "negative"}, "relevance": 0.556969}, {"text": "heart diseases", "sentiment": {"score": -0.730726, "label": "negative"}, "relevance": 0.553165}, {"text": "various blockbuster drugs", "sentiment": {"score": -0.565222, "label": "negative"}, "relevance": 0.54827}, {"text": "extensive pipeline drugs", "sentiment": {"score": -0.688519, "label": "negative"}, "relevance": 0.541685}, {"text": "cerebrovascular heart disease", "sentiment": {"score": -0.846962, "label": "negative"}, "relevance": 0.53404}, {"text": "rheumatic fever", "sentiment": {"score": -0.787412, "label": "negative"}, "relevance": 0.528776}, {"text": "anti-dyslipidemics drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522831}, {"text": "anti-thrombotics drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522764}, {"text": "coronary heart disease", "sentiment": {"score": -0.825321, "label": "negative"}, "relevance": 0.521614}, {"text": "drug segment", "sentiment": {"score": -0.315563, "label": "negative"}, "relevance": 0.508964}, {"text": "various heart diseases", "sentiment": {"score": -0.788244, "label": "negative"}, "relevance": 0.499142}, {"text": "cerebrovascular disease", "sentiment": {"score": -0.715034, "label": "negative"}, "relevance": 0.486377}, {"text": "high blood pressure", "sentiment": {"score": -0.868769, "label": "negative"}, "relevance": 0.482239}, {"text": "Anti-hypertensive drug segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47981}, {"text": "Anti-dyslipidemics drug segment", "sentiment": {"score": -0.294374, "label": "negative"}, "relevance": 0.479073}, {"text": "Anti-thrombotics drug segment", "sentiment": {"score": -0.336752, "label": "negative"}, "relevance": 0.478599}, {"text": "North America", "sentiment": {"score": -0.450286, "label": "negative"}, "relevance": 0.4747}, {"text": "reduced blood supply", "sentiment": {"score": -0.907142, "label": "negative"}, "relevance": 0.474347}, {"text": "high growth rates", "sentiment": {"score": -0.470383, "label": "negative"}, "relevance": 0.473594}, {"text": "Daiichi Sankyo Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472349}, {"text": "manufacturing companies", "sentiment": {"score": -0.115897, "label": "negative"}, "relevance": 0.471296}, {"text": "drug manufacturing companies", "sentiment": {"score": -0.559413, "label": "negative"}, "relevance": 0.470758}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": -0.336336, "label": "negative"}, "relevance": 0.469983}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468314}, {"text": "Hoffmann-La Roche Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467513}, {"text": "Forest Laboratories Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.465748}, {"text": "heart failure", "sentiment": {"score": -0.815548, "label": "negative"}, "relevance": 0.465487}, {"text": "Abbott Laboratories Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.465482}, {"text": "rapid product launches", "sentiment": {"score": -0.559413, "label": "negative"}, "relevance": 0.464539}, {"text": "Co. Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.461665}, {"text": "kawasaki disease", "sentiment": {"score": -0.832513, "label": "negative"}, "relevance": 0.454668}, {"text": "Benicar/Benicar HCT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452405}, {"text": "Micardis/Micardis HCT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452376}, {"text": "Exforge/Exforge HCT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452252}, {"text": "Major problems", "sentiment": {"score": -0.815548, "label": "negative"}, "relevance": 0.446591}, {"text": "subarachnoid hemorrhage", "sentiment": {"score": -0.306977, "label": "negative"}, "relevance": 0.445872}, {"text": "life-style diseases", "sentiment": {"score": -0.785924, "label": "negative"}, "relevance": 0.444669}, {"text": "common types", "sentiment": {"score": -0.639135, "label": "negative"}, "relevance": 0.442975}, {"text": "common causes", "sentiment": {"score": -0.559769, "label": "negative"}, "relevance": 0.442411}, {"text": "stringent wages", "sentiment": {"score": 0.443516, "label": "positive"}, "relevance": 0.442199}]}, "extracted_metadata": {"sha1": "81064c8b063a08a2ced7fdff2485fcb4afa8883c", "filename": "1542110741997.zip-3dade74e28be591a166c05590eca1b4c.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/3776", "https://www.persistencemarketresearch.com/market-research/cardiovascular-drugs-market.asp"], "title": "Global Cardiovascular Drugs Incur Steady Growth", "forum_title": "Research Insights \u2013 Page 49 \u2013 Find Market Research"}, {"id": "fkDSYFc9pWfRzBKFR3q3n-oBv_5LCGnz4O4_r0bK58zLG1ZXlhaJ-uatCq1VnYoY", "result_metadata": {"score": 32.725178}, "author": "Market Research Future", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Capitalism", "relevance": 0.881203, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}, {"text": "Rumination syndrome", "relevance": 0.7832, "dbpedia_resource": "http://dbpedia.org/resource/Rumination_syndrome"}, {"text": "Health care", "relevance": 0.76208, "dbpedia_resource": "http://dbpedia.org/resource/Health_care"}, {"text": "Supply and demand", "relevance": 0.721158, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}], "categories": [{"score": 0.542924, "label": "/health and fitness"}, {"score": 0.485104, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.4719, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [{"type": "partOfMany", "sentence": "Rumination Syndrome Market Comprehensive Top Players Analysis in 2018 | Global Healthcare Industry Size, Growth Rate and Demand by 2023", "score": 0.584584, "arguments": [{"text": "Growth Rate", "location": [105, 116], "entities": [{"type": "Person", "text": "Growth Rate"}]}, {"text": "Players Analysis", "location": [45, 61], "entities": [{"type": "Person", "text": "Players Analysis"}]}]}, {"type": "partOfMany", "sentence": "Rumination Syndrome Market Comprehensive Top Players Analysis in 2018 | Global Healthcare Industry Size, Growth Rate and Demand by 2023", "score": 0.757045, "arguments": [{"text": "Demand", "location": [121, 127], "entities": [{"type": "Person", "text": "Demand"}]}, {"text": "Players Analysis", "location": [45, 61], "entities": [{"type": "Person", "text": "Players Analysis"}]}]}], "keywords": [{"text": "Rumination Syndrome Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.900993}, {"text": "Global Healthcare Industry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646213}, {"text": "Growth Rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48915}, {"text": "Comprehensive Top Players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.398927}, {"text": "Demand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25743}]}, "crawl_date": "2018-11-13T08:18:06Z", "url": "https://www.openpr.com/news/1364273/Rumination-Syndrome-Market-Comprehensive-Top-Players-Analysis-in-2018-Global-Healthcare-Industry-Size-Growth-Rate-and-Demand-by-2023.html", "host": "openpr.com", "text": "Ltd., Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, Johnson & Johnson, Bayer AG, Otsuka Pharmaceutical Co.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T08:20:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.808409, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0.764515, "label": "positive"}, "text": "Middle East", "relevance": 0.74244, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.695791, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.654747, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": -0.640841, "label": "negative"}, "text": "U.K.", "relevance": 0.653736, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.556524, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.209485, "label": "positive"}, "text": "WHO", "relevance": 0.553456, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "Chicken Lips", "dbpedia_resource": "http://dbpedia.org/resource/Chicken_Lips"}}, {"count": 1, "sentiment": {"score": 0.764515, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.55118, "type": "GeographicFeature"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "South America", "relevance": 0.537481, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 1, "sentiment": {"score": -0.724307, "label": "negative"}, "text": "South America", "relevance": 0.534626, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.326553, "label": "negative"}, "text": "diarrhea", "relevance": 0.529961, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Diarrhea", "dbpedia_resource": "http://dbpedia.org/resource/Diarrhea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.518316, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.739541, "label": "negative"}, "text": "celiac disease", "relevance": 0.499474, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Disease"], "name": "Coeliac disease", "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}}, {"count": 1, "sentiment": {"score": -0.562259, "label": "negative"}, "text": "India", "relevance": 0.497854, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "esomeprazole", "relevance": 0.493811, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Malaysia", "relevance": 0.487238, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Malaysia", "dbpedia_resource": "http://dbpedia.org/resource/Malaysia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk A/S", "relevance": 0.485511, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 1, "sentiment": {"score": -0.357396, "label": "negative"}, "text": "Takeda Pharmaceuticals", "relevance": 0.481586, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.651537, "label": "negative"}, "text": "diverticulitis", "relevance": 0.480749, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Diverticulitis", "dbpedia_resource": "http://dbpedia.org/resource/Diverticulitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.479983, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Americas", "relevance": 0.473151, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astra Zeneca", "relevance": 0.472523, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Otsuka Pharmaceutical Co", "relevance": 0.470583, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.469187, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.466347, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.464479, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "rabeprazole", "relevance": 0.459813, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.456154, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "PoliticalDistrict", "Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Country"], "name": "Italy", "dbpedia_resource": "http://dbpedia.org/resource/Italy"}}, {"count": 1, "sentiment": {"score": -0.836509, "label": "negative"}, "text": "MarketPfizer Inc.", "relevance": 0.455452, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.236466, "label": "negative"}, "text": "Bayer AG", "relevance": 0.451959, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medtronic", "relevance": 0.448375, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Medtronic", "dbpedia_resource": "http://dbpedia.org/resource/Medtronic"}}, {"count": 1, "sentiment": {"score": -0.59777, "label": "negative"}, "text": "Valent Pharmaceuticals", "relevance": 0.447074, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "omeprazole", "relevance": 0.442202, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "lansoprazole", "relevance": 0.442023, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.441665, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Spain", "dbpedia_resource": "http://dbpedia.org/resource/Spain"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.440311, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "pantoprazole", "relevance": 0.427549, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Plc", "relevance": 0.425843, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co. Ltd.", "relevance": 0.402846, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6%", "relevance": 0.402846, "type": "Quantity"}], "sentiment": {"document": {"score": -0.529263, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Syndrome Market SegmentationThe Global Rumination Syndrome Market", "keywords": [{"text": "SegmentationThe Global Rumination"}, {"text": "Syndrome Market"}]}, "sentence": "Press release from: Market Research Future Rumination Syndrome Market Rumination Syndrome Market SegmentationThe Global Rumination Syndrome Market is segmented by diagnosis, treatment, and end-user.", "object": {"text": "segmented by diagnosis, treatment, and end-user", "keywords": [{"text": "end-user"}, {"text": "diagnosis"}, {"text": "treatment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by diagnosis, treatment, and end-user", "keywords": [{"text": "end-user"}, {"text": "diagnosis"}, {"text": "treatment"}]}, "sentence": "Press release from: Market Research Future Rumination Syndrome Market Rumination Syndrome Market SegmentationThe Global Rumination Syndrome Market is segmented by diagnosis, treatment, and end-user.", "object": {"text": "Syndrome Market", "keywords": [{"text": "Syndrome Market"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The diagnosis segment", "keywords": [{"text": "diagnosis segment"}]}, "sentence": " The diagnosis segment is further sub-segmented into esophagogastroduodenoscopy, gastric emptying, and others.", "object": {"text": "further sub-segmented"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Furthermore, on the basis of treatment, the market is segmented into behavior therapy and medication.", "object": {"text": "segmented into behavior therapy", "keywords": [{"text": "behavior"}, {"text": "therapy"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Furthermore, on the basis of treatment, the market is segmented into behavior therapy and medication.", "object": {"text": "into behavior therapy and medication", "keywords": [{"text": "medication"}, {"text": "behavior"}, {"text": "therapy"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The medication segment", "keywords": [{"text": "medication segment"}]}, "sentence": " The medication segment has been sub-segmented into proton pump inhibitors and others.", "object": {"text": "sub-segmented into proton pump inhibitors and others", "keywords": [{"text": "proton pump inhibitors"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "Proton pump inhibitors", "keywords": [{"text": "Proton pump inhibitors"}]}, "sentence": " Proton pump inhibitors are sub-segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others.", "object": {"text": "sub-segmented into esomeprazole", "keywords": [{"text": "esomeprazole"}], "entities": [{"type": "Drug", "text": "esomeprazole"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on end-user, the market is segmented into gastroenterology clinics, hospitals, research centers, and others.Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa.", "object": {"text": "segmented into gastroenterology clinics", "keywords": [{"text": "gastroenterology clinics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on end-user, the market is segmented into gastroenterology clinics, hospitals, research centers, and others.Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa.", "object": {"text": "into gastroenterology clinics, hospitals, research centers", "keywords": [{"text": "gastroenterology clinics"}, {"text": "hospitals"}, {"text": "research centers"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "gastroenterology clinics, hospitals, research centers, and others.Based on region the market", "keywords": [{"text": "gastroenterology clinics"}, {"text": "research centers"}, {"text": "hospitals"}, {"text": "region"}]}, "sentence": " Based on end-user, the market is segmented into gastroenterology clinics, hospitals, research centers, and others.Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa.", "object": {"text": "into Americas, Europe, Asia Pacific, and the Middle East and Africa", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "Americas"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Americas", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The American rumination syndrome market", "keywords": [{"text": "American rumination syndrome"}]}, "sentence": " The American rumination syndrome market is segmented into two regions, namely, North America and South America.", "object": {"text": "segmented into two regions, namely, North America and South America", "keywords": [{"text": "regions"}, {"text": "North America"}, {"text": "South America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "South America", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The American rumination syndrome market", "keywords": [{"text": "American rumination syndrome"}]}, "sentence": " The American rumination syndrome market is segmented into two regions, namely, North America and South America.", "object": {"text": "into two regions, namely, North America and South America", "keywords": [{"text": "regions"}, {"text": "North America"}, {"text": "South America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "South America", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is further segmented into the U.S. and Canada.", "object": {"text": "further segmented into the U.S. and Canada", "keywords": [{"text": "U.S."}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "both Eastern and Western European countries which are involved in the deployment of the rumination syndrome", "keywords": [{"text": "rumination syndrome"}, {"text": "Western European countries"}, {"text": "deployment"}, {"text": "Eastern"}]}, "sentence": " The European region includes both Eastern and Western European countries which are involved in the deployment of the rumination syndrome.", "object": {"text": "The European region", "keywords": [{"text": "European region"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "both Eastern and Western European countries", "keywords": [{"text": "Western European countries"}, {"text": "Eastern"}]}, "sentence": " The European region includes both Eastern and Western European countries which are involved in the deployment of the rumination syndrome.", "object": {"text": "involved in the deployment of the rumination syndrome", "keywords": [{"text": "rumination syndrome"}, {"text": "deployment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "both Eastern and Western European countries", "keywords": [{"text": "Western European countries"}, {"text": "Eastern"}]}, "sentence": " The European region includes both Eastern and Western European countries which are involved in the deployment of the rumination syndrome.", "object": {"text": "in the deployment of the rumination syndrome", "keywords": [{"text": "rumination syndrome"}, {"text": "deployment"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "are involved", "normalized": "be involve"}}, {"subject": {"text": "Countries", "keywords": [{"text": "Countries"}]}, "sentence": " Countries that are majorly involved in the rumination syndrome market are the U.K., France, Germany, Spain, and Italy, among others.Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders cover a wide range of diseases.", "object": {"text": "majorly involved"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Countries", "keywords": [{"text": "Countries"}]}, "sentence": " Countries that are majorly involved in the rumination syndrome market are the U.K., France, Germany, Spain, and Italy, among others.Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders cover a wide range of diseases.", "object": {"text": "in the rumination syndrome market", "keywords": [{"text": "rumination syndrome market"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "syndrome market", "keywords": [{"text": "syndrome market"}]}, "sentence": " Countries that are majorly involved in the rumination syndrome market are the U.K., France, Germany, Spain, and Italy, among others.Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders cover a wide range of diseases.", "object": {"text": "the U.K., France, Germany, Spain, and Italy,", "keywords": [{"text": "U.K."}, {"text": "France"}, {"text": "Germany"}, {"text": "Spain"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"type": "Location", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Spain", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Spain", "dbpedia_resource": "http://dbpedia.org/resource/Spain"}}, {"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["HumanLanguage", "PoliticalDistrict", "Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Country"], "name": "Italy", "dbpedia_resource": "http://dbpedia.org/resource/Italy"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "a wide range of diseases", "keywords": [{"text": "wide range"}, {"text": "diseases"}]}, "sentence": " Countries that are majorly involved in the rumination syndrome market are the U.K., France, Germany, Spain, and Italy, among others.Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders cover a wide range of diseases.", "object": {"text": "among others.Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders", "keywords": [{"text": "Rumination Syndrome Market"}, {"text": "Sample Report"}, {"text": "HighlightsGastrointestinal disorders"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "cover", "normalized": "cover"}}, {"subject": {"text": "approximately 6% of the total European population", "keywords": [{"text": "total European population"}], "entities": [{"type": "Quantity", "text": "6"}]}, "sentence": " According to the WHO, approximately 6% of the total European population is suffering from GI disorders.", "object": {"text": "suffering from GI disorders", "keywords": [{"text": "GI disorders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "approximately 6% of the total European population", "keywords": [{"text": "total European population"}], "entities": [{"type": "Quantity", "text": "6"}]}, "sentence": " According to the WHO, approximately 6% of the total European population is suffering from GI disorders.", "object": {"text": "from GI disorders", "keywords": [{"text": "GI disorders"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "is suffering", "normalized": "be suffer"}}, {"subject": {"text": "Factors", "keywords": [{"text": "Factors"}]}, "sentence": " Factors such as increasing investments in research activities and growing population are responsible for the growth of the market in this region.", "object": {"text": "investments", "keywords": [{"text": "investments"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "Factors such as increasing investments in research activities and growing population", "keywords": [{"text": "research activities"}, {"text": "investments"}, {"text": "Factors"}, {"text": "population"}]}, "sentence": " Factors such as increasing investments in research activities and growing population are responsible for the growth of the market in this region.", "object": {"text": "responsible for the growth of the market in this region", "keywords": [{"text": "growth"}, {"text": "market"}, {"text": "region"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "this unhygienic food and improper diet", "keywords": [{"text": "improper diet"}, {"text": "unhygienic food"}]}, "sentence": " Besides, this unhygienic food and improper diet are responsible for causing many GI disorders.", "object": {"text": "responsible for causing many GI disorders", "keywords": [{"text": "GI disorders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "this unhygienic food and improper diet", "keywords": [{"text": "improper diet"}, {"text": "unhygienic food"}]}, "sentence": " Besides, this unhygienic food and improper diet are responsible for causing many GI disorders.", "object": {"text": "many GI disorders", "keywords": [{"text": "GI disorders"}]}, "action": {"verb": {"text": "cause", "tense": "present"}, "text": "causing", "normalized": "cause"}}, {"subject": {"text": "Incorrect self-diagnosis and introduction of many misbranded and spurious drugs in the market", "keywords": [{"text": "Incorrect self-diagnosis"}, {"text": "spurious drugs"}, {"text": "introduction"}, {"text": "market"}]}, "sentence": " Incorrect self-diagnosis and introduction of many misbranded and spurious drugs in the market are likely to be responsible for hampering the rumination syndrome market growth during the forecast period.Key Players in the Global Rumination Syndrome MarketPfizer Inc., Valent Pharmaceuticals, Medtronic, Astra Zeneca, Eisai Co. Ltd., Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, Johnson & Johnson, Bayer AG, Otsuka Pharmaceutical Co.", "object": {"text": "responsible"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "to be", "normalized": "to be"}}, {"subject": {"text": "Incorrect self-diagnosis and introduction of many misbranded and spurious drugs in the market", "keywords": [{"text": "Incorrect self-diagnosis"}, {"text": "spurious drugs"}, {"text": "introduction"}, {"text": "market"}]}, "sentence": " Incorrect self-diagnosis and introduction of many misbranded and spurious drugs in the market are likely to be responsible for hampering the rumination syndrome market growth during the forecast period.Key Players in the Global Rumination Syndrome MarketPfizer Inc., Valent Pharmaceuticals, Medtronic, Astra Zeneca, Eisai Co. Ltd., Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, Johnson & Johnson, Bayer AG, Otsuka Pharmaceutical Co.", "object": {"text": "the rumination syndrome market growth", "keywords": [{"text": "rumination syndrome market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hampering", "normalized": "hamper"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Ltd, and others.Regional Rumination Syndrome Market Summary:According to MRFR analysis, North America holds the largest market and is mainly driven by the presence of major market players, high healthcare spending, and continuous technological development.", "object": {"text": "the largest market", "keywords": [{"text": "largest market"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Ltd, and others.Regional Rumination Syndrome Market Summary:According to MRFR analysis, North America holds the largest market and is mainly driven by the presence of major market players, high healthcare spending, and continuous technological development.", "object": {"text": "mainly driven by the presence of major market players, high healthcare spending, and continuous technological development", "keywords": [{"text": "continuous technological development"}, {"text": "high healthcare spending"}, {"text": "major market players"}, {"text": "presence"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "market players", "keywords": [{"text": "market players"}]}, "sentence": " Furthermore, established market players in the market lead to globalization by pushing new products and services into developing countries and emerging economies.", "action": {"verb": {"text": "establish", "tense": "past"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "new products and services", "keywords": [{"text": "new products"}, {"text": "services"}]}, "sentence": " Furthermore, established market players in the market lead to globalization by pushing new products and services into developing countries and emerging economies.", "object": {"text": "into developing countries and emerging economies", "keywords": [{"text": "economies"}, {"text": "countries"}]}, "action": {"verb": {"text": "push", "tense": "present"}, "text": "pushing", "normalized": "push"}}, {"subject": {"text": "South America", "keywords": [{"text": "South America"}], "entities": [{"type": "Location", "text": "South America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " South America is expected to be the fastest growing market for the American rumination syndrome market due to technologically advanced devices for diagnosis and increasing demand for treatment options of chronic diseases during the forecast period 2018\u20132023.The European rumination syndrome market is expected to exhibit growth during the forecast period, 2018 to 2023 with an increasing emphasis on research and developmental activities for improvement in diagnosis and treatment methods.", "object": {"text": "the fastest growing market", "keywords": [{"text": "fastest growing market"}], "entities": [{"type": "Location", "text": "South America", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "syndrome market", "keywords": [{"text": "syndrome market"}]}, "sentence": " South America is expected to be the fastest growing market for the American rumination syndrome market due to technologically advanced devices for diagnosis and increasing demand for treatment options of chronic diseases during the forecast period 2018\u20132023.The European rumination syndrome market is expected to exhibit growth during the forecast period, 2018 to 2023 with an increasing emphasis on research and developmental activities for improvement in diagnosis and treatment methods.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "syndrome market", "keywords": [{"text": "syndrome market"}]}, "sentence": " South America is expected to be the fastest growing market for the American rumination syndrome market due to technologically advanced devices for diagnosis and increasing demand for treatment options of chronic diseases during the forecast period 2018\u20132023.The European rumination syndrome market is expected to exhibit growth during the forecast period, 2018 to 2023 with an increasing emphasis on research and developmental activities for improvement in diagnosis and treatment methods.", "object": {"text": "growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "increasing expenditure on healthcare by these countries in Europe", "keywords": [{"text": "expenditure"}, {"text": "healthcare"}, {"text": "countries"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Additionally, increasing expenditure on healthcare by these countries in Europe also accelerates the growth of the market.Asia Pacific is expected to grow at a faster pace during the forecast period, 2018\u20132023.", "object": {"text": "the growth of the market.Asia Pacific", "keywords": [{"text": "market.Asia Pacific"}, {"text": "growth"}]}, "action": {"verb": {"text": "accelerate", "tense": "present"}, "text": "accelerates", "normalized": "accelerate"}}, {"subject": {"text": "The growth", "keywords": [{"text": "growth"}]}, "sentence": " The growth is majorly attributed to the increasing patient population in developing countries and increasing investments in the healthcare sector.", "object": {"text": "to the increasing patient population in developing countries and increasing investments in the healthcare sector", "keywords": [{"text": "patient population"}, {"text": "healthcare sector"}, {"text": "investments"}, {"text": "countries"}]}, "action": {"verb": {"text": "attribute", "tense": "past"}, "text": "attributed", "normalized": "attribute"}}, {"subject": {"text": "investments", "keywords": [{"text": "investments"}]}, "sentence": " The growth is majorly attributed to the increasing patient population in developing countries and increasing investments in the healthcare sector.", "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "India", "keywords": [{"text": "India"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " For instance, India is experiencing high demand for GI and related disorder drugs.", "object": {"text": "experiencing high demand for GI and related disorder drugs", "keywords": [{"text": "related disorder drugs"}, {"text": "high demand"}, {"text": "GI"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "India", "keywords": [{"text": "India"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " For instance, India is experiencing high demand for GI and related disorder drugs.", "object": {"text": "high demand for GI and related disorder drugs", "keywords": [{"text": "related disorder drugs"}, {"text": "high demand"}, {"text": "GI"}]}, "action": {"verb": {"text": "experience", "tense": "present"}, "text": "is experiencing", "normalized": "be experience"}}, {"subject": {"text": "major pharmaceutical drug manufacturers", "keywords": [{"text": "major pharmaceutical drug"}, {"text": "manufacturers"}]}, "sentence": " Moreover, major pharmaceutical drug manufacturers are using their technology and services to develop new drugs for GI diseases to meet the growing demand.", "object": {"text": "using their technology and services", "keywords": [{"text": "technology"}, {"text": "services"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "major pharmaceutical drug manufacturers", "keywords": [{"text": "major pharmaceutical drug"}, {"text": "manufacturers"}]}, "sentence": " Moreover, major pharmaceutical drug manufacturers are using their technology and services to develop new drugs for GI diseases to meet the growing demand.", "object": {"text": "their technology and services", "keywords": [{"text": "technology"}, {"text": "services"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "are using", "normalized": "be use"}}, {"subject": {"text": "major pharmaceutical drug manufacturers", "keywords": [{"text": "major pharmaceutical drug"}, {"text": "manufacturers"}]}, "sentence": " Moreover, major pharmaceutical drug manufacturers are using their technology and services to develop new drugs for GI diseases to meet the growing demand.", "object": {"text": "new drugs", "keywords": [{"text": "new drugs"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "healthcare in Malaysia", "keywords": [{"text": "Malaysia"}, {"text": "healthcare"}], "entities": [{"type": "Location", "text": "Malaysia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "Malaysia", "dbpedia_resource": "http://dbpedia.org/resource/Malaysia"}}]}, "sentence": " Furthermore, healthcare in Malaysia is segmented into a government universal healthcare scheme and a private healthcare system.", "object": {"text": "segmented into a government universal healthcare scheme and a private healthcare system", "keywords": [{"text": "universal healthcare scheme"}, {"text": "private healthcare"}, {"text": "government"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "healthcare in Malaysia", "keywords": [{"text": "Malaysia"}, {"text": "healthcare"}], "entities": [{"type": "Location", "text": "Malaysia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "Malaysia", "dbpedia_resource": "http://dbpedia.org/resource/Malaysia"}}]}, "sentence": " Furthermore, healthcare in Malaysia is segmented into a government universal healthcare scheme and a private healthcare system.", "object": {"text": "into a government universal healthcare scheme and a private healthcare system", "keywords": [{"text": "universal healthcare scheme"}, {"text": "private healthcare"}, {"text": "government"}], "entities": []}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The private healthcare system", "keywords": [{"text": "private healthcare"}], "entities": []}, "sentence": " The private healthcare system is growing rapidly, especially, in urban areas due to increasing wealthy and middle-class population, geriatric population, urbanization, and high-quality healthcare and medicines.", "object": {"text": "growing rapidly, especially, in urban areas due to increasing wealthy and middle-class population, geriatric population, urbanization, and high-quality healthcare and medicines", "keywords": [{"text": "middle-class population"}, {"text": "geriatric population"}, {"text": "high-quality healthcare"}, {"text": "urban areas"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the rapidly growing economies of the Asia Pacific region", "keywords": [{"text": "rapidly growing economies"}, {"text": "Asia Pacific region"}], "entities": [{"type": "GeographicFeature", "text": "Asia Pacific"}]}, "sentence": " Thus, the rapidly growing economies of the Asia Pacific region are expected to provide vital support to the global rumination syndrome market.The Middle Eastern and African market for the rumination syndrome exhibits a steady rise with an increase in the number of healthcare facilities providing treatments of chronic conditions and the flourishing growth of the medical devices market.", "object": {"text": "vital support", "keywords": [{"text": "vital support"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "are expected to provide", "normalized": "be expect to provide"}}, {"subject": {"text": "the rumination syndrome", "keywords": [{"text": "rumination syndrome"}]}, "sentence": " Thus, the rapidly growing economies of the Asia Pacific region are expected to provide vital support to the global rumination syndrome market.The Middle Eastern and African market for the rumination syndrome exhibits a steady rise with an increase in the number of healthcare facilities providing treatments of chronic conditions and the flourishing growth of the medical devices market.", "object": {"text": "a steady rise with an increase in the number of healthcare facilities providing treatments of chronic conditions and the flourishing growth of the medical devices market", "keywords": [{"text": "steady rise"}, {"text": "medical devices market"}, {"text": "flourishing growth"}, {"text": "chronic conditions"}], "entities": []}, "action": {"verb": {"text": "exhibit", "tense": "present"}, "text": "exhibits", "normalized": "exhibit"}}, {"subject": {"text": "the awareness about the rumination syndrome", "keywords": [{"text": "rumination syndrome"}, {"text": "awareness"}]}, "sentence": " In the African region, the awareness about the rumination syndrome is fueling the growth of the market.", "object": {"text": "fueling the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "sentence": " In the African region, the awareness about the rumination syndrome is fueling the growth of the market.", "object": {"text": "the awareness about the rumination syndrome", "keywords": [{"text": "rumination syndrome"}, {"text": "awareness"}]}, "action": {"verb": {"text": "fuel", "tense": "present"}, "text": "is fueling", "normalized": "be fuel"}}], "concepts": [{"text": "Medicine", "relevance": 0.968476, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Europe", "relevance": 0.77304, "dbpedia_resource": "http://dbpedia.org/resource/Europe"}, {"text": "AstraZeneca", "relevance": 0.600706, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Pharmaceutical drug", "relevance": 0.58872, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Economics", "relevance": 0.582351, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Irritable bowel syndrome", "relevance": 0.541175, "dbpedia_resource": "http://dbpedia.org/resource/Irritable_bowel_syndrome"}, {"text": "United States", "relevance": 0.52764, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Middle East", "relevance": 0.470057, "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}, {"text": "North America", "relevance": 0.455871, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacology", "relevance": 0.439717, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Healthcare", "relevance": 0.417612, "dbpedia_resource": "http://dbpedia.org/resource/Healthcare"}, {"text": "South America", "relevance": 0.398694, "dbpedia_resource": "http://dbpedia.org/resource/South_America"}, {"text": "Novo Nordisk", "relevance": 0.393725, "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}, {"text": "Western Europe", "relevance": 0.363503, "dbpedia_resource": "http://dbpedia.org/resource/Western_Europe"}, {"text": "Gastroenterology", "relevance": 0.359493, "dbpedia_resource": "http://dbpedia.org/resource/Gastroenterology"}, {"text": "Drug", "relevance": 0.350788, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Pacific Ocean", "relevance": 0.347446, "dbpedia_resource": "http://dbpedia.org/resource/Pacific_Ocean"}, {"text": "Americas", "relevance": 0.345592, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Universal health care", "relevance": 0.337779, "dbpedia_resource": "http://dbpedia.org/resource/Universal_health_care"}, {"text": "European countries", "relevance": 0.334015, "dbpedia_resource": "http://dbpedia.org/resource/European_countries"}, {"text": "Disease", "relevance": 0.330351, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Coeliac disease", "relevance": 0.328727, "dbpedia_resource": "http://dbpedia.org/resource/Coeliac_disease"}, {"text": "Asia", "relevance": 0.325668, "dbpedia_resource": "http://dbpedia.org/resource/Asia"}, {"text": "Health economics", "relevance": 0.324527, "dbpedia_resource": "http://dbpedia.org/resource/Health_economics"}, {"text": "Rumination syndrome", "relevance": 0.322402, "dbpedia_resource": "http://dbpedia.org/resource/Rumination_syndrome"}, {"text": "Chronic", "relevance": 0.31638, "dbpedia_resource": "http://dbpedia.org/resource/Chronic_(medicine)"}, {"text": "Asia-Pacific", "relevance": 0.312366, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "Otsuka Pharmaceutical Co.", "relevance": 0.311833, "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical_Co."}, {"text": "Health care system", "relevance": 0.307912, "dbpedia_resource": "http://dbpedia.org/resource/Health_care_system"}, {"text": "Developed country", "relevance": 0.305464, "dbpedia_resource": "http://dbpedia.org/resource/Developed_country"}, {"text": "Health care in the United States", "relevance": 0.304859, "dbpedia_resource": "http://dbpedia.org/resource/Health_care_in_the_United_States"}, {"text": "Economic growth", "relevance": 0.304654, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "Americas", "relevance": 0.298571, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Diseases and disorders", "relevance": 0.29511, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Economics terminology", "relevance": 0.295072, "dbpedia_resource": "http://dbpedia.org/resource/Economics_terminology"}, {"text": "Abdominal pain", "relevance": 0.294533, "dbpedia_resource": "http://dbpedia.org/resource/Abdominal_pain"}], "categories": [{"score": 0.624611, "label": "/health and fitness/disease/gerd and acid reflux"}, {"score": 0.549406, "label": "/health and fitness/disorders"}, {"score": 0.330165, "label": "/health and fitness/disease/ibs and crohn's disease"}], "relations": [{"type": "locatedAt", "sentence": "Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa.", "score": 0.674576, "arguments": [{"text": "Asia", "location": [816, 820], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [821, 828], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Thus, the rapidly growing economies of the Asia Pacific region are expected to provide vital support to the global rumination syndrome market.", "score": 0.520715, "arguments": [{"text": "Asia", "location": [4445, 4449], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [4450, 4457], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "hasAttribute", "sentence": "Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders cover a wide range of diseases.", "score": 0.716459, "arguments": [{"text": "www.marketresearchfuture.com/sample_request/", "location": [1328, 1372], "entities": [{"type": "Person", "text": "www.marketresearchfuture.com/sample_request/"}]}, {"text": "diseases", "location": [1463, 1471], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "locatedAt", "sentence": "According to the WHO, approximately 6% of the total European population is suffering from GI disorders.", "score": 0.307133, "arguments": [{"text": "population", "location": [1534, 1544], "entities": [{"type": "Person", "text": "population"}]}, {"text": "European", "location": [1525, 1533], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Beside common diseases such as rumination syndrome, diarrhea, and chronic diseases such as celiac disease, diverticulitis, and irritable bowel syndrome help in contributing a huge share of the GI drug market.", "score": 0.633303, "arguments": [{"text": "chronic diseases", "location": [1643, 1659], "entities": [{"type": "HealthCondition", "text": "chronic diseases"}]}, {"text": "diseases", "location": [1591, 1599], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "partOfMany", "sentence": "Beside common diseases such as rumination syndrome, diarrhea, and chronic diseases such as celiac disease, diverticulitis, and irritable bowel syndrome help in contributing a huge share of the GI drug market.", "score": 0.443242, "arguments": [{"text": "celiac disease", "location": [1668, 1682], "entities": [{"type": "HealthCondition", "text": "celiac disease"}]}, {"text": "chronic diseases", "location": [1643, 1659], "entities": [{"type": "HealthCondition", "text": "chronic diseases"}]}]}, {"type": "partOfMany", "sentence": "Beside common diseases such as rumination syndrome, diarrhea, and chronic diseases such as celiac disease, diverticulitis, and irritable bowel syndrome help in contributing a huge share of the GI drug market.", "score": 0.528565, "arguments": [{"text": "diverticulitis", "location": [1684, 1698], "entities": [{"type": "HealthCondition", "text": "diverticulitis"}]}, {"text": "chronic diseases", "location": [1643, 1659], "entities": [{"type": "HealthCondition", "text": "chronic diseases"}]}]}, {"type": "employedBy", "sentence": "Key Players in the Global Rumination Syndrome MarketPfizer Inc., Valent Pharmaceuticals, Medtronic, Astra Zeneca, Eisai Co. Ltd., Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, Johnson & Johnson, Bayer AG, Otsuka Pharmaceutical Co. Ltd, and others.", "score": 0.61353, "arguments": [{"text": "Valent Pharmaceuticals", "location": [2294, 2316], "entities": [{"type": "Person", "text": "Valent Pharmaceuticals"}]}, {"text": "Medtronic", "location": [2318, 2327], "entities": [{"type": "Organization", "text": "Medtronic", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Additionally, increasing expenditure on healthcare by these countries in Europe also accelerates the growth of the market.", "score": 0.513854, "arguments": [{"text": "countries", "location": [3527, 3536], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Europe", "location": [3540, 3546], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific is expected to grow at a faster pace during the forecast period, 2018-2023.", "score": 0.746451, "arguments": [{"text": "Pacific", "location": [3594, 3601], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [3589, 3593], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Thus, the rapidly growing economies of the Asia Pacific region are expected to provide vital support to the global rumination syndrome market.", "score": 0.407497, "arguments": [{"text": "region", "location": [4458, 4464], "entities": [{"type": "GeopoliticalEntity", "text": "African region"}]}, {"text": "Asia", "location": [4445, 4449], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Thus, the rapidly growing economies of the Asia Pacific region are expected to provide vital support to the global rumination syndrome market.", "score": 0.517634, "arguments": [{"text": "region", "location": [4458, 4464], "entities": [{"type": "GeopoliticalEntity", "text": "African region"}]}, {"text": "Pacific", "location": [4450, 4457], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The American rumination syndrome market is segmented into two regions, namely, North America and South America.", "score": 0.587211, "arguments": [{"text": "regions", "location": [924, 931], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "South America", "location": [959, 972], "entities": [{"type": "GeopoliticalEntity", "text": "South America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "The European region includes both Eastern and Western European countries which are involved in the deployment of the rumination syndrome.", "score": 0.181291, "arguments": [{"text": "European", "location": [1039, 1047], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "region", "location": [1048, 1054], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "The European region includes both Eastern and Western European countries which are involved in the deployment of the rumination syndrome.", "score": 0.761608, "arguments": [{"text": "European", "location": [1089, 1097], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Western", "location": [1081, 1088], "entities": [{"type": "GeopoliticalEntity", "text": "Western"}]}]}, {"type": "locatedAt", "sentence": "The European region includes both Eastern and Western European countries which are involved in the deployment of the rumination syndrome.", "score": 0.515295, "arguments": [{"text": "countries", "location": [1098, 1107], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Western", "location": [1081, 1088], "entities": [{"type": "GeopoliticalEntity", "text": "Western"}]}]}, {"type": "basedIn", "sentence": "The European region includes both Eastern and Western European countries which are involved in the deployment of the rumination syndrome.", "score": 0.390906, "arguments": [{"text": "countries", "location": [1098, 1107], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "European", "location": [1089, 1097], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Countries that are majorly involved in the rumination syndrome market are the U.K., France, Germany, Spain, and Italy, among others.", "score": 0.848951, "arguments": [{"text": "U.K.", "location": [1251, 1255], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "France", "location": [1257, 1263], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders cover a wide range of diseases.", "score": 0.572176, "arguments": [{"text": "www.marketresearchfuture.com/sample_request/", "location": [1328, 1372], "entities": [{"type": "Person", "text": "www.marketresearchfuture.com/sample_request/"}]}, {"text": "Report", "location": [1318, 1324], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Get a Sample Report at www.marketresearchfuture.com/sample_request/6047 Rumination Syndrome Market HighlightsGastrointestinal disorders cover a wide range of diseases.", "score": 0.702657, "arguments": [{"text": "Rumination Syndrome Market HighlightsGastrointestinal disorders", "location": [1377, 1440], "entities": [{"type": "Organization", "text": "Rumination Syndrome Market HighlightsGastrointestinal disorders"}]}, {"text": "Report", "location": [1318, 1324], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}], "keywords": [{"text": "rumination syndrome market", "sentiment": {"score": -0.619374, "label": "negative"}, "relevance": 0.93489}, {"text": "global rumination syndrome", "sentiment": {"score": 0.0439989, "label": "positive"}, "relevance": 0.724484}, {"text": "Syndrome Market Rumination", "sentiment": {"score": -0.604524, "label": "negative"}, "relevance": 0.666041}, {"text": "American rumination syndrome", "sentiment": {"score": -0.51383, "label": "negative"}, "relevance": 0.661211}, {"text": "SegmentationThe Global Rumination", "sentiment": {"score": -0.604524, "label": "negative"}, "relevance": 0.614736}, {"text": "Rumination Syndrome MarketPfizer", "sentiment": {"score": -0.836509, "label": "negative"}, "relevance": 0.602652}, {"text": "others.Regional Rumination Syndrome", "sentiment": {"score": -0.377949, "label": "negative"}, "relevance": 0.600741}, {"text": "European rumination syndrome", "sentiment": {"score": -0.724307, "label": "negative"}, "relevance": 0.598844}, {"text": "rumination syndrome market.The", "sentiment": {"score": 0.764515, "label": "positive"}, "relevance": 0.584702}, {"text": "proton pump inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526377}, {"text": "syndrome market growth", "sentiment": {"score": -0.836509, "label": "negative"}, "relevance": 0.511698}, {"text": "Syndrome Market HighlightsGastrointestinal", "sentiment": {"score": -0.687843, "label": "negative"}, "relevance": 0.507884}, {"text": "GI drug market", "sentiment": {"score": -0.656979, "label": "negative"}, "relevance": 0.499821}, {"text": "Syndrome Market Report", "sentiment": {"score": -0.704433, "label": "negative"}, "relevance": 0.49854}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.488816}, {"text": "major market players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487729}, {"text": "forecast period", "sentiment": {"score": -0.724307, "label": "negative"}, "relevance": 0.486633}, {"text": "fastest growing market", "sentiment": {"score": -0.724307, "label": "negative"}, "relevance": 0.486126}, {"text": "irritable bowel syndrome", "sentiment": {"score": -0.656979, "label": "negative"}, "relevance": 0.478682}, {"text": "medical devices market", "sentiment": {"score": 0.764515, "label": "positive"}, "relevance": 0.477445}, {"text": "GI disorders", "sentiment": {"score": -0.662701, "label": "negative"}, "relevance": 0.473174}, {"text": "forecast period.Key Players", "sentiment": {"score": -0.836509, "label": "negative"}, "relevance": 0.468705}, {"text": "Western European countries", "sentiment": {"score": -0.537116, "label": "negative"}, "relevance": 0.467919}, {"text": "total European population", "sentiment": {"score": -0.578189, "label": "negative"}, "relevance": 0.467839}, {"text": "high healthcare spending", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466598}, {"text": "South America", "sentiment": {"score": -0.724307, "label": "negative"}, "relevance": 0.463942}, {"text": "government universal healthcare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462501}, {"text": "Asia Pacific", "sentiment": {"score": 0.764515, "label": "positive"}, "relevance": 0.461624}, {"text": "chronic diseases", "sentiment": {"score": -0.731924, "label": "negative"}, "relevance": 0.460906}, {"text": "Novo Nordisk A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459057}, {"text": "Research Report Enabled", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458785}, {"text": "rapidly growing economies", "sentiment": {"score": 0.764515, "label": "positive"}, "relevance": 0.4587}, {"text": "Eisai Co. Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458484}, {"text": "Asia Pacific region", "sentiment": {"score": 0.764515, "label": "positive"}, "relevance": 0.458293}, {"text": "Market Summary", "sentiment": {"score": -0.377949, "label": "negative"}, "relevance": 0.457832}, {"text": "largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457732}, {"text": "major pharmaceutical drug", "sentiment": {"score": -0.662848, "label": "negative"}, "relevance": 0.457553}, {"text": "market lead", "sentiment": {"score": 0.365922, "label": "positive"}, "relevance": 0.457275}, {"text": "technologically advanced devices", "sentiment": {"score": -0.724307, "label": "negative"}, "relevance": 0.457274}, {"text": "related disorder drugs", "sentiment": {"score": -0.562259, "label": "negative"}, "relevance": 0.4552}, {"text": "private healthcare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454968}, {"text": "continuous technological development", "sentiment": {"score": 0.374575, "label": "positive"}, "relevance": 0.454372}, {"text": "African market", "sentiment": {"score": 0.764515, "label": "positive"}, "relevance": 0.453423}, {"text": "diagnosis segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442018}, {"text": "European region", "sentiment": {"score": -0.537116, "label": "negative"}, "relevance": 0.439895}, {"text": "research centers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43801}, {"text": "Press release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436979}, {"text": "healthcare facilities", "sentiment": {"score": 0.764515, "label": "positive"}, "relevance": 0.436942}, {"text": "common diseases", "sentiment": {"score": -0.74206, "label": "negative"}, "relevance": 0.436499}, {"text": "research activities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436425}]}, "extracted_metadata": {"sha1": "372d6a448842e3b737b01a13f362a23661df8806", "filename": "1542097086724.zip-94c5c6590ac162da20321e2773002107.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/sample_request/6047", "https://www.marketresearchfuture.com/reports/rumination-syndrome-market-6047"], "title": "Rumination Syndrome Market Comprehensive Top Players Analysis in 2018 | Global Healthcare Industry Size, Growth Rate and Demand by 2023", "forum_title": "openPR.com - Newsfeed"}, {"id": "m1XJIPv4CKYo5IYKwhxZVQhJ98WelV6P4TJE-0LX3G6fc5lHb090tw7B_1PkJ2fS", "result_metadata": {"score": 32.12798}, "author": "mylubbocktv.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GammaDelta Therapeutics", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.576828, "label": "/science/medicine/pharmacology"}, {"score": 0.526844, "label": "/technology and computing/enterprise technology/data management"}, {"score": 0.397177, "label": "/science/medicine/oncology"}], "relations": [{"type": "locatedAt", "sentence": "GammaDelta Therapeutics Announces Publication of New Data in Nat", "score": 0.982742, "arguments": [{"text": "New Data", "location": [49, 57], "entities": [{"type": "GeopoliticalEntity", "text": "New Data"}]}, {"text": "Nat", "location": [61, 64], "entities": [{"type": "GeopoliticalEntity", "text": "Nat"}]}]}], "keywords": [{"text": "GammaDelta Therapeutics Announces", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.978493}, {"text": "Nat", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438665}, {"text": "New Data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.383506}, {"text": "Publication", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.205224}]}, "crawl_date": "2018-11-13T13:45:58Z", "url": "http://www.mylubbocktv.com/story/39468874/gammadelta-therapeutics-announces-publication-of-new-data-in-nature-immunology-describing-the-independent-immune-function-of-gamma-delta-t-cell", "host": "mylubbocktv.com", "text": "In May 2017 , GammaDelta Therapeutics entered into a strategic collaboration with Takeda Pharmaceutical Co.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T00:00:00-05:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.791709, "label": "negative"}, "text": "GammaDelta Therapeutics", "relevance": 0.884935, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.610376, "label": "positive"}, "text": "Professor Adrian Hayday", "relevance": 0.713615, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GammaDelta Therapeutics Ltd", "relevance": 0.643396, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.610376, "label": "positive"}, "text": "GammaDelta", "relevance": 0.44194, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Paolo Paoletti", "relevance": 0.435303, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.410735, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Francis Crick Institute", "relevance": 0.395871, "type": "Organization", "disambiguation": {"subtype": [], "name": "Francis Crick Institute", "dbpedia_resource": "http://dbpedia.org/resource/Francis_Crick_Institute"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "King's College London", "relevance": 0.363068, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.45258, "label": "negative"}, "text": "Nature Immunology", "relevance": 0.298958, "type": "PrintMedia", "disambiguation": {"subtype": [], "name": "Nature Immunology", "dbpedia_resource": "http://dbpedia.org/resource/Nature_Immunology"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.275951, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Melandri", "relevance": 0.269, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.59887, "label": "negative"}, "text": "bowel disease", "relevance": 0.267115, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.24737, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.245498, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cancer Research Technology Limited", "relevance": 0.240485, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.23719, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abingworth", "relevance": 0.220192, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr Oliver Nussbaumer", "relevance": 0.212394, "type": "Person"}], "sentiment": {"document": {"score": 0.314241, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Findings", "keywords": [{"text": "Findings"}]}, "sentence": " Findings support development of ?d T cells for gastrointestinal diseases", "object": {"text": "development of ?d T cells for gastrointestinal diseases", "keywords": [{"text": "gastrointestinal diseases"}, {"text": "cells"}, {"text": "development"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "an emerging biotech company", "keywords": [{"text": "biotech company"}]}, "sentence": " GammaDelta Therapeutics Ltd, an emerging biotech company developing novel immunotherapies for cancer and other diseases announced today the publication in Nature Immunology of new data examining the biological role of gamma delta (?d) T cell receptors.", "object": {"text": "novel immunotherapies", "keywords": [{"text": "novel immunotherapies"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "the publication in Nature Immunology of new data", "keywords": [{"text": "Nature Immunology"}, {"text": "new data"}, {"text": "publication"}], "entities": [{"type": "PrintMedia", "text": "Nature Immunology", "disambiguation": {"subtype": [], "name": "Nature Immunology", "dbpedia_resource": "http://dbpedia.org/resource/Nature_Immunology"}}]}, "sentence": " GammaDelta Therapeutics Ltd, an emerging biotech company developing novel immunotherapies for cancer and other diseases announced today the publication in Nature Immunology of new data examining the biological role of gamma delta (?d) T cell receptors.", "object": {"text": "the biological role of gamma delta", "keywords": [{"text": "biological role"}, {"text": "gamma delta"}]}, "action": {"verb": {"text": "examine", "tense": "present"}, "text": "examining", "normalized": "examine"}}, {"subject": {"text": "The study", "keywords": [{"text": "study"}]}, "sentence": " The study shows for the first time how ?d T cell receptors can act independently from other immune signals, functioning as a two-pronged device to discriminate cancer cells from normal cells before proceeding to kill them.", "object": {"text": "for the first time how ?d T cell receptors can act independently from other immune signals, functioning as a two-pronged device to discriminate cancer cells from normal cells before proceeding to kill them", "keywords": [{"text": "normal cells"}, {"text": "immune signals"}, {"text": "cell receptors"}, {"text": "cancer cells"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "shows", "normalized": "show"}}, {"subject": {"text": "?d T cell receptors", "keywords": [{"text": "cell receptors"}]}, "sentence": " The study shows for the first time how ?d T cell receptors can act independently from other immune signals, functioning as a two-pronged device to discriminate cancer cells from normal cells before proceeding to kill them.", "object": {"text": "from other immune signals", "keywords": [{"text": "immune signals"}]}, "action": {"verb": {"text": "act", "tense": "future"}, "text": "can act", "normalized": "can act"}}, {"subject": {"text": "The receptors", "keywords": [{"text": "receptors"}]}, "sentence": " The receptors combine so-called innate immunity with so-called adaptive immunity by using different regions of the receptor to recognise different molecular targets, one associated with healthy tissues and the other associated with malignant cells.", "object": {"text": "so-called innate immunity", "keywords": [{"text": "so-called innate immunity"}]}, "action": {"verb": {"text": "combine", "tense": "present"}, "text": "combine", "normalized": "combine"}}, {"subject": {"text": "The receptors", "keywords": [{"text": "receptors"}]}, "sentence": " The receptors combine so-called innate immunity with so-called adaptive immunity by using different regions of the receptor to recognise different molecular targets, one associated with healthy tissues and the other associated with malignant cells.", "object": {"text": "different regions", "keywords": [{"text": "different regions"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "using", "normalized": "use"}}, {"subject": {"text": "one"}, "sentence": " The receptors combine so-called innate immunity with so-called adaptive immunity by using different regions of the receptor to recognise different molecular targets, one associated with healthy tissues and the other associated with malignant cells.", "object": {"text": "with healthy tissues and the other associated with malignant cells", "keywords": [{"text": "healthy tissues"}, {"text": "malignant cells"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The study focused on ?d T cells", "keywords": [{"text": "cells"}, {"text": "study"}]}, "sentence": " The study focused on ?d T cells that line the gut surface where cancers often develop.", "object": {"text": "the gut surface where cancers often develop", "keywords": [{"text": "gut surface"}, {"text": "cancers"}]}, "action": {"verb": {"text": "line", "tense": "present"}, "text": "line", "normalized": "line"}}, {"subject": {"text": "cancers", "keywords": [{"text": "cancers"}]}, "sentence": " The study focused on ?d T cells that line the gut surface where cancers often develop.", "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develop", "normalized": "develop"}}, {"subject": {"text": "the findings", "keywords": [{"text": "findings"}]}, "sentence": " By casting greater light on the complex gut immune system, the findings also enable further exploration of the causes and possible treatments for inflammatory bowel disease.", "object": {"text": "greater light", "keywords": [{"text": "greater light"}]}, "action": {"verb": {"text": "cast", "tense": "present"}, "text": "casting", "normalized": "cast"}}, {"subject": {"text": "the findings", "keywords": [{"text": "findings"}]}, "sentence": " By casting greater light on the complex gut immune system, the findings also enable further exploration of the causes and possible treatments for inflammatory bowel disease.", "object": {"text": "further exploration of the causes and possible treatments for inflammatory bowel disease", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "possible treatments"}, {"text": "exploration"}, {"text": "causes"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "Paolo Paoletti , CEO at GammaDelta,", "keywords": [{"text": "Paolo Paoletti"}, {"text": "CEO"}, {"text": "GammaDelta"}], "entities": [{"type": "Person", "text": "Paolo Paoletti"}, {"type": "JobTitle", "text": "CEO"}, {"type": "Company", "text": "GammaDelta"}]}, "sentence": " Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "object": {"text": "We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories", "keywords": [{"text": "Professor Adrian Hayday"}, {"text": "productive collaboration"}, {"text": "laboratories"}, {"text": "GammaDelta"}], "entities": [{"type": "Company", "text": "GammaDelta"}, {"type": "Person", "text": "Professor Adrian Hayday"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Deeper understanding of the fundamental biology of ?d T cells", "keywords": [{"text": "Deeper understanding"}, {"text": "fundamental biology"}, {"text": "cells"}]}, "sentence": " Deeper understanding of the fundamental biology of ?d T cells is crucial to exploiting their potential for therapeutic applications.\"", "object": {"text": "crucial to exploiting their potential for therapeutic applications", "keywords": [{"text": "therapeutic applications"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the fundamental biology of ?d T cells", "keywords": [{"text": "fundamental biology"}, {"text": "cells"}]}, "sentence": " Deeper understanding of the fundamental biology of ?d T cells is crucial to exploiting their potential for therapeutic applications.\"", "object": {"text": "their potential"}, "action": {"verb": {"text": "exploit", "tense": "future"}, "text": "exploiting", "normalized": "exploit"}}, {"subject": {"text": "Adrian Hayday", "keywords": [{"text": "Adrian Hayday"}], "entities": [{"type": "Person", "text": "Professor Adrian Hayday"}]}, "sentence": " Commenting on the findings, Adrian Hayday said: \"I am very excited about these unexpected findings, which are a key step in unravelling the complex mechanisms by which ?d T cells attempt to maintain tissue integrity in the face of an unending spectrum of microbial and chemical challenges.\"", "object": {"text": "on the findings", "keywords": [{"text": "findings"}]}, "action": {"verb": {"text": "Commenting", "tense": "present"}, "text": "Commenting", "normalized": "Commenting"}}, {"subject": {"text": "Adrian Hayday", "keywords": [{"text": "Adrian Hayday"}], "entities": [{"type": "Person", "text": "Professor Adrian Hayday"}]}, "sentence": " Commenting on the findings, Adrian Hayday said: \"I am very excited about these unexpected findings, which are a key step in unravelling the complex mechanisms by which ?d T cells attempt to maintain tissue integrity in the face of an unending spectrum of microbial and chemical challenges.\"", "object": {"text": "\"I am very excited about these unexpected findings, which are a key step in unravelling the complex mechanisms by which ?d T cells attempt to maintain tissue integrity in the face of an unending spectrum of microbial and chemical challenges", "keywords": [{"text": "unending spectrum"}, {"text": "unexpected findings"}, {"text": "tissue integrity"}, {"text": "complex mechanisms"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The ?dTCR", "keywords": [{"text": "dTCR"}]}, "sentence": " The ?dTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness.", "object": {"text": "innate immunity", "keywords": [{"text": "innate immunity"}]}, "action": {"verb": {"text": "combine", "tense": "present"}, "text": "combines", "normalized": "combine"}}, {"subject": {"text": "The ?dTCR", "keywords": [{"text": "dTCR"}]}, "sentence": " The ?dTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness.", "object": {"text": "spatially distinct regions for agonist selection and antigen responsiveness", "keywords": [{"text": "spatially distinct regions"}, {"text": "antigen responsiveness"}, {"text": "agonist selection"}]}, "action": {"verb": {"text": "utilize", "tense": "present"}, "text": "utilizing", "normalized": "utilize"}}, {"subject": {"text": "GammaDelta Therapeutics", "keywords": [{"text": "GammaDelta Therapeutics"}], "entities": [{"type": "Company", "text": "GammaDelta Therapeutics"}]}, "sentence": " GammaDelta Therapeutics is working to develop improved immunotherapies for cancer and other serious diseases.", "object": {"text": "working to develop improved immunotherapies for cancer and other serious diseases", "keywords": [{"text": "improved immunotherapies"}, {"text": "cancer"}, {"text": "diseases"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "GammaDelta Therapeutics", "keywords": [{"text": "GammaDelta Therapeutics"}], "entities": [{"type": "Company", "text": "GammaDelta Therapeutics"}]}, "sentence": " GammaDelta Therapeutics is working to develop improved immunotherapies for cancer and other serious diseases.", "object": {"text": "to develop improved immunotherapies for cancer and other serious diseases", "keywords": [{"text": "improved immunotherapies"}, {"text": "cancer"}, {"text": "diseases"}]}, "action": {"verb": {"text": "work", "tense": "present"}, "text": "is working", "normalized": "be work"}}, {"subject": {"text": "GammaDelta Therapeutics", "keywords": [{"text": "GammaDelta Therapeutics"}], "entities": [{"type": "Company", "text": "GammaDelta Therapeutics"}]}, "sentence": " GammaDelta Therapeutics is working to develop improved immunotherapies for cancer and other serious diseases.", "object": {"text": "improved immunotherapies for cancer and other serious diseases", "keywords": [{"text": "immunotherapies"}, {"text": "cancer"}, {"text": "diseases"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "The company's research and development", "keywords": [{"text": "company"}]}, "sentence": " The company's research and development is focused on exploiting the unique properties of tissue resident gamma delta (?d) T cells, which are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathology.", "object": {"text": "the unique properties of tissue resident gamma delta (?d) T cells, which are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathology", "keywords": [{"text": "tissue resident gamma"}, {"text": "conserved population"}, {"text": "immune responses"}, {"text": "unique properties"}]}, "action": {"verb": {"text": "exploit", "tense": "future"}, "text": "exploiting", "normalized": "exploit"}}, {"subject": {"text": "GammaDelta Therapeutics", "keywords": [{"text": "GammaDelta Therapeutics"}], "entities": [{"type": "Company", "text": "GammaDelta Therapeutics"}]}, "sentence": " GammaDelta Therapeutics was founded in 2016 by Abingworth with support from Cancer Research Technology Limited based on research undertaken by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute.", "object": {"text": "founded in 2016 by Abingworth", "keywords": [{"text": "Abingworth"}], "entities": [{"type": "Company", "text": "Abingworth"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Abingworth with support from Cancer Research Technology Limited based on research undertaken by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute", "keywords": [{"text": "Francis Crick Institute"}, {"text": "Professor Adrian Hayday"}, {"text": "Dr Oliver Nussbaumer"}, {"text": "Cancer Research Technology"}], "entities": [{"type": "Company", "text": "Abingworth"}, {"type": "Company", "text": "Cancer Research Technology Limited"}, {"type": "Person", "text": "Professor Adrian Hayday"}, {"type": "Person", "text": "Dr Oliver Nussbaumer"}, {"type": "Organization", "text": "King's College London"}, {"type": "Organization", "text": "Francis Crick Institute", "disambiguation": {"subtype": [], "name": "Francis Crick Institute", "dbpedia_resource": "http://dbpedia.org/resource/Francis_Crick_Institute"}}]}, "sentence": " GammaDelta Therapeutics was founded in 2016 by Abingworth with support from Cancer Research Technology Limited based on research undertaken by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute.", "object": {"text": "GammaDelta Therapeutics", "keywords": [{"text": "GammaDelta Therapeutics"}], "entities": [{"type": "Company", "text": "GammaDelta Therapeutics"}]}, "action": {"verb": {"text": "found", "tense": "past"}, "text": "was founded", "normalized": "be found"}}, {"subject": {"text": "by Professor Adrian Hayday and Dr Oliver Nussbaumer", "keywords": [{"text": "Professor Adrian Hayday"}, {"text": "Dr Oliver Nussbaumer"}], "entities": [{"type": "Person", "text": "Professor Adrian Hayday"}, {"type": "Person", "text": "Dr Oliver Nussbaumer"}]}, "sentence": " GammaDelta Therapeutics was founded in 2016 by Abingworth with support from Cancer Research Technology Limited based on research undertaken by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute.", "object": {"text": "research", "keywords": [{"text": "research"}]}, "action": {"verb": {"text": "undertake", "tense": "past"}, "text": "undertaken", "normalized": "undertake"}}, {"subject": {"text": "The company's offices and laboratories", "keywords": [{"text": "laboratories"}, {"text": "company"}, {"text": "offices"}]}, "sentence": " The company's offices and laboratories are located in London, UK .", "action": {"verb": {"text": "locate", "tense": "past"}, "text": "are located", "normalized": "be locate"}}], "concepts": [{"text": "Immune system", "relevance": 0.971825, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Cancer", "relevance": 0.695684, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Innate immune system", "relevance": 0.594057, "dbpedia_resource": "http://dbpedia.org/resource/Innate_immune_system"}, {"text": "Adaptive immune system", "relevance": 0.57879, "dbpedia_resource": "http://dbpedia.org/resource/Adaptive_immune_system"}, {"text": "Humoral immunity", "relevance": 0.477852, "dbpedia_resource": "http://dbpedia.org/resource/Humoral_immunity"}, {"text": "Immunity", "relevance": 0.467697, "dbpedia_resource": "http://dbpedia.org/resource/Immunity_(medical)"}, {"text": "Thymus", "relevance": 0.455973, "dbpedia_resource": "http://dbpedia.org/resource/Thymus"}, {"text": "Medicine", "relevance": 0.410731, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Immunology", "relevance": 0.402903, "dbpedia_resource": "http://dbpedia.org/resource/Immunology"}, {"text": "Inflammatory bowel disease", "relevance": 0.400671, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Antibody", "relevance": 0.397447, "dbpedia_resource": "http://dbpedia.org/resource/Antibody"}, {"text": "Bacteria", "relevance": 0.375858, "dbpedia_resource": "http://dbpedia.org/resource/Bacteria"}, {"text": "Francis Crick", "relevance": 0.369202, "dbpedia_resource": "http://dbpedia.org/resource/Francis_Crick"}, {"text": "Oncology", "relevance": 0.366815, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Antigen", "relevance": 0.345331, "dbpedia_resource": "http://dbpedia.org/resource/Antigen"}, {"text": "Infectious disease", "relevance": 0.344795, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Chief executive officer", "relevance": 0.33889, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Major histocompatibility complex", "relevance": 0.335583, "dbpedia_resource": "http://dbpedia.org/resource/Major_histocompatibility_complex"}, {"text": "White blood cell", "relevance": 0.324617, "dbpedia_resource": "http://dbpedia.org/resource/White_blood_cell"}, {"text": "Protein", "relevance": 0.324576, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}, {"text": "Inflammation", "relevance": 0.32435, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "B cell", "relevance": 0.316851, "dbpedia_resource": "http://dbpedia.org/resource/B_cell"}, {"text": "Natural killer cell", "relevance": 0.297081, "dbpedia_resource": "http://dbpedia.org/resource/Natural_killer_cell"}, {"text": "University College London", "relevance": 0.293842, "dbpedia_resource": "http://dbpedia.org/resource/University_College_London"}, {"text": "Malignancy", "relevance": 0.291944, "dbpedia_resource": "http://dbpedia.org/resource/Malignancy"}, {"text": "T cell", "relevance": 0.28278, "dbpedia_resource": "http://dbpedia.org/resource/T_cell"}, {"text": "Vaccination", "relevance": 0.280371, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination"}, {"text": "King's College London", "relevance": 0.277395, "dbpedia_resource": "http://dbpedia.org/resource/King's_College_London"}, {"text": "Biopsy", "relevance": 0.27133, "dbpedia_resource": "http://dbpedia.org/resource/Biopsy"}, {"text": "T cell receptor", "relevance": 0.270427, "dbpedia_resource": "http://dbpedia.org/resource/T_cell_receptor"}], "categories": [{"score": 0.758792, "label": "/health and fitness/disease"}, {"score": 0.383582, "label": "/science/medicine/immunology"}, {"score": 0.338117, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "agentOf", "sentence": "d T cells for gastrointestinal diseases GammaDelta Therapeutics Ltd, an emerging biotech company developing novel immunotherapies for cancer and other diseases announced today the publication in Nature Immunology of new data examining the biological role of gamma delta (?d) T cell receptors.", "score": 0.596281, "arguments": [{"text": "GammaDelta Therapeutics Ltd", "location": [140, 167], "entities": [{"type": "Organization", "text": "GammaDelta Therapeutics\nGammaDelta Therapeutics"}]}, {"text": "announced", "location": [260, 269], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "score": 0.532809, "arguments": [{"text": "Paolo Paoletti", "location": [1295, 1309], "entities": [{"type": "Person", "text": "Paolo Paoletti"}]}, {"text": "said", "location": [1331, 1335], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOfMany", "sentence": "Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "score": 0.700058, "arguments": [{"text": "Paolo Paoletti", "location": [1295, 1309], "entities": [{"type": "Person", "text": "Paolo Paoletti"}]}, {"text": "We", "location": [1338, 1340], "entities": [{"type": "Person", "text": "their"}]}]}, {"type": "employedBy", "sentence": "Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "score": 0.680089, "arguments": [{"text": "CEO", "location": [1312, 1315], "entities": [{"type": "Person", "text": "Paolo Paoletti"}]}, {"text": "GammaDelta", "location": [1319, 1329], "entities": [{"type": "Organization", "text": "GammaDelta Therapeutics\nGammaDelta Therapeutics"}]}]}, {"type": "participantIn", "sentence": "Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "score": 0.551852, "arguments": [{"text": "We", "location": [1338, 1340], "entities": [{"type": "Person", "text": "their"}]}, {"text": "collaboration", "location": [1375, 1388], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "participantIn", "sentence": "Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "score": 0.564476, "arguments": [{"text": "GammaDelta", "location": [1397, 1407], "entities": [{"type": "Organization", "text": "GammaDelta Therapeutics\nGammaDelta Therapeutics"}]}, {"text": "collaboration", "location": [1375, 1388], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "ownerOf", "sentence": "Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "score": 0.471541, "arguments": [{"text": "Adrian Hayday", "location": [1422, 1435], "entities": [{"type": "Person", "text": "Adrian Hayday"}]}, {"text": "laboratories", "location": [1438, 1450], "entities": [{"type": "Facility", "text": "laboratories"}]}]}, {"type": "agentOf", "sentence": "\" Commenting on the findings, Adrian Hayday said: \"I am very excited about these unexpected findings, which are a key step in unravelling the complex mechanisms by which ?", "score": 0.995616, "arguments": [{"text": "Adrian Hayday", "location": [1614, 1627], "entities": [{"type": "Person", "text": "Adrian Hayday"}]}, {"text": "said", "location": [1628, 1632], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "foundedOn", "sentence": "GammaDelta Therapeutics was founded in 2016 by Abingworth with support from Cancer Research Technology Limited based on research undertaken by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute.", "score": 0.520233, "arguments": [{"text": "GammaDelta Therapeutics", "location": [2521, 2544], "entities": [{"type": "Organization", "text": "GammaDelta Therapeutics\nGammaDelta Therapeutics"}]}, {"text": "2016", "location": [2560, 2564], "entities": [{"type": "Date", "text": "2016", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "employedBy", "sentence": "GammaDelta Therapeutics was founded in 2016 by Abingworth with support from Cancer Research Technology Limited based on research undertaken by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute.", "score": 0.626069, "arguments": [{"text": "Oliver Nussbaumer", "location": [2695, 2712], "entities": [{"type": "Person", "text": "Oliver Nussbaumer"}]}, {"text": "King's College London", "location": [2716, 2737], "entities": [{"type": "Organization", "text": "King's College London", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "partOf", "sentence": "The company's offices and laboratories are located in London, UK .", "score": 0.837243, "arguments": [{"text": "company", "location": [2775, 2782], "entities": [{"type": "Organization", "text": "GammaDelta Therapeutics\nGammaDelta Therapeutics"}]}, {"text": "offices", "location": [2785, 2792], "entities": [{"type": "Organization", "text": "offices", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "timeOf", "sentence": "d T cells for gastrointestinal diseases GammaDelta Therapeutics Ltd, an emerging biotech company developing novel immunotherapies for cancer and other diseases announced today the publication in Nature Immunology of new data examining the biological role of gamma delta (?d) T cell receptors.", "score": 0.98615, "arguments": [{"text": "today", "location": [270, 275], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [260, 269], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "The company's offices and laboratories are located in London, UK .", "score": 0.477122, "arguments": [{"text": "offices", "location": [2785, 2792], "entities": [{"type": "Organization", "text": "offices", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "London", "location": [2825, 2831], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "locatedAt", "sentence": "The company's offices and laboratories are located in London, UK .", "score": 0.901368, "arguments": [{"text": "laboratories", "location": [2797, 2809], "entities": [{"type": "Facility", "text": "laboratories"}]}, {"text": "London", "location": [2825, 2831], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "locatedAt", "sentence": "The company's offices and laboratories are located in London, UK .", "score": 0.960384, "arguments": [{"text": "London", "location": [2825, 2831], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}, {"text": "UK", "location": [2833, 2835], "entities": [{"type": "GeopoliticalEntity", "text": "UK"}]}]}, {"type": "participantIn", "sentence": "In May 2017 , GammaDelta Therapeutics entered into a strategic collaboration with Takeda Pharmaceutical Co. Contact For GammaDelta Therapeutics Ltd: Paolo Paoletti , MD Chief Executive Officer T: +44 (0)207-691-1122 http://www.gammadeltatx.com", "score": 0.651402, "arguments": [{"text": "GammaDelta Therapeutics", "location": [2852, 2875], "entities": [{"type": "Organization", "text": "GammaDelta Therapeutics\nGammaDelta Therapeutics"}]}, {"text": "collaboration", "location": [2901, 2914], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "participantIn", "sentence": "In May 2017 , GammaDelta Therapeutics entered into a strategic collaboration with Takeda Pharmaceutical Co. Contact For GammaDelta Therapeutics Ltd: Paolo Paoletti , MD Chief Executive Officer T: +44 (0)207-691-1122 http://www.gammadeltatx.com", "score": 0.763065, "arguments": [{"text": "Takeda Pharmaceutical Co.\nContact\nFor GammaDelta Therapeutics Ltd", "location": [2920, 2985], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co.\nContact\nFor GammaDelta Therapeutics Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "collaboration", "location": [2901, 2914], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}]}, {"type": "locatedAt", "sentence": "The findings arose from an ongoing collaboration between GammaDelta and Professor Adrian Hayday's laboratories at King's College London and The Francis Crick Institute.", "score": 0.487517, "arguments": [{"text": "collaboration", "location": [428, 441], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}, {"text": "laboratories", "location": [491, 503], "entities": [{"type": "Facility", "text": "laboratories"}]}]}, {"type": "locatedAt", "sentence": "Paolo Paoletti , CEO at GammaDelta, said: \"We are delighted with the productive collaboration between GammaDelta and Professor Adrian Hayday's laboratories.", "score": 0.728303, "arguments": [{"text": "collaboration", "location": [1375, 1388], "entities": [{"type": "EventMeeting", "text": "collaboration"}]}, {"text": "laboratories", "location": [1438, 1450], "entities": [{"type": "Facility", "text": "laboratories"}]}]}, {"type": "locatedAt", "sentence": "The findings arose from an ongoing collaboration between GammaDelta and Professor Adrian Hayday's laboratories at King's College London and The Francis Crick Institute.", "score": 0.366704, "arguments": [{"text": "Adrian Hayday", "location": [475, 488], "entities": [{"type": "Person", "text": "Adrian Hayday"}]}, {"text": "laboratories", "location": [491, 503], "entities": [{"type": "Facility", "text": "laboratories"}]}]}, {"type": "employedBy", "sentence": "The findings arose from an ongoing collaboration between GammaDelta and Professor Adrian Hayday's laboratories at King's College London and The Francis Crick Institute.", "score": 0.429922, "arguments": [{"text": "Adrian Hayday", "location": [475, 488], "entities": [{"type": "Person", "text": "Adrian Hayday"}]}, {"text": "King's College London", "location": [507, 528], "entities": [{"type": "Organization", "text": "King's College London", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "ownerOf", "sentence": "The findings arose from an ongoing collaboration between GammaDelta and Professor Adrian Hayday's laboratories at King's College London and The Francis Crick Institute.", "score": 0.303228, "arguments": [{"text": "King's College London", "location": [507, 528], "entities": [{"type": "Organization", "text": "King's College London", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "laboratories", "location": [491, 503], "entities": [{"type": "Facility", "text": "laboratories"}]}]}, {"type": "affectedBy", "sentence": "d T cell receptors can act independently from other immune signals, functioning as a two-pronged device to discriminate cancer cells from normal cells before proceeding to kill them.", "score": 0.505056, "arguments": [{"text": "them", "location": [779, 783], "entities": [{"type": "Person", "text": "them"}]}, {"text": "kill", "location": [774, 778], "entities": [{"type": "EventViolence", "text": "kill"}]}]}, {"type": "locatedAt", "sentence": "The receptors combine so-called innate immunity with so-called adaptive immunity by using different regions of the receptor to recognise different molecular targets, one associated with healthy tissues and the other associated with malignant cells.", "score": 0.632525, "arguments": [{"text": "receptors", "location": [789, 798], "entities": [{"type": "Facility", "text": "receptors"}]}, {"text": "regions", "location": [885, 892], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "The receptors combine so-called innate immunity with so-called adaptive immunity by using different regions of the receptor to recognise different molecular targets, one associated with healthy tissues and the other associated with malignant cells.", "score": 0.534762, "arguments": [{"text": "receptor", "location": [900, 908], "entities": [{"type": "Substance", "text": "receptor"}]}, {"text": "receptors", "location": [789, 798], "entities": [{"type": "Facility", "text": "receptors"}]}]}], "keywords": [{"text": "GammaDelta Therapeutics", "sentiment": {"score": -0.791709, "label": "negative"}, "relevance": 0.955542}, {"text": "Professor Adrian Hayday", "sentiment": {"score": 0.610376, "label": "positive"}, "relevance": 0.853975}, {"text": "Francis Crick Institute", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.707954}, {"text": "so-called innate immunity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606242}, {"text": "so-called adaptive immunity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595336}, {"text": "cell receptors", "sentiment": {"score": -0.252797, "label": "negative"}, "relevance": 0.589869}, {"text": "Paolo Paoletti", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580978}, {"text": "cells", "sentiment": {"score": -0.520249, "label": "negative"}, "relevance": 0.568762}, {"text": "gamma delta", "sentiment": {"score": -0.45258, "label": "negative"}, "relevance": 0.563578}, {"text": "different molecular targets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556494}, {"text": "College London", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556354}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.59887, "label": "negative"}, "relevance": 0.556309}, {"text": "spatially distinct regions", "sentiment": {"score": 0.382314, "label": "positive"}, "relevance": 0.548548}, {"text": "Cancer Research Technology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543059}, {"text": "Dr Oliver Nussbaumer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539158}, {"text": "resident gamma delta", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538861}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537071}, {"text": "cancer cells", "sentiment": {"score": -0.627582, "label": "negative"}, "relevance": 0.534783}, {"text": "malignant cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532253}, {"text": "normal cells", "sentiment": {"score": -0.627582, "label": "negative"}, "relevance": 0.530622}, {"text": "novel immunotherapies", "sentiment": {"score": -0.45258, "label": "negative"}, "relevance": 0.511333}, {"text": "unexpected findings", "sentiment": {"score": 0.464738, "label": "positive"}, "relevance": 0.504506}, {"text": "immune signals", "sentiment": {"score": -0.252796, "label": "negative"}, "relevance": 0.49652}, {"text": "improved immunotherapies", "sentiment": {"score": -0.791709, "label": "negative"}, "relevance": 0.496303}, {"text": "gastrointestinal diseases", "sentiment": {"score": -0.467771, "label": "negative"}, "relevance": 0.495348}, {"text": "gut surface", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.493902}, {"text": "complex gut", "sentiment": {"score": 0.27119, "label": "positive"}, "relevance": 0.492183}, {"text": "new data", "sentiment": {"score": -0.45258, "label": "negative"}, "relevance": 0.489264}, {"text": "biological role", "sentiment": {"score": -0.45258, "label": "negative"}, "relevance": 0.489185}, {"text": "biotech company", "sentiment": {"score": -0.45258, "label": "negative"}, "relevance": 0.488505}, {"text": "antigen responsiveness", "sentiment": {"score": 0.382314, "label": "positive"}, "relevance": 0.488493}, {"text": "agonist selection", "sentiment": {"score": 0.382314, "label": "positive"}, "relevance": 0.488377}, {"text": "Nature Immunology", "sentiment": {"score": -0.45258, "label": "negative"}, "relevance": 0.48781}, {"text": "ongoing collaboration", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487187}, {"text": "unending spectrum", "sentiment": {"score": -0.35806, "label": "negative"}, "relevance": 0.486487}, {"text": "productive collaboration", "sentiment": {"score": 0.610376, "label": "positive"}, "relevance": 0.485876}, {"text": "immune responses", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485777}, {"text": "greater light", "sentiment": {"score": 0.27119, "label": "positive"}, "relevance": 0.48504}, {"text": "possible treatments", "sentiment": {"score": -0.59887, "label": "negative"}, "relevance": 0.484672}, {"text": "Deeper understanding", "sentiment": {"score": 0.740673, "label": "positive"}, "relevance": 0.483958}, {"text": "two-pronged device", "sentiment": {"score": -0.627582, "label": "negative"}, "relevance": 0.483864}, {"text": "healthy tissues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483539}, {"text": "different regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.482519}, {"text": "key step", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.482298}, {"text": "fundamental biology", "sentiment": {"score": 0.740673, "label": "positive"}, "relevance": 0.480535}, {"text": "therapeutic applications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.480484}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.479546}, {"text": "complex mechanisms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.479125}, {"text": "chemical challenges", "sentiment": {"score": -0.35806, "label": "negative"}, "relevance": 0.478879}, {"text": "tissue integrity", "sentiment": {"score": -0.35806, "label": "negative"}, "relevance": 0.478689}]}, "extracted_metadata": {"sha1": "b3f26f2350b99ad98651c290f2a01291aeb08e2f", "filename": "1542116758497.zip-34721e0df86fbbf02f2b2d1134325dd7.xml", "file_type": "json"}, "external_links": ["https://doi.org/10.1038/s41590-018-0253-5", "http://www.xmlnews.org/ns/"], "title": "GammaDelta Therapeutics Announces Publication of New Data in Nat", "forum_title": "Health Care"}, {"id": "kwrZM-XnccoCz-kmTpkOTZbZOliebcakUFNntwNLpNX_6QNdj3-4S95H_783Io34", "result_metadata": {"score": 31.985332}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.32966, "label": "negative"}, "text": "Shire Pharmaceuticals Group Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.296837, "label": "positive"}, "text": "The Vanguard Group", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "The Vanguard Group", "dbpedia_resource": "http://dbpedia.org/resource/The_Vanguard_Group"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Shire Pharmaceuticals Group Ltd", "keywords": [{"text": "Pharmaceuticals Group"}], "entities": [{"type": "Company", "text": "Shire Pharmaceuticals Group Ltd"}]}, "sentence": "Shire Pharmaceuticals Group Ltd (JE00B2QKY057) : Form 8.3 - The Vanguard Group, Inc.: Shire plc", "action": {"verb": {"text": "Form", "tense": "present"}, "text": "Form", "normalized": "Form"}}], "concepts": [], "categories": [{"score": 0.525488, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.516065, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.458515, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Shire Pharmaceuticals Group", "sentiment": {"score": -0.32966, "label": "negative"}, "relevance": 0.916723}, {"text": "Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629597}, {"text": "Vanguard Group", "sentiment": {"score": 0.296837, "label": "positive"}, "relevance": 0.421473}]}, "crawl_date": "2018-11-12T15:42:11Z", "url": "http://lesechos-comfi.lesechos.fr/actualite.html?id=821813", "host": "lesechos-comfi.lesechos.fr", "text": "If it is a cash offer or possible cash offer , state \"N /A \" Yes, Takeda Pharmaceutical Company Limited 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T14:52:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.996573, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.898617, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.78799, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.720693, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.317463, "label": "positive"}, "text": "The Vanguard Group, Inc.", "relevance": 0.693683, "type": "Company"}], "sentiment": {"document": {"score": -0.315458, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "he"}, "sentence": "(a) Full name of discloser : The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): T he naming of nominee or vehicle companies is insufficient .", "object": {"text": "T"}, "action": {"verb": {"text": "name", "tense": "present"}, "text": "naming", "normalized": "name"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer , state \"N /A \" Yes, Takeda Pharmaceutical Company Limited 2.", "object": {"text": "a cash offer or possible cash offer , state \"N /A \" Yes, Takeda Pharmaceutical Company Limited 2", "keywords": [{"text": "possible cash offer"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "state"}, {"text": "/A"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant sec urities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.920188, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Offer and acceptance", "relevance": 0.901341, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "The Vanguard Group", "relevance": 0.900802, "dbpedia_resource": "http://dbpedia.org/resource/The_Vanguard_Group"}, {"text": "Uniform Commercial Code", "relevance": 0.749843, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}], "categories": [{"score": 0.570178, "label": "/real estate/buying and selling homes"}, {"score": 0.47496, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.454542, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.94356}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.861577}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.785595}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.75508}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.749609}, {"text": "test practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.74495}, {"text": "possible cash offer", "sentiment": {"score": 0.408536, "label": "positive"}, "relevance": 0.735127}, {"text": "Vanguard Group", "sentiment": {"score": 0.317463, "label": "positive"}, "relevance": 0.562737}, {"text": "vehicle companies", "sentiment": {"score": -0.451797, "label": "negative"}, "relevance": 0.541385}, {"text": "Novem ber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535479}, {"text": "offeror/offeree Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510444}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508748}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503204}, {"text": "relevant sec", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.490858}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471217}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467978}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333988}, {"text": "discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.305857}, {"text": "interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303179}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.287482}, {"text": "nominee", "sentiment": {"score": -0.451797, "label": "negative"}, "relevance": 0.285132}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.28331}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280491}, {"text": "controller", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.268174}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257848}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257664}, {"text": "Owner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257564}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256681}, {"text": "trust", "sentiment": {"score": 0.575723, "label": "positive"}, "relevance": 0.253618}, {"text": "settlor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253428}, {"text": "identity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250835}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249498}, {"text": "/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248215}, {"text": "Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248056}]}, "extracted_metadata": {"sha1": "e5813d71481e4af165ddfa627b13d32b1d622208", "filename": "1542037331582.zip-79b5f41d9ee31ba0030a2e7ea02ce8e8.xml", "file_type": "json"}, "external_links": ["http://www.facebook.com/2008/fbml"], "title": "Shire Pharmaceuticals Group Ltd (JE00B2QKY057) : Form 8.3 - The Vanguard Group, Inc.: Shire plc", "forum_title": "Webdisclosure.com - Financial Communication"}, {"id": "KgREfDl0YAGmIegbYrIO7aJQtIK2_uJ51q0v41DGVBanZ8KVfBjadUHMqxPtbKmZ", "result_metadata": {"score": 31.855347}, "author": "Norges Bank", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.670187, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.492359, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Norges Bank", "sentiment": {"score": -0.230595, "label": "negative"}, "relevance": 0.966282}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.8818}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240447}]}, "crawl_date": "2018-11-13T10:26:28Z", "url": "https://www.prnewswire.co.uk:443/news-releases/norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-898202772.html", "host": "prnewswire.co.uk", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T10:16:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.821602, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Yes Shire PLC", "relevance": 0.542036, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.535954, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.535633, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.520445, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.500547, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.49238, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.467733, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.467733, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.467733, "type": "Quantity"}], "sentiment": {"document": {"score": 0.497473, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d Yes Shire PLC 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: TOTAL: 9,490,558 1.19 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}]}, "sentence": " Class of relevant security: Ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 6,939,558 0.87 (2) Cash-settled derivatives: 2,551,000 0.32 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 9,490,558 1.19 All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "9,490,558 1.19 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " Class of relevant security: Ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 6,939,558 0.87 (2) Cash-settled derivatives: 2,551,000 0.32 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 9,490,558 1.19 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "CFD Nature", "keywords": [{"text": "CFD Nature"}]}, "sentence": " CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options)", "object": {"text": "e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options)", "keywords": [{"text": "long/short position Number"}, {"text": "Stock-settled derivative transactions"}, {"text": "reference securities Price"}, {"text": "unit"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Class of relevant security Product description e.g. call option", "keywords": [{"text": "relevant security Product"}, {"text": "e.g. call option"}, {"text": "Class"}, {"text": "description"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " If there are no such agreements, arrangements or understandings, state \u201cnone\u201d (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d (c) Attachments", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state \u201cnone\u201d (c) Attachments", "object": {"text": "to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "future acquisition"}, {"text": "disposal"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 13/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 13/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "+4724073297 Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Date of disclosure: 13/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.983176, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.550026, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.529491, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.521886, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.472035, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.443198, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.426905, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.414715, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.390872, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option contract", "relevance": 0.37431, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Unit type", "relevance": 0.372297, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Derivative", "relevance": 0.36387, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Security", "relevance": 0.362904, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Uniform Commercial Code", "relevance": 0.361397, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.361141, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Moneyness", "relevance": 0.33899, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Norges Bank", "relevance": 0.33859, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.713365, "label": "/real estate/buying and selling homes"}, {"score": 0.513799, "label": "/finance/financial news"}, {"score": 0.27548, "label": "/finance/investing/day trading"}], "relations": [{"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Purchase 25,000 JPY 4,504.9320 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.726237, "arguments": [{"text": "i", "location": [3141, 3142], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [3144, 3151], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3741, 3746], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3751, 3755], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4115, 4121], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4132, 4139], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 13/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5008, 5014], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5022, 5026], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5169, 5193], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5161, 5166], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5328, 5333], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5347, 5374], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.935536}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.850987}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.740742}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.733846}, {"text": "disclosure Dealing Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662006}, {"text": "short positions", "sentiment": {"score": -0.294205, "label": "negative"}, "relevance": 0.661976}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61763}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593228}, {"text": "reference securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574905}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.574172}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568318}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.550922}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550135}, {"text": "relevant security Purchase/sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549443}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.548327}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542475}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53759}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532457}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531577}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530714}, {"text": "long/short position Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528887}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528598}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528409}, {"text": "possible cash offer", "sentiment": {"score": 0.403939, "label": "positive"}, "relevance": 0.524034}, {"text": "Expiry date Option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523983}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.408511, "label": "negative"}, "relevance": 0.522803}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521109}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.520985}, {"text": "Chiaroni Telephone number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51781}, {"text": "unit Type e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516981}, {"text": "conversion Details Price", "sentiment": {"score": 0.287349, "label": "positive"}, "relevance": 0.516489}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514287}, {"text": "Product description e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513143}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512308}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499133}, {"text": "person", "sentiment": {"score": 0.211637, "label": "positive"}, "relevance": 0.491585}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.490771}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.480799}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476881}, {"text": "Norges Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47544}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474029}, {"text": "vehicle companies", "sentiment": {"score": -0.502591, "label": "negative"}, "relevance": 0.471073}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.469677}, {"text": "option arrangement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468401}, {"text": "employee options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468369}, {"text": "interests", "sentiment": {"score": -0.294205, "label": "negative"}, "relevance": 0.467683}, {"text": "Stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467657}, {"text": "Cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467197}, {"text": "SOURCE Norges", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466197}, {"text": "Public disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464605}]}, "extracted_metadata": {"sha1": "7b86d3aa73160197acecd8136a6b8ae5900e8cc8", "filename": "1542104788549.zip-49ba8e73d426922d9ca043f7f379fd87.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "PR Newswire:"}]}